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Abstract 
Empirically, depth of coma and duration of post-traumatic amnesia offer 
insufficient prognostic accuracy for neuropsychological outcomes following TBI. 
Recently, serum S100B has been proposed in the associated literature as a potential 
prognostic biomarker for outcome following TBI. Unfortunately, most of the studies 
investigating S100B have utilised crude outcome measures or mortality as the 
dependent variable in research design. This study aimed to investigate the 
relationship between S100B levels and existing TBI diagnostic measures, and to 
quantify its ability to predict future cognitive impairment, post-concussion syndrome 
symptomatology, and quality of life. 
127 participants who presented to the Royal Hobart Hospital following a TBI 
were recruited for this longitudinal study. On presentation, serum samples were 
collected, freeze-stored, and then batch analysed for acute S100B levels. Participants 
completed a cognitive battery two months post injury, and then completed the British 
Columbia Post-Concussion Inventory and the Quality of Life Inventory six months 
post injury. 
S100B levels were significantly correlated with depth of coma and duration 
of post-traumatic amnesia, and regression analyses showed that duration of post-
traumatic amnesia could be predicted accurately by using S100B. Serum S100B 
concentrations accounted for a significant proportion of variance in various 
symptoms of post-concussion syndrome and poorer quality of life – however, S100B 
in isolation offers insufficient prognostic accuracy for these clinical outcomes. 
Unfortunately, however, S100B was not able to predict future cognitive impairment, 
suggesting that cognitive prognoses based on biological factors alone while in an 
acute setting remain elusive, if not illusive. 
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Chapter One 
Overview of the Thesis 
Traumatic brain injury (TBI) refers to permanent or transient neurological 
dysfunction that has resulted from an external force to the brain. It is one of the most 
common neurological conditions, and unfortunately, the mortality and chronic 
disability that can result from TBI has improved little in the last 20 years (Masson et 
al., 2001). TBI can cause debilitating impairments to a person’s physical, cognitive, 
behavioural and social functioning (Hammond et al., 2004). Although it is generally 
accepted that the long-term prognosis for mild and moderate cognitive recovery 
following TBI is good, it is also the case that a proportion of these patients will 
experience limited and incomplete recoveries (McAllister et al., 2006). 
TBI is nearly always associated with cognitive deficits, but the extent of these 
deficits is considered to be highly variable (Isoniemi, Tenovuo, Portin, Himaned & 
Kairisto, 2006). The most commonly reported cognitive impairments that follow TBI 
occur in the domains of short-term memory, attention, executive functioning and 
speed of information processing; and these impairments have been well documented 
in the associated literature (Binder, Rohling & Larrabee, 1997; Dockree et al., 2006; 
Gentilini, Nichelli & Schoenhuber, 1989; Levin, High & Ewing-Cobbs, 1988; 
McAllister et al., 2006; Rapoport et al., 2005; Stuss et al., 1989).  
Beers et al. (2007) have stated that increasing the accuracy of prediction of 
neuropsychological outcomes following TBI is essential. The authors argue that 
prognoses based on more reliable prediction methods can provide patients and their 
carers with accurate information and realistic expectations for outcome, and facilitate 
effective and appropriate referrals to rehabilitation services. Further, de Krujik et al. 
(2002) suggest that time and expenses that are invested in follow-up sessions with 
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specialists would be drastically reduced if there was a reliable means to identify 
those who are most expected to exhibit persistent symptoms while they are still in the 
context of an acute presentation.  
TBI is regularly contextualised according to the “primary” and “secondary” 
components of the injury. The primary insult in TBI is most often the focal damage 
caused by the contact injury and the resulting diffuse axonal damage (Feala et al., 
2013). Secondary injuries occur in the minutes to hours following the primary injury, 
involving alterations and interactions in cerebral blood flow and deranged 
biochemical metabolism. It is recognised that these secondary injuries significantly 
contribute to poor outcomes following TBI, and as such, the management of TBI 
patients is primarily targeted towards treatment of these secondary pathologies (Stein 
et al., 2012). It is argued that a better understanding of the cellular and molecular 
mechanisms implicated in pathophysiological changes following TBI is necessary in 
order to facilitate more accurate prognoses for functional outcomes (Böhmer et al., 
2011). 
Clinically, classifications of mild, moderate or severe TBI are dependent on 
the patient’s depth of coma, duration of post-traumatic amnesia, and duration of loss 
of consciousness (Begaz et al., 2006; Muñoz-Cespedes, Rios-Lago, Paul & Maetsu, 
2005). Unfortunately, these measures when used to guide diagnostic evaluation are 
limited in their prognostic power. 
Due to TBI causing diffuse axonal and small vessel injury that is often 
undetectable by computerised tomography (CT), emerging research has begun to 
investigate the relationship between brain-related proteins and TBI outcome (Vos & 
Verbeek, 2002; Begaz, Kyriacou, Segal, & Bazarian 2006).  At a cellular level 
following TBI, the blood brain barrier is known to be disrupted and permeated, thus 
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allowing for brain specific molecules to enter the peripheral system. An indicator of 
blood brain barrier disruption would be beneficial to the TBI prognostic literature in 
order to guide clinical management and prognoses for these patients.  
In medical sciences, biomarkers are used to provide diagnostic or prognostic 
information towards an altered physiological condition or disease state (Gonçalves, 
Leite & Nardin, 2008). Biomarkers can be detected and monitored in a variety of 
bodily fluids and tissues, and they may be detected in the human system by 
specifically contrasted imaging techniques, or alternatively, through laboratory 
analysis of the specific fluid or tissue (Jeter et al., 2013). Without exception, 
biomarker research has been the largest growing area in the domain of TBI 
prognostic literature.  
The current direction of TBI biomarker research has focussed towards the 
investigation of the S100 calcium binding protein B (S100B) as it has been shown to 
fulfil the criteria of an ideal brain damage biomarker (Korfias et al., 2006). Primarily, 
S100B has been researched to determine a critical concentration level for indicating 
brain death following injury (Regner, Kaufman, Friedman & Chemale, 2001), and to 
signify the presence of post-traumatic lesions (Biberthaler et al., 2006). However, 
brain death and the lesions following TBI are dichotomous outcomes, and not 
representative of the majority of TBI prognoses. As such, there exists a need to 
investigate the utility of S100B in prognosticating specific recovery outcomes that 
are dimensional in nature, and of concern for the sequelae experienced by survivors 
of TBI.  
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The aim of the present thesis was to investigate the prognostic utility for 
serum S100B following TBI, with specific emphasis on neuropsychological 
functioning as the definable outcomes. Using a large prospective sample of TBI 
patients, across each classification of severity, this longitudinal population study 
aimed to examine the relationships that exist between S100B and current acute 
measures of TBI severity. Further, this thesis aimed to elucidate the ability for S100B 
to make prognoses for duration of post-traumatic amnesia, severity of cognitive 
impairment, presence of symptoms of post-concussion syndrome, and deficits in 
domains that are associated with quality of life.  
In Study One, this thesis aimed to identify potential relationships between 
serum levels of S100B and the current acute measures for classifying TBI severity – 
namely the depth of coma, and duration of post-traumatic amnesia. Further, Study 
One aimed to quantify the accuracy that S100B holds in prognosing duration of post-
traumatic amnesia, and whether this prognostic accuracy is superior to that of depth 
of coma. In Study Two, this thesis aimed to quantify the variability demonstrated in 
cognitive impairment at two months post TBI and the ability for S100B to prognose 
such impairment. Lastly, in Study Three, this thesis aimed to examine deficits in 
domains of quality of life and the severity of post-concussion syndrome 
symptomatology at six months post injury, and to investigate the ability for S100B to 
prognose such deficit and symptom severity. 
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Chapter 2 
Traumatic Brain Injury: Diagnosis and Acute Management 
2.1 Definition of Traumatic Brain Injury 
Traumatic brain injury (TBI) refers to permanent or transient neurological 
dysfunction that has resulted from an external force to the brain. Such forces can 
include a blunt force trauma, or a piercing or cracking of the skull (Fortune & Wen, 
1999). Further, TBI can occur without a person’s head ever making direct contact 
with another object. Sudden acceleration or deceleration can cause the brain to 
violently rotate and make contact with the skull’s internal architecture resulting in 
stretching and snapping of microscopic neural axons (Czubaj, 1996). Beyond the 
initial neurological tearing and shearing, a cascade of biological reactions also results 
from the trauma to the brain (Park, Bell & Baker, 2008). When defining TBI, an 
important distinction must be made between TBI and “head injury” as they are often 
used synonymously (De Krujik, Twijnstra, & Leffers, 2001). Although both result 
from contact and/or acceleration and deceleration of the head, only TBI is associated 
with loss of consciousness, post-traumatic amnesia, and focal neurological signs. 
Further, it is important to note that the definition of TBI excludes trauma that has 
resulted from stroke, anoxia, encephalitis and brain tumours (Koch, Merz & Lynch, 
1995). 
Currently, TBI is one of the most common neurological conditions, surpassed 
in incidence only by migraine headache and herpes zoster (Kennedy et al., 2006), 
and was recently referred to by the Traumatic Brain Injury Overview (2011) as the 
“signature wound of the Iraq and the Afghanistan wars.” The number of 
hospitalisations for TBI is 20 times that of spinal cord injuries, and diagnoses are 
more prevalent than breast cancer, multiple sclerosis, and Parkinson’s disease 
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(Flanagan, Hibbard, Riordan & Gordon, 2006). Unfortunately, despite the advances 
that have been made in the early detection and management of these patients’ 
injuries, the mortality and chronic disability that can result from TBI has improved 
little in the last 20 years (Masson et al., 2001). Current estimates approximate that 
50% of patients admitted after a “severe” TBI will be at least moderately disabled, 
and close to 30% will die from their injuries (Mercier et al., 2013).  
Aetiological studies have demonstrated that road traffic accidents account for 
the largest proportion of TBIs, and that males outnumber females by three to one. 
This sex differential is often suggested to be due to males exhibiting higher levels of 
risk taking behaviour (Khan, Baguley & Cameron, 2003). Further, TBI occurs most 
commonly in young adults, coinciding with important life events such as completing 
education, career development, and starting families (Khan et al., 2003). In the 
younger adult population, TBI is the leading cause of brain death – and, therefore, 
the primary source for organ transplantation (Regner, Kaufman, Friedman, & 
Chemale, 2001). Beyond early adulthood, however, it should be noted that there is a 
second peak for TBI prevalence in older adulthood (Rapoport, McCullagh, Streiner 
& Feinstein, 2003). Injuries to the elderly are often due to falls (Khan et al., 2003) 
and they are more likely than younger adults to have substantial disabilities and 
fatalities in the acute period following injury, even after more mild injuries 
(Rapoport, Herrmann, Kiss & Feinstein, 2006). 
Australian estimates suggest that 150 per 100 000 people are admitted to 
hospital with TBI annually (Fortune & Wen, 1999). However, Khan, Baguley and 
Cameron (2003) suggest that this figure most likely underestimates the true incidence 
of TBI because of classification and diagnostic errors, as well as the under-reporting 
of more mild injuries. In Tasmanian hospitals, there are over 100 emergency room 
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presentations of TBI each month, and the incidence of TBI in the Tasmanian 
population has steadily increased by approximately 6.5% each year for the last seven 
years (Tuck & Skilbeck, 2013). Unfortunately, the rate of TBI continues to increase 
despite safety improvements in the workplace, the increase of airbags in vehicles, 
and the enforcement of speed limits (Hergenroeder et al., 2007). 
TBI is considered to be a heterogeneous disorder – classified by presentation, 
aetiology, and pathology. Further, it is often associated with a variety of intracranial 
pathologies such as intraventricular haemorrhage, diffuse axonal injury, contusion, 
and haematomas (Sharma & Laskowitz, 2012). As such, TBI is regularly 
contextualised according to the “primary” and “secondary” components of the injury. 
The primary insult in TBI is most often the focal damage caused by the contact 
injury and the resulting diffuse axonal damage (Feala et al., 2013). The mechanism 
and magnitude of the primary injury dictate the type and degree of the damage 
sustained by the patient (Sharma et al. 2012). Secondary injuries, however, occur in 
the minutes to hours following the primary injury. These events involve alterations 
and interactions in cerebral blood flow and deranged biochemical metabolism, 
leading to oedema, oxidative stress, inflammation, ischaemia, increased intracranial 
pressure, apoptosis, and necrosis (Bellander et al., 2011; Feala et al., 2013). It is 
recognised that these secondary injuries significantly contribute to poor outcomes 
following TBI, and as such, the management of TBI patients is primarily targeted 
towards treatment of these secondary pathologies (Stein et al., 2012). However, the 
heterogeneous nature of secondary injuries following TBI makes the prognosis of 
outcomes especially difficult (Loane & Faden, 2010). As such, it is argued that a 
better understanding of the cellular and molecular mechanisms implicated in 
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pathophysiological changes following TBI is necessary in order to facilitate more 
accurate prognoses for functional outcomes (Böhmer et al., 2011). 
 
2.2 Current Practice for Diagnosis of TBI 
Clinically, classifications of mild, moderate or severe TBI are dependent on 
the patient’s depth of coma (often measured by Teasdale and Jennett’s (1974) 
Glasgow Coma Scale (GCS)), duration of post-traumatic amnesia, and duration of 
loss of consciousness (Begaz et al., 2006; Muñoz-Cespedes et al., 2005). 
Unfortunately, these measures when used to guide diagnostic evaluation are limited 
in their prognostic power, and are often obscured by extracranial injuries or the 
necessity for the patient to be sedated (Sharma & Laskowitz, 2012). Recently, 
predictive models have been developed to estimate likelihood of poor outcome 
following TBI – however, these prognostic models based on clinical/diagnostic 
measures have been inadequate (Walder et al., 2013).  
The Glasgow Coma Scale (GCS; Teasdale & Jennett, 1976) measures 
patients’ level of consciousness ranging from three – deep unconsciousness, to 
fifteen – normal alertness. A patient’s score on the GCS is determined by evaluating 
their ability to open their eyes, and to provide verbal, and motor responses to 
stimulation (Hergenroeder et al., 2007). As a screening tool following TBI, the GCS 
is simple to complete by medical, paramedical, and nursing personnel and thus 
facilitates interdisciplinary diagnostic communication. Although the GCS is the 
current “gold standard” for diagnosing TBI severity in the acute setting, there exists 
an unacceptable level of outcome variability in the measure’s classification 
populations (Ingebrigsten et al., 2000). Further, the GCS is highly susceptible to the 
effects of drugs and alcohol, and possesses issues with inter-rater reliability and poor 
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predictive power when used in isolation (Walder et al., 2013). Sharma and Laskowitz 
(2012) add that the validity of the GCS is compromised by intubation and sedation of 
the patient, and that it is difficult to ascertain the change in functioning in patients 
with premorbid neurological conditions. Consequently, the GCS has limited utility as 
a reliable tool for clinical prognoses (Beers, Berger & Adelson, 2007). In fact, 
Hergenroeder et al. (2008) and Korfias et al. (2007) conclude that although the GCS 
is currently used to stratify the magnitude and extent of brain damage, it possesses 
insufficient predictive value for making reliable outcome prognoses. Subsequently, a 
niche exists to determine adjunctive prognostic information from additional sources, 
given the questionable prognostic validity of the GCS and other diagnostic measures 
(Sharma & Laskwotiz, 2012). 
Raabe et al. (2003) and Mussack et al. (2006) elucidate the limitations of 
these diagnostic measures in the acute management setting. The authors state that 
TBI patients are often sedated, intubated, artificially ventilated and uncooperative 
with neurological examination. Further, up to between 35% and 50% of TBIs occur 
within the context of alcohol consumption (Brin, Borucki, & Ambrosch, 2011) and 
as a result, it can often be unclear in the acute setting whether neurological and 
neurobehavioural deficits are attributable to intoxication. Further, assessing patient 
history, performing reliable clinical examination (such as GCS), and obtaining a 
stable CT can be extremely difficult with intoxicated patients.  
Beyond neurological examination, the circumstances described above often 
make it difficult to clinically determine the duration of patients’ post-traumatic 
amnesia and loss of consciousness. Post-traumatic amnesia is defined as a state of 
clinical disorientation and inability to consolidate memory following injury (Nakase-
Thompson, Sherer, Yablon, Nick, & Trzepacz, 2004). Subjectively, post-traumatic 
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amnesia can be ascertained by asking the patient to recall their first memory 
following the injury, and calculating the lapsed time. However, due to their 
subjective and self-reporting nature, a patient’s own recollections of the duration(s) 
of their post-traumatic amnesia and loss of consciousness are far from being reliable 
sources for accurate quantitative interval- or ratio-scale information. It is important 
to note, however, that despite its prognostic limitations, the duration that a patient 
spends in post-traumatic amnesia is considered to strongly influence expectancies for 
immediate cognitive impairment and recovery (Lezak, Howieson, & Loring, 2004). 
Subsequently, objective measures of post-traumatic amnesia have been adopted into 
guidelines for clinical management of TBI. One such commonly adopted measure is 
the Westmead Post-Traumatic Amnesia scale (WPTA; Marosszecky, Ryan, Shores, 
Batchelor, & Marosszeky, 1998). The WPTA operationally defines duration of post-
traumatic amnesia as the period of time where new memories are not consolidated, 
and not merely the time between the injury and the patient’s first subjectively 
recalled memory.  
At a cellular level following TBI, the blood brain barrier is known to be 
disrupted and permeated, thus allowing for brain specific molecules to enter the 
body’s peripheral system. As a result, assessment of the blood brain barrier’s 
integrity may have important implications for the patient’s diagnosis and prognosis – 
however, the assessment of the blood brain barrier is not routine in current clinical 
guidelines due to the available techniques being considered too invasive. The current 
gold standard measurement of blood brain integrity involves the simultaneous 
collection of the patient’s cerebrospinal fluid and peripheral serum and then 
analysing both samples for albumin and calculating a ratio-quotient between the 
samples (Blyth et al., 2009). Given the complicated and painfully invasive nature of 
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cerebrospinal fluid extraction from conscious patients, a less invasive indicator of 
blood brain barrier disruption would be beneficial to the TBI prognostic literature in 
order to guide clinical management for these patients. 
Beyond clinical classification, for patients who have endured a moderate or 
severe TBI, the current emergency room standard protocol is to perform cranial 
computerised tomography (CT) and/or magnetic resonance imaging (MRI) if 
available, to investigate the presence and extent of intracranial injuries (Biberthaler 
et al., 2001). As a result, many hospitals over-triage to imaging departments in order 
to make sure that patients with intracranial complications are not missed (Calcagnile, 
Undén, & Undén, 2012). In fact, between 80 and 95 percent of CTs conducted after 
mild head injury detect no abnormalities (Ruan, Noyes, & Bazarian, 2009). 
Additionally, while these techniques are considered to be readily available in acute 
settings, the consistent use of imaging in patients with minor head injury can lead to 
side-effects related to radiation exposure, greater health care costs, and difficulties 
associated with performing the procedures in uncooperative patients (Calcagnile, 
Holmen, Chew, & Unden, 2013; Kondziolka, 2013). As such, it can be argued that 
although these techniques are patently necessary in the context of severe pathology 
such that the risks of not conducting imaging far outweigh the costs, the reverse may 
not be true when the injury is less severe.  
Despite the progress in neurological monitoring technologies, CT and MRI 
are not efficient methods for the effective prognosis of outcome (Korfias et al., 2006; 
Mussack et al., 2006). Further, current imaging techniques rarely provide definitive 
biological indicators of secondary injury (Niogi & Mukherjee, 2010) and are 
statistically insensitive to mild injury (Sharma et al., 2012). Nevertheless, surgical 
decisions in critical care management of TBI patients remain highly dependent on 
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the results of neuroimaging, in conjunction with the monitoring of intracranial 
pressure (Yokobori, 2013). Recently, however, attention in the associated literature 
has turned towards reducing unnecessary imaging procedures, and investigating 
alternative techniques for confirmatory diagnoses.  
 
2.3 Acute Management of TBI 
The traditional goal for acute care of TBI in emergency departments has been 
physiological stabilisation of the patient, followed by minimising any further injury 
from secondary factors such as a drop in blood pressure leading to hypotension, a 
lack of oxygen leading to anoxia, or the introduction of infection in the brain through 
a skull fracture (Kennedy, Lumpkin & Grissom, 2006). Additionally, focus is often 
centred on identifying “severe” and “moderate” TBI patients who will require close 
monitoring or urgent neurosurgical intervention. However, approximately three 
quarters of patients sustain only “mild” injury, and are often discharged from the 
emergency room after only a brief period of observation (Begaz, Kyriacou, Segal & 
Bazarian, 2006). Diaz-Arrastia et al. (2013) opine that mild TBIs are difficult to 
diagnose as symptoms are primarily subjective, and often overlap with psychological 
disorders that confound the clinical picture. Further, many mild injuries go 
undiagnosed due to being overlooked because of more immediate medical concerns. 
Therefore, the practice of discharging “mild” TBI patients without admission and 
monitoring can be problematic, attributable to the consistent finding that despite 
many patients possessing otherwise identical injury factors and clinical management, 
their individual recovery and outcomes can be markedly different (Feala et al., 2013). 
In fact, patients who have sustained a mild injury still remain at risk of developing 
life threatening intracranial complications. As such, there exists an unmet need to 
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effectively manage the heterogeneity of TBI pathologies, and to personalise 
interventions to optimise recovery (Okonkwo et al., 2013). 
Tate, McDonald and Lulham (1998) warn that vigilance is needed to detect 
mild injuries that can produce future neurological implications due to complications 
such as intracranial haematoma. The authors identify that future complications are 
often not being recognised in emergency departments due to the absence of expert 
TBI response teams and conservative screening and treatment policies. Recently, 
proton magnetic resonance spectroscopy, functional neuroimaging and cognitive 
assessments have all emerged as potential tools for investigation and identification of 
functional deficits following TBI (Yeo et al., 2006; Muñoz-Cespedes et al., 2005). 
Unfortunately, these techniques currently remain very expensive, require expert 
training, and are not feasible in an emergency department setting. 
 Theoretically, acute prognostic variables in the medical model of disease rely 
on a balance between sensitivity and specificity – and the preference for either a 
highly sensitive predictor with low specificity, or a highly specific predictor with low 
sensitivity is dependent on the nature of the disease. Unden and Romner (2007) state 
that TBI management needs a measure with very high sensitivity. In other words, the 
treating doctor needs a measure by which a negative result will accurately predict a 
more favourable outcome following their injury. Hergenroeder et al. (2007) state that 
although there have been improvements in response times, acute management, and 
survivability of TBI, there have not been any major improvements in the prognostic 
accuracy that can be offered to patients regarding their post-injury outcomes.  
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Chapter 3 
Outcomes, Recoveries, and Prognoses following Traumatic Brain Injury 
3.1 Impacts and Outcomes following TBI 
TBI can cause debilitating impairments to a person’s physical, cognitive, 
behavioural and social functioning (Hammond et al., 2004). While most people 
recover from these impairments without significant long-term consequences, it is 
well acknowledged that a substantial proportion of cases will develop persistent 
neurological and cognitive symptoms such as headache, impaired memory, and 
difficulty concentrating. The persistence of these symptoms is often referred to as 
post-concussion syndrome (PCS; Begaz et al., 2006). Current literature suggests that 
between 15 and 25 percent of individuals who sustain a TBI will suffer symptoms of 
PCS to the degree that their daily functioning is markedly impaired (McAllister, 
Flashman, McDonald & Saykin, 2006). To date, regrettably little is known about the 
pathophysiological aetiology of PCS (Di Battista, Rhind, & Baker, 2013). The ability 
to predict these outcomes would be invaluable in identifying patients who are likely 
to require rehabilitation, and to encourage the patient and their carers to be vigilant 
for reporting future symptoms (Dash, Zhao, Hergenroeder, & Moore, 2010). 
The psychosocial and emotional responses to TBI can include symptoms of 
depression and an inability to execute effective coping strategies (Jacobson, 1995), 
leading to a reduction in activity levels, a decrease in social functioning and 
difficulty expressing needs (Rapoport et al., 2003). Economically, the occupational 
disability that is often associated with TBI and post-concussive syndrome can result 
in a considerable financial burden for the patient (Thurman, 2001; Blundon & Smits, 
2000). TBI can also place economic and emotional strain on the families of the 
injured, particularly due to the high incidence of TBI in young adults (Flanagan, 
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1999). While the likelihood of a favourable recovery is grossly higher for patients 
who have sustained a mild injury as opposed to moderate or severe, many patients 
with mild TBI still report impaired ability to fulfil work and undertake family 
responsibilities. In fact, Diaz-Arrastia et al. (2013) argue that at a societal level, it is 
likely that the financial burden that results from mild injuries is at least equivalent to 
that resulting from severe injuries, attributable to its much higher prevalence in the 
population. 
Some of the most disruptive symptoms experienced by patients who have 
sustained a TBI include behavioural issues, mood changes, impulsiveness, and 
increased likelihood of depression and sleep disturbance. As such, these behavioural 
changes can create marked complications with the patient’s rehabilitation (Dash et 
al., 2010). Blundon and Smits (2000) refer to rehabilitative TBI patients as the 
“walking wounded” in that most will not suffer from permanent physical 
impairments that are obvious to the passing eye of the layman. However, less visible 
cognitive, emotional, and behavioural impairments continue to affect their daily 
lives. Further, each person endures a unique constellation of after-effects following a 
TBI and it cannot be assumed that the magnitude, effect or duration of these 
symptoms will be trivial or mild (Czubaj, 1996; Corrigan, Whiteneck & Mellick, 
2004). Koch et al. (1995) add that these difficulties can be exacerbated for patients 
who do not receive appropriate diagnosis and treatment intervention. For Rapoport, 
McCullagh, Shammi and Feinstein (2005), and McAllister et al. (2006), the most 
challenging functional difficulties faced by TBI patients are impairments in their 
cognitive functioning. 
Cognitive functioning includes a range of basic and complex domains. Basic 
cognitive processes include attention, orientation, and memory, whereas the more 
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complex processes include planning, sequencing, problem solving, and organising. 
Individuals use these cognitive processes in nearly every aspect of their functional 
lives (Blundon & Smits, 2000). TBI can affect overall cognitive processes and have a 
differential effect on processes within these domains (Carney et al., 1999). 
Inherently, there is a great need to understand the effects of TBI on cognitive 
functioning (Colantonio, Ratcliff, Chase & Vernich, 2004) and to obtain a prognosis 
for cognitive recovery as soon as possible after injury.  
TBI is nearly always associated with cognitive deficits, but the extent of these 
deficits is considered to be highly variable (Isoniemi, Tenovuo, Portin, Himanen & 
Kairisto, 2006). Cognitive sequelae are considered to be the most disabling of post-
morbid symptoms and contribute more to persisting disability than comorbidly 
sustained physical injuries (Rapoport et al., 2005). Unfortunately however, Packard, 
Weaver and Ham (1993) suggest that cognitive symptoms are regularly overlooked 
by patients and their clinicians, and subjective cognitive complaints following TBI 
are often not objectively supported by structural neuroimaging techniques such as 
fMRI spectroscopy and CT scans (Koch et al., 1995; Lannoo, Colardyn, & 
Vandekerckhove, 1998). Consequently, discrepancies between objective findings and 
subjective complaints have meant that the concerns of some patients have been 
missed, discounted, or ignored. 
The most commonly reported cognitive impairments that follow TBI occur in 
the domains of short-term memory, attention, executive functioning and speed of 
information processing; and these impairments have been well documented in the 
associated literature (Binder, Rohling & Larrabee, 1997; Dockree et al., 2006; Levin, 
High & Ewing-Cobbs, 1988; McAllister et al., 2006; Rapoport et al., 2005; 
Schoenhuber & Gentilini, 1989; Stuss et al., 1989). At a more finite level, specific 
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deficits exhibited in problem-solving, set-shifting, self-monitoring, and impulse 
control can have marked effects on more global cognitive domains (Sun & Feng, 
2013). Further, cognitive impairments have also been found to occur in paired-
associated learning and reaction time (Salmond, Chatfield, Menon, Pickard & 
Sahakin, 2005). However, it is the impairments to memory, information processing, 
and executive functioning that are considered to be most frustrating to clinical TBI 
populations (Chan, 2005). This finding is understandable, as all of the 
aforementioned domains are essential for high-functioning occupational, social and 
personal readaptation following TBI (Muñoz-Cespedes et al., 2005). 
McAllister et al. (2006) posit that the most commonly reported memory 
complaints for TBI patients are often associated with working memory, which refers 
to the ability to hold recently acquired information in mind and to manipulate it in 
light of incoming material. However, the authors note that complaints are also made 
in reference to lower-order memory processes such as encoding and retrieval of 
information. This finding is supported by Freeman and Godfrey (2000), who suggest 
that of all of the cognitive deficits that can follow TBI, impairments to patients’ 
memory and information processing appear the most frequently. With reference to 
executive functioning, Clement and Kennedy (2003) found that the domain of 
executive functioning is often more impaired than other cognitive processes 
following TBI, despite not being as overtly recognisable as deficits in memory and 
information processing. Further, they suggest that the recovery of this domain is 
comparatively prolonged. The unique recovery pattern of the executive functioning 
domain following TBI is often attributed to the damage caused to specific 
neurological structures of the prefrontal cortex (Czubaj, 1996). 
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 Neurologically, axonal stretching, twisting, bending and snapping can be 
disastrous for cognitive processes (Elliot, 1996). TBIs are most often associated with 
damage to the frontal lobes of the brain, resulting in a variety of cognitive and 
neurobehavioural disturbances. The neurobehavioural disorders that often result from 
frontal lobe injuries include impulsivity, affect disregulation, and impairments in 
self-control in accordance to social context (Czubaj, 1996). Cognitive disorders that 
are frequently associated with frontal lobe injury include distractibility, loss of skills 
surrounding abstraction and problem solving, impaired cognitive flexibility, and 
impaired initiation of action (Koch et al., 1995). 
Damage to the prefrontal cortex is considered to be the primary cause of 
executive dysfunction following TBI (Rapoport et al., 2005). However, impaired 
executive function has also been found with trauma to subcortical structures such as 
the thalamus, limbic system, basal ganglia, and cerebellum (McAllister et al., 2006). 
As a result, executive dysfunction is highly prominent in the cognitive sequelae of 
TBI due to the often diffuse nature of traumatic injury. 
Elliot (2003) posits that successful executive processing involves subcortical 
and posterior cortical regions working in concert with the prefrontal cortex. With 
reference to working memory, this domain is likely to be impeded if damage has 
been sustained by the temporal lobes and the pre-frontal cortex (Soeda et al., 2005). 
Injury to the left temporal lobe will often result in impairments to verbal learning and 
memory, auditory attention and discrimination, and disturbances in language – 
whereas damage suffered by the right temporal lobe will often result in impairments 
in visio-spatial perception (Czubaj, 1996). Unfortunately, the outcome measures that 
are traditionally utilised in prognostic research are insufficiently sensitive to the 
unique neuropsychological impairments that most commonly result from TBI. As 
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such, any translational implications that are made from such studies are limited in 
ascertaining true predictors of neuropsychological recovery following TBI. 
 
3.2 Neuropsychological Recovery following TBI 
For the majority of TBI patients, good recovery outcomes are expected for 
the first months following injury. Unfortunately, however, not enough is known 
about the nature of recovery and residual impairment across the stages of recovery 
(McAllister et al., 2006). Further, Millis et al (2001) suggest that there is more to be 
understood regarding the extent to which severity and premorbid factors influence 
impaired cognitive recovery following TBI. Millis and colleagues (2001) argue that 
prior studies have failed to address these research questions due to small samples, 
insufficient power, inadequate follow-up criteria, or poor statistical design. Salmond 
et al. (2005) add that many of these studies have relied on insensitive measures of 
cognitive deficit. Hence, there is a need for research to utilise measures with robust 
reliability and predictive validity (Beers et al., 2007), and these measures should be 
applied following discharge, across the course of recovery (Van Baalen et al., 2006). 
Unfortunately, robust cognitive measures are often considered to be “elegant” 
measures of outcome, and too expensive or difficult to incorporate into TBI research 
design (Lo, Jones, & Minns, 2009). Further, by requiring in-person follow-up 
evaluations in longitudinal TBI research, the attrition rate is often markedly impacted 
(Topolovec-Vranic et al., 2011). 
Beyond the acute-phase of rapid recovery of consciousness, orientation, and 
continuous memory, not enough is known for improvements made over time 
(Hammond, Hart, Bushnick, Corrigan, & Sasser, 2004). Further, there is a clear 
variability in outcomes and recovery patterns across individuals with equivalent 
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injury profiles. Although it is generally accepted that the long-term prognosis for 
mild and moderate cognitive recovery following TBI is good, it is also the case that 
there exists a proportion of these patients who will experience limited and 
incomplete recoveries (McAllister et al., 2006). Studies have even found that some 
patients may actually demonstrate a steady decline, even at a younger age – however, 
these trajectories are exceptionally rare (Teasdale, Murray & Nicoll, 2005). Given 
the range of potential outcomes, the accurate determination of which patients will 
spontaneously recover and which will endure long-lasting impairments is notoriously 
difficult (Van Baalen et al., 2006). 
Muñoz-Cespedes et al. (2005) speculate that there are two distinct 
mechanisms that influence cognitive recovery following TBI. The first is a neural 
mechanism that operates from the instant that the injury occurs. The authors suggest 
that this mechanism will recover or reach a plateau within six months following the 
injury. Secondly, the authors propose a personal-agency mechanism, implying that 
improvement beyond six months is dependent on the patient’s development of 
compensatory strategies and adaptation to the residual effects of their injury.  
It is often suggested that recovery of premorbid cognitive functioning is 
expected to occur for most TBI patients (Elliot, 2003). This is supported by the 
results of Yeo et al. (2006) who found that the majority of associated 
neurometabolite recovery takes place in the first two months following the injury, 
with additional slow minimal improvements up to six months. Muñoz-Cespedes et al. 
(2005) add that the recovery of premorbid social behaviour and personality traits also 
occurs predominantly within the first six months following a TBI.  
Beyond the six-month period, Hopkins and Jackson (2006) found that 
minimal improvements are made in neurocognitive functioning between six-months 
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and twelve-months, with some patients improving for up to three-years before their 
trajectory enters a plateau. Further, research conducted by Millis et al. (2001) found 
that some patients exhibited neurocognitive impairments even at five years post-
injury, leading the researchers to speculate that neurocognitive sequelae may be 
permanent for some patients. Patients who complain of long-term 
neuropsychological and somatic symptoms are regarded as suffering from persistent 
PCS. The associated literature reports that the risk factors for PCS include duration 
of post-traumatic amnesia and loss of consciousness (Iverson, Lovell, & Smith, 
2000), age, sex, a previous incidence of TBI (Binder, 1997), and comorbid 
depression (Busch & Alpern, 1998). However, none of these diagnostic and 
premorbid factors have been proven to be reliable as a true prognostic variable for 
the development of PCS (Stapert, et al., 2005). 
 
3.3 The Need for Accurate Prognostics 
Beers et al. (2007) have stated that increasing the accuracy of prediction of 
neuropsychological outcomes following TBI is essential. The authors argue that 
prognoses based on more reliable prediction methods can provide patients and their 
carers with accurate information and realistic expectations for outcome, and facilitate 
effective and appropriate referrals to rehabilitation services. Further, de Krujik et al. 
(2002) suggest that time and expenses that are invested in follow-up sessions with 
specialists would be drastically reduced if there was a reliable means to identify 
those who are most expected to exhibit persistent symptoms while they are still in the 
context of an acute presentation. If appropriate rehabilitation services are made 
available to these patients, it may be possible to reduce the number of patients whose 
conditions become chronic, and to minimise the financial costs that they encounter 
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during rehabilitation (Savola & Hillborn, 2003). Townend, Guy, Pani, Martin and 
Yates (2002) and Hammond et al. (2004) add that effective clinical prognoses can 
determine practical resource allocation, and therefore, maximise the resources and 
treatment options that are made available to the patient. 
Identification of a highly sensitive prognostic variable for TBI could also be 
of use in the medico-legal context. Ingebrigsten et al. (1999) suggest that such a 
variable may prove that neuropsychological disability or impairment after a 
traumatic event is in fact due to the TBI, and not to stress disorder, systemic injury or 
other causes. Hergenroeder et al. (2008) add that in the example of shaken baby 
syndrome, unreported trauma in concert with non-specific indistinguishable 
symptoms (irritability and vomiting) may result in the abuse going undetected. Such 
a prognostic tool would indicate the need for brain imaging and the implementation 
of abuse reporting procedures. Unfortunately, the diagnosis, prognosis, and treatment 
of TBI are hindered by the current lack of such a variable. Contemporary methods of 
imaging (CT, MRI, and fMRI) rarely provide definitive indicators of biological 
damage following TBI (Okonkwo et al., 2013). 
Due to TBI causing diffuse axonal and small vessel injury that is often 
undetectable by computerised tomography, emerging research has begun to 
investigate the relationship between brain-related proteins and TBI outcome (Vos & 
Verbeek, 2002; Begaz, Kyriacou, Segal, & Bazarian 2006).  More specifically, the 
current research has focussed on the biochemical changes that result from structural 
damage to neuronal cells. This damage causes a leakage of certain proteins into the 
patient’s extracellular matrix and cerebrospinal fluid (Zemlan et al., 2002). As a 
result, if the blood-brain barrier is damaged, these proteins are released into the 
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patient’s peripheral circulation, where they can be sampled and measured (Begaz, et 
al., 2006). 
Clearly, the appropriate and accurate identification of patients that are likely 
to experience post-traumatic complications is of high clinical importance and, as a 
result, prognostics is the direction of current neuropsychological TBI literature. The 
ability to focus early intervention resources on these high-risk patients can only be 
achieved by a reliable prognostic indicator of sustained damage. The current trend 
for prognostic medical research has veered away from measures that require 
subjective responses and recollections from the patient (such as GCS, and duration of 
post-traumatic amnesia and loss of consciousness) towards investigating the 
differential benefit offered by objective pathophysiological measures for outcome 
(Berger, Beers, Richichi, Wiesman, & Adelson, 2007).  However, as de Boussard et 
al. (2005) suggest, the pathophysiological basis for cognitive impairment is far from 
clear in neuropsychological literature. As a result, neuropsychological outcome 
research is beginning to incorporate biomedical variables as constituents of 
prognostic study. 
 The biomedical sequelae that follows TBI is an increasingly active area of 
neuropsychological research, and may provide a new assessment of severity with 
robust prognostic validity that is immediately available at the time of injury (Begaz 
et al., 2006). Consequently, a comprehensive understanding of the post-traumatic 
release patterns of brain-specific proteins could help to identify patients who are at 
risk of developing long-term neuropsychological dysfunction (Herrmann et al., 
2001). The identification of a brain-specific protein with prognostic value would 
constitute what is referred to in medical science models of disease as a “biomarker.” 
Currently, no serum biomarkers are routinely used in clinical presentations of TBI 
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(Okonkwo et al., 2013). Nevertheless, because of the medical need outlined above, 
there has been a heightened scientific interest in identifying molecular biomarkers of 
TBI. 
 
Chapter 4 
Biomarkers and Traumatic Brain Injury 
 
4.1 Biomarkers 
In medical sciences, biomarkers are used to provide diagnostic or prognostic 
information towards an altered physiological condition or disease state (Gonçalves, 
Leite & Nardin, 2008). Further, biomarkers provide objective indications for 
effective patient management and can detect disease and injury that may have been 
overlooked in routine clinical evaluation (Unden & Romner, 2009). As such, 
Kondziolka (2013) states that nothing transcends medical disciplines more than the 
concept of defining biomarkers – adding that a desire resides in all physicians to be 
able to quantify a measure that can accurately predict the presence or absence of an 
active pathology and thus be used to forecast prognoses for recovery.  
Biomarkers can be detected and monitored in a variety of bodily fluids and 
tissues, and they may be detected in the human system by specifically contrasted 
imaging techniques, or alternatively, through laboratory analysis of the specific fluid 
or tissue (Jeter et al., 2013). The majority of established biomarkers are evaluated in 
the serum component of a patient’s peripheral blood sample. Blood serum is the 
component of a collected blood sample that is neither a clotting factor nor a blood 
cell – rather, it is the blood plasma with the fibrinogens removed. The use of blood as 
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the source for biomarkers is attractive due to its accessibility, low invasiveness, 
minimal cost, and simple collection and processing (Hergenroeder et al., 2008).  
Biomarkers are widely used in many areas of medicine as a means of 
monitoring progression of pathology and response to treatment. Subsequently, 
biomarkers have gradually entered the domain of clinical neurotraumatology (Thelin, 
Johannesson, Nelson, & Bellander, 2013). Potentially, an effective biomarker of TBI 
would identify the presence of processes that are difficult to image, such as diffuse 
axonal injury, and provide evidence of any ongoing tissue damage (Sharma & 
Laskowitz, 2012). Subsequently, the effective utility of biomarkers in TBI could help 
streamline patient priority, reduce waiting times, and determine which patients 
require emergency CT imaging (Egea-Guerrero, Murillo-Cabezas, & León-Carrión, 
2013). Ohrt-Nissen (2011) add that incorporating biomarkers into the management of 
TBI could also reduce the number of unnecessary CT imaging, and inherently lower 
the rate of negative findings in CTs conducted on TBI patients. In the context of 
continuing life support, Vos et al (2010) caution that when the withdrawal of 
treatment is being considered, physicians must be confident that a biomarker result 
on which the decision is being based is highly specific for the particular outcome 
(i.e., death or persistent vegetative state) and that the number of false-positives is 
extremely low. 
In current medical practice, serum biomarkers can be used to provide 
clinicians with information regarding the severity and course of the pathology of 
disease (Korfias et al., 2007). At present, serum biomarkers are common adjuncts to 
the clinical management of many conditions whereby the detected levels of specific 
biomarkers have been shown to correlate with the clinical severity of organ damage 
and functioning for a variety of pathologies (Shore et al., 2007). Some examples of 
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established biomarkers include creatinine for renal failure, troponin I for myocardial 
injury, prostate specific antigen for prostate cancer, and amylase for pancreatitis. 
These biomarkers have been shown to be specific to the cells of their respective 
organ systems and are subsequently used to ascertain information about the 
diagnosis, prognosis, and effect of treatment for the patient (Raabe et al., 2003). In 
fact, Goyal et al. (2013) state that proteomic biomarkers are currently part of 
mainstream clinical care for almost every organ system except the brain. Ideally, for 
the biomarker to be attractive for clinical use it should be easy to access, fast and 
inexpensive to process, and simple to interpret (Oknonkwo, 2013). 
Sharma and Laskowitz (2012) argue that candidate biomarkers (for any 
condition or disease) should be subjected to rigorous study in order to elucidate and 
define their ability to provide adjunctive information in the clinical presentation for 
which they will be used. As such, the model for biomarker development in TBI can 
be framed analogously to models for any other medical presentation. In the 
oncological prognostic literature, five phases of biomarker development have been 
identified. Pepe, Etzioni and Feng (2001) state these phases as: 1. Identifying 
promising molecules; 2. Clinical assay development and validation; 3. Retrospective 
longitudinal studies on patients with known outcomes; 4. Prospective screening 
studies to determine whether a condition can be identified; and 5. Measurement of 
the impact of screening on reducing the burden of the condition on the population. 
Logically, these phases could be applied to the study of TBI.  However, 
Hergenroeder, Redell, Moore and Dash (2008) state that while biomarker profiling 
has proven to be useful in detecting oncological pathologies, the utility for 
biomarkers in the management of TBI is at an early stage of investigation. Papa et al. 
(2013) add that despite the infancy of the application of proteomic biomarkers in 
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TBI, the ongoing advances in the understanding of human neurobiochemistry can 
provide insight into the pathways by which TBI can be understood and the context 
by which biomarkers can be applied. 
Hergenroeder et al. (2008) posit that the identification of a specific TBI 
biomarker would aid in the diagnoses of TBI and polytrauma, identify patients at risk 
of developing secondary complications, and potentially, make accurate predictions 
for patients’ neuropsychological recoveries. Sun and Feng (2013) add that, with 
advancing technologies, biomarkers may elucidate the mechanisms that are involved 
in TBI and identify new strategies for therapeutic intervention. However, the 
translation of TBI biomarker research into clinically useful prognostic tools has not 
been successful to date (Lo et al., 2009). As such, several challenges still exist in 
effectively modelling the heterogeneity that is observed in TBI outcomes (Niyonkuru 
et al., 2013). Attempts to resolve these challenges are currently being facilitated by 
an increased focus on identifying biomarkers for outcome prognoses, with a growing 
emphasis on translational application of the findings. One such application would be 
elucidating the role of biomarkers in the prognosis of neuropsychological impairment 
following TBI, by exploring the mechanisms that underlie the changes in in the 
respective biomarker of injury (Sun & Feng, 2013). 
Indeed, without exception, biomarker research has been the largest growing 
area in the domain of TBI prognostic literature. Figure 4.1 below depicts the increase 
in peer-reviewed publications per year containing “biomarker” and “brain injury” in 
key words for the last twenty years (source: http://www.pubmed.com). 
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Figure 4.1 “Brain Injury” and “Biomarker” articles published annually 
 
 
Shore et al. (2007) argue that the increase in recent biomarker research for 
TBI is attributable to the fact that no single definitive biomarker currently exists for 
indicating brain damage severity. The prospect of establishing a routine 
neurobiochemical marker for TBI has led to a growth of experimental and clinical 
neurotraumatology studies being conducted by biochemical scientists, neurologists, 
and haematologists – all incorporating hypothesised biomarkers of brain damage into 
their research design (Herrman et al., 2001). Subsequently, the inclusion of an ideal 
biomarker into the evidence-based guidelines for TBI diagnosis and prognosis is 
eagerly anticipated across many medical sciences (Petzold et al., 2002). 
Unfortunately, however, Papa et al. (2013) suggest that the flurry of research in the 
area is limited by small sample sizes, unstandardised sample collection practices, and 
disparate outcome measures. Inherently, more work is necessary to clarify the unique 
diagnostic and prognostic utility of candidate proteins in order to classify them as 
potential biomarkers for TBI (Nyonkuru et al., 2013). 
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In broad terms, the Biomarkers Definitions Working Group (2001) state that 
a biomarker should indicate the presence or absence of disease/injury, and should be 
able to stage or classify its severity. More topically, Pelinka, Toegal, Mauritz and 
Redl (2003) state that an ideal biomarker for TBI should be highly specific for the 
brain, highly sensitive for TBI, appear rapidly in the serum, and be released in a 
time-locked sequence with trauma. Yokobori et al. (2013) expand this by stating that 
the specificity of an ideal TBI biomarker would indicate that TBI is uniquely present 
and accurately reflect the severity of the damage, and the sensitivity of the biomarker 
would be sufficient to indicate that changes in the marker are easily identifiable. 
Korfias et al. (2006) add that an ideal biomarker should also have no age or sex 
variability, and a consistent relationship between the serum concentration and the 
level of specific tissue damage. The criteria and standards for an ideal biomarker of 
TBI are expanded by Weber and Maas (2007). The authors argue that the biomarker 
should originate in the central nervous system with no contribution from 
extracerebral sources, release from damaged neurons or glial cells, and express an 
unlimited passage through the blood-brain barrier. 
Understanding the role of the blood brain barrier and its functional status in 
secondary pathologies is crucial to establishing biomarkers for TBI. Unfortunately, 
current imaging techniques lack the resolution that is necessary to accurately 
determine the functional status and integrity of the blood brain barrier’s anatomical 
structure. The blood brain barrier consists of only a single layer of capillary 
endothelium that, when intact, prevents the diffusion of most water-soluble 
molecules over 500 Daltons (Da). When damaged however, brain related proteins are 
able to enter the peripheral circulation (Blyth et al., 2009). Conversely, damage also 
permits entry of blood-borne materials into the brain. The intrusion of these materials 
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into the brain has been linked with increased intracranial pressure, and altered 
biochemical homeostasis following TBI (Dash et al., 2010). It is the detection of 
brain specific proteins in the peripheral system, rather than the opposite, that has 
attracted the focus of prognostic research. Logically, the presence and magnitude of 
any brain related protein in the peripheral system would indicate permeation of the 
blood brain barrier and thus, measuring the protein may facilitate diagnosis in an 
otherwise equivocal presentation.  
Recently, several biochemical substances have been studied to find such an 
ideal marker for indicating brain cell damage, however, the associated research has 
commonly shown that these markers both lack specificity and fail to provide reliable 
information for the diagnosis and treatment of TBI (Rainey, Lesko, Sacho, Lecky & 
Childs, 2009). This view is supported by Ucar, Baykal, Akyuz, Dosemeci and Toptas 
(2004) and Raabe et al. (2003) who add that lactic dehydrogenase, creatine kinase-
BB isoenzyme, neuron-specific enolase, and myelin basic protein have yet to prove 
their utility as biomarkers of TBI. However, Hergenroeder et al. (2008) suggest that 
these biomarkers can provide indications for secondary pathologies that are often 
associated with TBI, such as intracranial pressure.  
At present, there is insufficient clinical research to support biomarkers being 
used in a diagnostic framework to distinguish focal and diffuse injury (Yokobori et 
al., 2013). Calcagnile et al. (2013) add that identification of any brain specific 
biomarker for acute and chronic secondary pathologies could result in earlier 
diagnoses and improved accuracy of prognoses. Further, potential exists for 
biomarkers being used to select between targeted neurochemical interventions in 
order to treat damage to neurocellular networks (Papa et al., 2013). For this reason, 
prognostic biomarkers can potentially have a twofold purpose in the context of TBI – 
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namely, to predict recovery, and to stratify the risk for specific secondary pathologies 
(Di Battista, Rhind, & Baker, 2013). 
The current direction of TBI biomarker research has focussed towards the 
investigation of the S100 calcium binding protein B (S100B) (Ucar et al., 2004), as it 
has been shown to fulfil the criteria of an ideal brain damage biomarker (Korfias et 
al., 2006). In fact, Hergenroeder et al. (2008) state that S100B is now the most 
studied TBI biomarker to date and research into this protein is many years ahead of 
the work with other biomarkers. Primarily, S100B has been researched to determine 
a critical concentration level for indicating brain death following injury (Regner, 
Kaufman, Friedman & Chemale, 2001), and to signify the presence of post-traumatic 
lesions (Biberthaler et al., 2006). Under these clinical applications, S100B has been 
shown to be a sensitive and easily monitored biomarker for determining the 
pathophysiology of patients’ brain injuries (Savola et al., 2004). However, brain 
death and the lesions following TBI are dichotomous outcomes, and not 
representative of the majority of TBI prognoses.  As such, there exists a need to 
investigate the utility of S100B in prognosticating specific recovery outcomes that 
are dimensional in nature, and of concern for the sequelae experienced by survivors 
of TBI. More specifically, Sharma and Laskowitz (2012) opine that a truly effective 
biomarker of TBI would provide clinical information regarding cerebral responses to 
acute interventions, and identify patients at risk of developing long-term 
neuropsychological impairment following their injury. 
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4.2 S100 Calcium Binding Protein B (S100B) 
The S100 proteins were first identified by Moore (1965). The name of the 
protein arrangement is derived from its solubility in ammonium sulphate, which is at 
100% at a neutral pH (Fillipidis, Papadapoulos, Kapasalaki, & Fountas, 2010). The 
protein is composed of two subtypes, alpha and beta (or A and B). The alpha subtype 
is found in striated muscles such as the heart and kidneys, whereas the B subtype is 
found in high concentrations in astroglia. S100B is a calcium-binding protein that is 
produced by Schwann and glial cells (Biberthaler et al., 2001; Kleindeist & Bullock, 
2006) – however, it can also be found in small traces in several non-neuronal cells 
such as adipocytes (fat cells), chondrocytes (cartilage cells), skin, and glioblastoma 
and melanoma cells (Yokobori et al., 2013). Despite its expression in these 
extracranial sources, research conducted by Pham et al. (2010) clearly illustrated that 
changes in serum levels of S100B post TBI are dictated solely by extravasation 
across the damaged blood brain barrier. 
S100B has been shown to be important to the regulation of neuronal cellular 
homeostasis by exerting autocrine and paracrine functions to astrocytes and neurons 
in the brain. Astrocytes and glial cells are prevalent in the white matter and the basal 
ganglia of the brain, and the release of S100B from these sites following injury 
appears to reflect immediate cellular damage in the brain’s white matter (Sedaghat & 
Notopoulos, 2008). More specifically, the S100B protein has been shown to be 
related to the structures of the corpus callosum, the anterior forceps, and the superior 
longitudinal fasciculus. (Streitbürger et al., 2012). The S100B protein has a 
homodimeric structure, where each beta monomer is approximately 10.5 kDa in 
weight (Gonçalves et al., 2008), this structure regulates protein phosphorylation and 
is said to be fundamental to the proliferation and neurotrophy of astroglial cells 
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(Sedaghat & Notopoulos, 2008).  As such, at a cellular level, S100B has been 
implicated in the modulation of learning and memory due to the link between the 
proliferation of astroglial cells and cognitive performance (Ellis, Willoughby, Sparks 
& Chen, 2007).  
Following brain injury, S100B is hypothesised to be released from the brain 
into the bloodstream, via cerebrospinal fluid, due to permeation in the blood-brain 
barrier caused by the injury (Beers, Berger & Adelson, 2007). Ordinarily, S100B 
does not cross the intact blood-brain barrier (Hergenroeder et al., 2008), attributable 
to its molecular weight described above. Subsequently, the serum level of the S100B 
protein detected following TBI is indicative of a systemic inflammatory reaction, 
causing a decrease in the integrity of the blood-brain barrier, and more severe 
neurological disruption (Hergenroeder et al., 2008; Sedaghat & Notopoulos, 2008). 
Logically, the theory would follow that a patient’s level of serum S100B after injury 
should be inversely correlated with their outcome.  
At a microscopic level, the release of S100B to the peripheral blood stream 
following TBI is suggested to be the result of two processes. The first process 
suggests that astrocytic structural and membrane integrity is compromised as a result 
of injury related stretching. This process has been reported by electro-microscopic 
studies of stretch-injured astrocyte cultures. Inherently, increased S100B levels 
reflect the degree to which TBI related glial damage causes astrocytic reactions, also 
referred to as reactive astrogliosis (Bohmer et al., 2013). The second theorised 
process posits that the adenosine triphosphate nucleotides and glutamate amino acids 
are also released after TBI. Subsequently, the release of S100B may be partly 
attributable to astrocytic receptor activation by adenosine triphosphate and glutamate 
(Weber & Maas, 2007). As such, Michetti et al (2012) state that S100B levels are not 
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merely a consequence of cell damage, but also an indicator of secondary processes. It 
is therefore the secretion of the protein and its participation in secondary events that 
could offer pathogenic and therapeutic indications for TBI management and 
prognoses. 
The typical release pattern of S100B following TBI or ischaemic brain 
conditions involves an early peak immediately after the primary brain trauma, due to 
the increased permeability of the blood-brain barrier (Biberthaler et al., 2001; Raabe 
et al., 2003). Immediately following injury, the level of S100B in serum may rise up 
to concentrations of between 5-20µg/L. This initial high reading is attributed to 
damaged brain cells and an opening of the blood-brain barrier that only occurs in the 
first minutes after trauma (Raabe et al., 2003). The peak level of S100B in the 
peripheral system is said to remain for one to three hours post injury, before 
declining to an undetectable level (Begaz, Kyriacou, Segal & Bazarian, 2006). 
Townend et al. (2006) attribute this fall as either the closing of the blood-brain 
barrier, or the cessation of S100B production at a cellular level. Ingebrigsten, 
Waterloo, Jacobsen, Langbakk and Romner (1999) found that 45% of their sample 
population had declined to undetectable levels within six hours of their injury. 
However, Raabe et al. (2003) found that S100B can remain elevated for days if the 
patient is suffering from progressive secondary brain damage or chronic barrier 
disruption. 
As a result of the established release pattern for S100B following TBI, 
Townend et al. (2006) suggest that the timing for sampling patients’ blood is critical, 
and should be performed as early as possible following injury. Begaz et al. (2006) 
add that unless sampling is performed within three hours of injury, the potential 
utility for S100B in the emergency setting is critically compromised. Similarly, 
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Raabe et al. (2003) suggest that it is critical to know the time of the injury for 
accurate interpretation and outcome prediction. Serial-sampling research conducted 
by Woertgen, Rothoerl and Brawanski (2002) concluded that presentation levels of 
S100B, that are less than one hour post-injury, are the most reliable in correlating 
with injury severity, and suggest that future outcome researchers adopts this time-
point as the predictor variable. 
Wiesmann, Missler, Gottman and Gehring (1998) were the first researchers to 
publish findings to suggest that serum concentrations of S100B are not influenced by 
a patient’s blood-alcohol level. Vos and Verbeek (2002) attribute this finding to their 
conclusion that the astroglial compartment of the brain is not affected by alcohol 
intoxication, and resultantly, serum S100B concentrations are unaffected by alcohol 
intake. This finding has been supported by the research of Korfias et al. (2007) and 
Unden and Romner (2009). More recently, Calcagnile et al. (2013) conducted a 
prospective study of alcohol and S100B levels in 621 TBI patients. The researchers 
concluded that the presence and magnitude of alcohol had no effect on S100B levels, 
irrespective of whether the consumption was derived from patient history or from 
objective blood ethanol levels. The authors concluded that S100B can be used 
reliably in TBI regardless of intoxication. Similar conclusions were made in a 
prospective study on 107 TBI patients, using CT imaging as the dependent variable 
(Wolf et al., 2013), and also in a study that stratified 160 patients across four levels 
of intoxication (Lange, Brubacher, Iverson, Procycyshyn, & Mitrovic, 2010). Given 
that alcohol use is a significant risk factor for TBI (Lange et al., 2010) and 
approximately 35% to 50% of patients with TBI are intoxicated to some degree (Brin 
et al., 2011), all of the findings mentioned are especially pertinent to TBI biomarker 
research. Taken together, the immunity that S100B exhibits towards alcohol provides 
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additional clinical utility in the context of TBI beyond the demands of regular 
biomarker criteria. 
Further advantages of S100B as a biomarker include that it can be measured 
in the arterial and venous blood systems, it is not affected by haemolysis, and after 
collection it remains stable for several hours at room temperature without the need 
for immediate analysis or refrigeration (Korfias et al., 2007). Additionally, Unden 
and Romner (2009) suggest there may be significant cost-benefit potential should 
S100B be proven to be a true biomarker of TBI pathophysiology. Currently, the total 
cost of performing an S100B assay is 10% of the cost of performing cranial CT 
imagine and approximately 2-5% of the cost of one day of inpatient observation. 
Hergenroeder et al. (2008) add that cost savings can also be made by identifying 
appropriate management procedures for patients such as monitoring intracranial 
pressure, and referring for specific neurobehavioural and neuropsychological 
interventions. 
Gonçalves et al. (2008) note that several biochemical features of S100B are 
not well categorised, and subsequently, controversies exist regarding its clinical 
function and utility. Weber and Maas (2007) add that despite the growing body of 
evidence demonstrating an association between S100B and poor outcomes following 
TBI, researchers should be aware that proof of association is not necessarily a proof 
of causation. The implications of findings and models of causation are the current 
grounds for debate regarding serum S100B levels following TBI.  
Most commonly, debate exists as to whether S100B is neuroprotective or 
neurotrophic in its actions following TBI (De Boussard et al., 2005). Research 
conducted by Pleines et al. (2001) suggests that S100B stimulates neuronal survival 
and glial cell production – however, its upregulation of calcium binding potentially 
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contributes to post-traumatic neurotoxicity. The researchers concluded that their 
study could not determine whether S100B is detrimental or beneficial for the injured 
brain, or whether it simply reflects the severity of injury. Similarly, Kleindienst and 
Bullock (2006) found that while S100B had a neurotrophic effect on paracrine and 
neurite outgrowth in rats, administering S100B to post-injury rats actually improved 
the rats’ overall cognitive performance. Gonçalves et al. (2008) suggest that the 
dualistic view of S100B as being either “good” or “bad” simplifies clinical practice 
and delays the comprehension of the role that S100B plays in physiological 
conditions and brain disorders. 
 
4.3 S100B and TBI 
As with most biomedical science, the literature associated with S100B and 
TBI has its foundations in animal models of injury. In an exploratory rodent 
experiment, rats with S100B surgically infused into their hippocampi demonstrated 
dose-dependent increased performance in a long-term memory task, compared with 
sham control following TBI (Mello e Souza, Rohden, Meinhardt, Gonçalves, & 
Quillfeldt, 2000). Conversely, however, Winocur, Roder, and Lobaugh (2001) found 
that transgenic mice with overexpressive S100B demonstrated learning and memory 
impairment, compared to nontransgenic controls. As such, it is clear that animal 
experiments do not always reproduce the same results across studies. Feala et al. 
(2013) argue that these discrepancies are attributable to variations in species, injury 
type, and time course of sample collection. Further, the emphasis on sample size and 
statistical power is often not the same for “bench top” as opposed to “bedside” 
research (Marincola, 2003). Lastly, with specific reference to TBI, Walder et al. 
(2013) state that by contrast to animal experiments, patients with TBI have a 
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heterogeneous pattern of injury, and the different injuries sustained that result in 
different biomarkers being released make it difficult for translational associations to 
be made with clinical outcomes in human models. 
From a purely diagnostic perspective, S100B has been shown to be correlated 
with the existing classification measures of TBI. Böhmer et al. (2011) demonstrated 
that S100B levels are significantly higher in patients who have experienced a severe 
TBI, compared to healthy controls. Beyond “severe” classification, Savola et al. 
(2004) found that S100B was hierarchically correlated across mild, moderate, and 
severe classifications of TBI. The researchers added that their results indicated a high 
negative predictive power suggesting that a normal S100B level, recorded shortly 
after injury, excludes significant brain injury pathology with high accuracy. 
Similarly, S100B has been shown to differentiate concussion from superficial scalp 
injury with 94% sensitivity and 100% specificity (Matek, Vajtr, Krška, Springer, & 
Zima, 2012). Further, Vajtr et al (2012) demonstrated that S100B levels can be used 
to differentiate diffuse axonal injuries from focal injuries. 
Beyond routine classification measures, a study conducted by Korfias et al. 
(2007) found that high S100B levels were also correlated with other diagnostic 
measures such as severity of papillary status and CT examinations. In fact, a number 
of studies have investigated the relationship between S100B and diagnostic CT 
examinations, and this domain is arguably the most prolific area of translational 
S100B research. The rationale for these imaging studies is that biomarkers could be 
used to rule out TBI, allow better use of triage resources, save on operational costs, 
and avoid exposing patients to unnecessary radiation from imaging (Mercier et al., 
2013). 
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Using the Marshal CT classification system (Marshal et al., 1992), Herrmann 
et al. (2001) found that S100B levels were significantly correlated with CT severity 
in a cohort of TBI patients. Further, by comparing CT scans of 60 TBI patients in 
which two thirds had “positive” CTs (i.e., a remarkable pathology), Cervellin et al. 
(2012) found that S100B levels were significantly higher in the CT positive group. 
The researchers demonstrated that S100B levels indicated positive CT results with 
100% sensitivity and 58% specificity. Similarly, using only mild TBI patients, 
studies conducted by Morochovič et al. (2009) and Bazarian et al. (2013) which 
respectively found that S100B levels indicated abnormal (positive) CT scans with 
90% and 83% sensitivity, and 34% and 30% specificity.  
As mentioned earlier in the discussion of TBI diagnosis, the current gold 
standard measurement of blood brain integrity involves calculating a ratio-quotient 
between albumin levels found in cerebrospinal fluid and peripheral serum. A study 
by Blyth et al. (2009) found that serum S100B levels held a significant relationship 
with albumin quotient levels. Further, the study showed that S100B could classify 
abnormal albumin quotient values with 80% sensitivity and 90% specificity. The 
researchers concluded that serum S100B elevations were therefore not only 
indicative of physical blood brain barrier disruption, but also of deranged osmotic 
functioning of the barrier following TBI. 
S100B has also been found to be correlated with secondary pathologies such 
as increased intracranial pressure, cerebral hypoxia, and intracranial haemorrhage. 
Research conducted by Petzold et al. (2002) illustrated that S100B is a sensitive 
biomarker for the development of elevated intracranial pressure, and suggest that it 
could be used as an indicator for follow up CT for patients who may have been 
discharged as a result of “mild” classification, in order to mitigate risk of increased 
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intracranial pressure. These results were replicated by studies conducted by Nylen et 
al. (2008) and Muller et al. (2007). Muller et al.’s discussion cautioned, however, 
that S100B should not entirely replace clinical examination or CT for patients with 
head injury who have suspected increased intracranial pressure. Beyond intracranial 
pressure, Stein et al. (2012) found that serum S100B levels were a highly specific, 
yet insensitive, indicator of cerebral hypoxia. The researchers conclude that despite 
only modest associations, the finding that S100B is detectable prior to the onset of 
cerebral hypoxia is important for the prediction of impending pathological events. 
Further, Wolf et al. (2013) demonstrated that S100B was able to identify future 
intracranial haemorrhage – however, the authors do not support the use of 
biomarkers in isolation to make such a diagnosis.  
As demonstrated by the diagnostic literature reviewed above, S100B 
possesses clinical utility in diagnosing and differentiating TBI, identifying secondary 
pathologies, and stratifying the severity of the patient’s injury. It is important to note, 
however, that the severity classification of an individual’s TBI does not necessarily 
equate to the severity of their future impairment – in short, diagnosis does not equal 
prognosis. 
For all TBI patients admitted to hospital, an unfavourable prognosis such as 
death, persistent vegetative state, or chronic severe disability could be the case for 
over 20% of these presentations (Egea-Guerrero, Murillo-Cabezas, & León-Carrión, 
2013). Further, TBIs are among the most common cause of violent deaths, and are 
commonplace following violent assaults (Ondrushka et al., 2013). As such the utility 
of S100B in medico-legal and forensic settings is an emerging research area in the 
associated prognostic literature. One such application is the potential role that S100B 
could facilitate in objectively determining the presence of TBI, either accidental or 
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abusive, in children and babies. Due to these patients presenting with non-specific 
symptoms, and often, the inability to communicate the aetiology of their injury, a 
minimally invasive serum biomarker could be used to rule out TBI pathology (Papa 
et al., 2013).  
A second medico-legal application for S100B as a biomarker for TBI relates 
to its use in prognosing brain death, and thus, facilitating decision-making related to 
organ transplants. Unfortunately, the number of organ donors in developed countries 
has progressively declined despite recent improvements in the process of organ 
donation and transplants. In order to identify potential organ donors, transplant teams 
require strict, efficient indicators of irreversible vegetative coma. Regression 
analyses conducted by Dimopoulou et al. (2003) found serum S100B to be an 
independent and highly predictive biomarker for trauma-induced brain death. 
Further, odds ratio analyses indicated that for every 1μg/L of S100B detected on 
admission, the probability for deteriorating to brain death more than doubles. 
Similarly, Raabe et al. (2003) found that serum S100B values that are greater than 
2μg/L present a high likelihood for a brain death diagnosis. More recently, Egea-
Guerrero et al. (2013) suggest that S100B could be used to detect patients at risk of 
brain death, and to identify them as potential donors. The authors studied 140 
survivors of severe TBI (based on GCS) and found that the 16 patients who 
developed brain death had significantly higher S100B concentrations, and that by 
using a cut-off of .37 μg/L, brain death was prognosed with 85.7% sensitivity and 
73.9% specificity.  
Egea-Guerrero et al.’s (2013) finding is supported by the earlier results of 
Böhmer et al. (2011) who found that the CSF levels of S100B taken between four 
and seven days post injury in people who died from TBI (n=5) where significantly 
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higher than those who survived their injuries (n=15). These findings have some 
inherent implications for the management of life-support for TBI patients. As 
mentioned previously, many TBI patients are young and often have no prior 
morbidity – as such the decision to withdraw life sustaining treatment needs to be 
based on sound prognostic modelling of survival likelihood (Mercier et al., 2013). 
With reference to post-mortem confirmation of TBI, Ondrushka et al. (2013) 
found that S100B is useful in characterising cause of death and survival time at 
forensic autopsy. The researchers found that both serum and CSF levels of S100B 
were significantly elevated in autopsy cases where TBI was known to be the explicit 
cause of death. Further, it was reported that serum levels of S100B were significantly 
inversely correlated with survival time following fatal head injuries. The researchers 
concluded that common autopsy practice could potentially incorporate forensic 
biochemistry in the event of controversial and equivocal TBI.  
 A number of studies have elucidated the role of the S100B protein where 
mortality is the dependent variable following TBI. A meta-analysis conducted by 
Mercier et al. (2013) found that, across six studies, a significant positive correlation 
exists between S100B concentrations and mortality in patients who had sustained 
moderate or severe TBIs. The researchers found that for mortality, serum threshold 
values of >3.0 μg/L yielded a specificity of 97%, however the sensitivity at this 
threshold was only 39%. It was concluded that the capacity for the S100B in the 
prediction of mortality in TBI patients offers potential utility as part of the decision 
making process in critical care. They add that there is potential for the biomarker to 
assist in situations where decisions about level of care are limited in their 
probabilistic expectations for the patient’s prognosis. 
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 Rodriguez- Rodriguez et al. (2012) conducted receiver operator 
characteristics of serum S100B levels as a predictor of mortality following severe 
TBI. Their analyses indicated that in a purely “severe” population (N=55), by using a 
cut-off of .46 μg/L, sensitivity in predicting mortality was 90% with a specificity of 
88.4%. The authors firmly conclude that serum S100B is a sensitive and effective 
biomarker for the early prediction of mortality following severe TBI. Likewise, as a 
by-product of their severity prognostic research outline above, Böhmer et al. (2011) 
reported that S100B levels were higher in patients that died during their study 
compared with those that survived. Though not the aim of their study, the researchers 
suggest that a role may exist for the S100B to be utilised in the prediction of 
potential fatality. 
 Beyond mortality outcomes, S100B has been investigated in relation to 
functional outcome for survivors of TBI. In this arm of S100B research, the Glasgow 
Outcome Scale (GOS; Jennett & Bond, 1975) or the extended version of the scale 
(GOS-E; Wilson, Pettigrew, & Teasdale, 1998) are by far the most often used 
measures of outcome. The GOS is a five-point ordinal scale that is completed by the 
clinician at the follow up consultation. The five outcome values, as determined by 
the GOS are: 1. Dead; 2. Vegetative State (meaning the patient is unresponsive, but 
alive); 3. Severely Disabled (conscious but the patient requires others for daily 
support due to disability); 4. Moderately Disabled (the patient is independent but 
disabled); and 5. Good Recovery (the patient has resumed most normal activities but 
may have minor residual problems). The GOS-E, however, is an eight-point ordinal 
scale whereby the Severely Disabled, Moderate Recovery, and Good Recovery 
outcome points are stratified into lower and upper bands.  
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Utilising the GOS-E at one month post-injury, Townend et al. (2002) reported 
that when adopting 0.48μg/L as a cut-off for “elevated,” patients with elevated levels 
of serum S100B had a significantly less favourable outcome one month after injury 
compared to patients who did not have elevated levels of serum S100B. Further, 
admission S100B levels have been shown to have an inverse relationship with GOS-
E outcome at three months (Kleindienst et al. 2010; Walder et al. 2013)) and six 
months (Raabe & Seifert, 2000) post injury. By comparison to other acute 
management measures, studies conducted by Woertgen et al. (2002), Nylen et al. 
(2008), and Wiesmann et al. (2010) all reported that serum S100B concentrations 
showed a higher correlation to GOS outcome than CT and GCS scores. Similarly, 
Vos et al. (2010) reported that S100B levels were a stronger predictor of 
unfavourable outcome at six months post injury than pupillary reactions and GCS 
score. The researchers conclude by advocating for biomarkers as adjunct procedures 
to the assessment and management of brain damage after TBI, and speculating that 
they may enhance prognostic accuracy for clinical outcome variables. 
Woertgen et al. (2002) caution that because of its simplicity, the GOS and the 
GOS-E are considerably non-specific, non-dimensional, and controversial. Di 
Battista et al. (2013) add that the utility of these scales as dependent variables in 
outcome research should be questioned, attributable to their limited application for 
specific clinical symptoms, and their potential for subjective interpretation. 
Moreover, it could be argued that the unique dimensionality of TBI patients and their 
outcomes cannot be accurately captured by a seven-point scale. Nevertheless, the 
GOS and GOS-E do constitute measures of outcome and contribute to top-down 
theories for biomarker prognoses.  
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4.4 S100B and Neuropsychological Outcome 
By stark contrast to the mortality and GOS/GOS-E studies outlined above, 
relatively little research has been conducted into neuropsychological outcomes 
following TBI (Watt, Shores, Baguley, Dorsch, & Fearnside, 2006). Inherently, 
rather than the conventional measures of TBI outcome such as mortality, brain death, 
and crude ordinal functional impairment, there exists a need for neuropsychological 
dependent variables to be incorporated into prognostic TBI research, such as 
cognitive impairment, post-concussion syndrome symptom identification, and 
deficits in quality of life. Pioneering research conducted by Waterloo, Ingebrigsten 
and Romner (1997) found that S100B levels were significantly inversely correlated 
with performances on computerised tests of attention, concentration, and speed of 
information processing. Although the study’s sample size was only seven and the 
participants had only had “mild” TBIs, the researchers concluded that further 
research should be conducted to investigate the prognostic merit of S100B for 
disordered neuropsychological functioning.  
Similarly to Waterloo et al (1997), Hermann et al (2001) recruited solely mild 
TBI patients for their study. The research design involved administering a battery of 
neuropsychological tests six months after TBI. The study found that serum levels of 
S100B on admission were strongly correlated with poor performance on measures of 
attention, discrimination, and memory. Despite clear correlations, however, Hermann 
et al.’s study had a very small sample size of 39, and used measures of 
neuropsychological functioning that are somewhat antiquated by today’s standards. 
Similarly, using an Australian sample of 23 severe TBI patients, Watt et al. (2006) 
investigated the ability of S100B to predict the extent of neuropsychological 
impairment following injury. Participants were subjected to a neuropsychological 
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battery following their injury, however unlike Hermann et al.’s study, participants 
were given this battery within two weeks of emerging from post-traumatic amnesia. 
Watt et al.’s battery involved the administration of a full WAIS-R (Wechsler, 1981), 
as well as assessments of auditory learning memory, verbal fluency, attention, 
concentration, and speed of information processing. The researchers suggest that 
their results indicate that post-traumatic serum concentrations of S100B not only 
reflect brain injury severity, but also relate to deficits in neuropsychological 
functioning.  
In reviewing Watt et al.’s findings, it is important to note that the conclusions 
generated by the study are applicable to the immediate outcome of TBI. However, as 
mentioned earlier in this review, the most variability in TBI patients’ 
neuropsychological outcome is across the first six months of post-injury recovery. 
Further, their study utilised a control group in order to investigate between-group 
differences in functioning, rather than examining magnitude of impairment at an 
individual level. As such, methodological manipulations are indicated for researching 
cognitive impairment following TBI in order to more fully elucidate the prognostic 
utility of a proposed independent variable. With reference to dependent variables, it 
is pertinent to ensure that neuropsychological consultation is short and uses a 
minimum number of simple measurement instruments (Van Baalen et al., 2006). 
Beyond direct assessments of cognitive functioning, other instruments have 
been utilised for investigating S100B and neuropsychological outcome. The 
Rivermead Post-Concussion Symptoms Questionnaire (RPQ; King, Crawford, 
Wenden & Wade 1995) is an instrument that is often used to measure the presence of 
PCS-related symptoms, with persistence and severity compared to before the injury. 
Savola and Hillborn (2003) found that levels of serum S100B were correlated with 
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RPQ scores at two and six weeks following injury. Likewise, Begaz et al. (2006) 
showed that patients who have suffered a mild TBI exhibit a correlation between 
levels of serum S100B, and sub-acute identification with symptoms of post-
concussion syndrome. Beyond the acute stage, Bazarian, Blyth, Zemlan and Stigman 
(2006) reported that serum S100B levels were correlated with RPQ scores at three 
months post-injury. Conversely, in a paediatric study, S100B did not predict which 
children who had sustained a TBI would develop PCS or the severity of their 
symptoms (Babcock, Byczkowski, Wade, Ho, & Bazarian, 2013).   
In an investigation of symptom identification, Sojka, Stålnacke, Björnstig and 
Karlsson (2006) found an association between serum levels of S100B and a number 
of symptoms related to stress disorders. Somatically, Kondziolka (2013) reported 
that TBI patients with higher levels of S100B more often complained of nausea and 
vomiting. From an organisational and rehabilitative perspective, Stranjalis et al. 
(2004) found that probability for returning to work following mild head injury was 
inversely correlated with levels of S100B. More recently, Egea-Guerrero et al. 
(2013) reported that serum S100B levels were correlated with time taken to return to 
work, and the reappearance of residual somatic symptoms six months post injury. 
The authors highlight the potential utility of the biomarker to be used in predicting 
the development of long-term sequelae for TBI patients’ quality of life. 
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Chapter 5 
Rationale for the Current Research 
 The aim of the present thesis was to investigate the prognostic utility for 
serum S100B following TBI, with specific emphasis on neuropsychological 
functioning as the definable outcomes. Using a large prospective sample of TBI 
patients, across each classification of severity, this longitudinal population study 
aimed to examine the relationships that exist between S100B and current acute 
measures of TBI severity. Further, this thesis aimed to elucidate the ability for S100B 
to make prognoses for duration of post-traumatic amnesia, severity of cognitive 
impairment, presence of symptoms of post-concussion syndrome, and deficits in 
domains that are associated with quality of life.  
In Study One, this thesis aimed to identify potential relationships between 
serum levels of S100B and the current acute measures for classifying TBI severity – 
namely the GCS, and the WPTA. Further, Study One aimed to quantify the accuracy 
that S100B holds in prognosing duration of post-traumatic amnesia as measured by 
the WPTA, and whether this prognostic accuracy is superior to that of GCS scores. 
In Study Two, this thesis aimed to quantify the variability demonstrated in cognitive 
impairment at two months post TBI and the ability for S100B to prognose such 
impairment. Rather than using between-group comparisons with healthy controls, 
Study Two defined impairment as the magnitude of discrepancy between post-injury 
functioning and quantified estimates of premorbid functioning. Lastly, in Study 
Three, this thesis aimed to examine deficits in domains of quality of life and the 
severity of post-concussion syndrome symptomatology at six months post injury, and 
to investigate the ability for S100B to prognose such deficit and symptom severity. 
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Chapter 6 
Study One: Serum S100B and Existing Diagnostic Variables (T0) 
6.1 Aims and Hypotheses 
The focus of Study One: T0 was on the diagnosis and management of TBI 
immediately following injury (i.e., 0 days post TBI). In this context, Study One 
aimed to investigate the diagnostic, categorical, and operational utility of a single 
collection of serum S100B, collected as soon as possible following injury. To 
elucidate this utility, Study One aimed to identify potential relationships between 
serum levels of S100B and the current acute measures for classifying TBI severity – 
namely the Glasgow Coma Scale, and the Westmead Post-Traumatic Amnesia Scale.  
With an emphasis on prognostic utility, Study One further aimed to quantify 
the accuracy that S100B holds in predicting duration of post-traumatic amnesia as 
measured by the WPTA and whether this prognostic accuracy is superior to that of 
GCS scores. In short, the aim was to quantify whether the number of days that a 
patient will spend in post-traumatic amnesia can be predicted from their acute 
presentation. 
As discussed in the preceding literature review, the presence of S100B has 
been shown to discriminate TBI from non-TBI patients (Bohmer et al., 2011; Matek 
et al., 2012), and also to discriminate severity of injury within TBI populations, as 
measured by the GCS (Naeimi et al., 2006; Savola et al., 2004). Serum S100B levels 
have also found to be significantly higher in patients who deteriorate to brain death 
compared to those who do not (Dimopolou et al., 2003). A number of imaging 
studies have also found a relationship between serum levels of S100B and the 
presence of secondary pathologies following injury (Bazarian et al., 2013; Cervellin 
et al., 2012; Herrman et al., 2001; Morochovic et al., 2009).  
50 
 
Beyond injury presence and severity, the literature has shown a significant 
inverse relationship between serum levels of S100B immediately after injury, and 
depth of coma as measured by the GCS (Herrmann et al., 2001; Korfias et al., 2007; 
Watt et al., 2006). Further, Watt et al. (2006) reported a strong positive relationship 
between S100B and duration of post-traumatic amnesia as measured by the WPTA. 
Based on the associated literature, the hypotheses for Study One: T0 were: 
H1: S100B levels would be significantly negatively correlated with GCS scores, 
i.e., the deeper the coma, the higher the level of S100B. 
H2: S100B levels would be significantly positively correlated with WPTA scores, 
i.e., the higher the level of S100B, the longer the patient will experience post-
traumatic amnesia. 
H3: As per H2, the relationship between S100B and WPTA would be such that 
length of WPTA can be algorithmically predicted by serum levels of S100B. 
 
6.2 Method 
6.2.1 Participants 
 Adult patients who presented to the Royal Hobart Hospital following a TBI 
were approached to participate in this study. Participants were provided with an 
information sheet for the study and a participant consent form. When patient consent 
was not possible due to coma or sedation, consent was sought from the patients’ next 
of kin. The patient’s information sheet, patient’s consent form, relative’s information 
sheet, and relatives consent form used in this study can be found in Appendix B. No 
participants received payment for participation in this study. 
In total, 127 adult TBI patients were recruited as participants for this study. 
The participant pool consisted of 96 (75.59%) males and 31 (24.41%) females. The 
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age range for participant recruitment was 18 ≤ 80, and the mean age of the 
participants was 41.23 years with a standard deviation of 16.66 years. The sex and 
age ratios in this study are consistent with Australian population epidemiology 
estimations (Fortune & Wen, 1999). 
This study approached all patients presenting with TBI to participate, and as 
such, various aetiologies of injury were evident within the participant pool. Table 6.1 
below displays the TBI aetiologies of the study’s participants. 
 
Table 6.1 
Aetiologies of Injury within the Participants 
Mechanism   n Percentage 
Motor vehicle accident  42 33.07% 
Fall from height   23 18.11% 
Assault    18 14.17% 
Motorbike accident  12 9.45% 
Mechanical fall   9 7.09% 
Falling object   5 3.94% 
Pedestrian versus car  4 3.15% 
Horse riding injury  4 3.15% 
Bicycle accident   3 2.36% 
Quadbike accident  3 2.36% 
Sports injury   2 1.57% 
Skateboard   1 0.79% 
Projectile   1 0.79% 
Note. N = 127 
 
Participants who had a blood sample taken immediately following their 
injury, received a GCS score on admission, and received WPTA testing during their 
admission (greater than one day) were included in analysis at the T0 time point.  
From the initial participant pool of 127 TBI patients, 79 participants met the 
inclusion criteria for the T0 time point. Table 6.2 displays the severity categorisation 
frequencies (as defined by Jennett and Teasdale, 1981) on the GCS and WPTA for 
the T0 participants. 
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Table 6.2 
Severity Categorisation Frequencies for Glasgow Coma Scale and Westmead Post-Traumatic Amnesia 
Scale 
Glasgow Coma Scale    Definition  Frequency 
Mild      GCS = 13<15  55 (69.62%) 
Moderate     GCS = 9<12  7 (8.86%) 
Severe      GCS = 3<8  17(21.52%) 
Westmead Post-Traumatic Amnesia Scale  Definition  Frequency 
Severe      WPTA = 1 to 7 days 39 (49.37%) 
Very Severe     WPTA = 8 days +  40 (50.63%) 
Note. N = 79.  
 
6.2.2 Materials 
6.2.2.1 Serum S100 Calcium Binding Protein B (S100B) Assay 
 Following injury, blood tests are performed on patients as part of routine 
acute medical management of TBI. For the participants of this study, S100B assay 
analyses were conducted on serum aliquots taken from blood samples taken as early 
as possible after injury. The post-injury sample time for this study’s population had a 
mean of 2.8 hours, and a standard deviation of 3.4 hours. 
 Serum samples were analysed using commercially available LIASON® S100 
assay kits. This kit is a two-step quantitative chemiluminescence sandwich 
immunoassay which uses directly coated magnetic particles and an isoluminol 
derivative. Blood samples taken from patients were centrifuged at 800-1000 rotations 
per minute for 10 minutes. Aliquots were taken from the resulting separated serum 
and frozen at -20° Celsius for analysis at a later date. Batch analyses of all collected 
samples were then conducted prior to the oldest samples becoming six months post 
injury.  
The S100B assays performed in this study were conducted on a commercially 
available LIAISON
®
 S100 analyser kit, following a two-site chemiluminescent 
immunoassay (CLIA) procedure. The LIAISON
®
 S100 analyser kit is stable at 2-8° 
Celsius until its expiry date and can be used for up to two weeks after being opened. 
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The minimum sample volume required for detection of S100B determination is 
100μL, and the procedure is capable of detecting S100B concentrations of between 
.02μg/L to 30μg/L.  
The LIAISON
®
 S100 assay manual cites that 95 percent of healthy 
individuals have serum S100B levels <.15μg/L. Assay analyses were conducted on 
samples taken from 15 non-TBI controls (serum samples from hospital presentations 
with confirmed non-TBI). The non-TBI controls in this study had a mean of 
0.097μg/L, and a standard deviation of .052μg/L, and the participants’ mean S100B 
level was 3.17μg/L, with a standard deviation of 5.72μg/L. 
All S100B analyses in this study were conducted by an independently hired 
medical scientist at the Royal Hobart Hospital department of pathology who was 
blinded to the names of the participants and the nature of their injuries. 
 
6.2.2.2 The Glasgow Coma Scale (GCS) 
The GCS (Teasdale and Jennett, 1974) is a brief objective rating scale that is 
used to assess a patient’s level of consciousness. Following injury, the evaluator tests 
the patient’s response to three domains, namely: eye opening (scale of 1-4); verbal 
communication (scale of 1-5); and, motor response to pain (scale of 1-6).  A GCS 
total score is the sum of the highest score in each of the three domains. As such, GCS 
total scores range from 3 to 15. Table 6.3 displays the scoring criteria for each of the 
GCS domains. 
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Table 6.3 
Scoring Criteria for the Glasgow Coma Scale 
Eye   Patient Response     Score 
Does not open eyes    1 
Opens eyes to pain (e.g., when pinched)  2 
Opens eyes when asked    3 
   Opens eyes normally    4 
Verbal   Patient Response     Score 
   Makes no noise     1 
   Unintelligible noise (e.g., groans)   2 
   Nonsensical speech    3 
   Coherent speech, yet confused/disoriented  4 
   Oriented, correct conversation   5 
Motor   Patient Response     Score 
   No motor response to pain   1 
   Extension (extensor posturing) to pain  2 
   Abnormal flexion (flexor posturing) to pain  3 
   Withdraws/pulls away from pain   4 
Localisation to pain    5 
   Follows simple motor commands   6 
 
 
Following TBI, the severity of a patient’s depth of consciousness is classified 
based on their GCS total score as being Mild (GCS: 15 ≥ 13), Moderate (GCS: 12 ≥ 
9), or Severe (GCS: ≤ 8). Patients’ level of consciousness is routinely monitored 
across triage and admission to quantify recovery of consciousness. For this study’s 
analyses, each patient’s earliest recorded GCS total score is used. These evaluations 
are often conducted on scene by ambulance officers, prior to the patient’s hospital 
admission. The GCS protocol can be found in Appendix C. 
 
6.2.2.3 Westmead Post-Traumatic Amnesia Scale (WPTA) 
 The WPTA (Marosszesky, Ryan, Shores, Batchelor, and Marosszesky, 1997) 
is a standardised scale that is regularly used in inpatient settings to objectively 
measure post-traumatic amnesia following TBI. In this context, post-traumatic 
amnesia is operationally defined as the period of time where new memories are not 
consolidated, and not merely the time between the injury and the patient’s first 
subjectively recalled memory. Administration of the WPTA involves asking the 
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patient seven orientation questions followed by five recognition/memory questions. 
The questions for the WPTA are displayed below in Table 6.4. 
 
Table 6.4 
Administered Questions for the Westmead Post-Traumatic Amnesia Scale 
Item  Question 
1  How old are you? 
2  What is your date of birth? 
3  What month are we in? 
4  What time of day is it? (morning, afternoon, or night) 
5  What day of the week is it? 
6  What year are we in? 
7  What is the name of this place? 
8  Have you seen my face before? 
9  What is my name? 
10, 11, & 12 What were the three pictures that I showed you yesterday? 
 
 
A patient is said to be out of post-traumatic amnesia if they can achieve a 
perfect score on the WPTA Scale for three consecutive days. Post-traumatic amnesia 
is deemed to have ended on the first of the three consecutive days of perfect recall.  
As per the WPTA protocol, the first day of perfect recall is used for this study’s 
analyses. The severity of a patient’s post-traumatic amnesia is classified based on 
their WPTA score as being Moderate (WPTA: < 1 days), Severe (WPTA: 1 ≤ 7 
days), and Very Severe (WPTA: > 8 days). The WPTA protocol can be found in 
Appendix C. 
 
6.2.3 Procedure 
 This study received Medical Ethics Approval by the Tasmanian Health and 
Human Research Ethics Committee (Ref. No H0010420; Appendix A).  
 Ambulance reports (contained in each patient’s medical records) were 
reviewed to record time of injury. For this study, the “call received” time noted on 
the ambulance report was used as the quantifiable approximation of actual time of 
injury.  
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In study one (T0), aliquots of serum were taken from participants’ earliest 
blood sample that had been collected during routine medical care, and the time of 
blood collection was recorded to quantify the collection time post-injury. Batch 
(group) analyses of patient aliquots were performed to determine serum S100B levels 
for each participant. 
GCS scores for each participant were recorded from their first evaluation 
post-injury. As mentioned in the Materials section, these initial GCS evaluations 
were often conducted on scene by ambulance officers prior to the patient’s admission 
to hospital. 
WPTA scores were collected from review of participants’ medical records. 
As WPTA screenings are regularly conducted as part of inpatient management of 
TBI, these evaluations were not conducted by the present researcher – rather, they 
were undertaken by occupational therapists and nurses involved in the patient’s care. 
 
6.2.4 Design and Analyses 
Patients’ S100B values and depth of coma (as measured by the GCS) 
constituted the independent variables, and duration of post-traumatic amnesia (as 
measured by the WPTA) constituted the dependent variable. Two-tailed bivariate 
correlations with Pearson coefficients were conducted to explore interrelationships 
between S100B and the existing diagnostic variables (GCS and WPTA).  
The ability for S100B to predict duration of post-traumatic amnesia was 
examined using robust linear regression, and subsequent regressions investigated 
whether the proportion of variance accounted for could be improved by including 
GCS scores in the model. Jarque-Bera analyses were conducted on the skewness and 
kurtosis of each model to test for normality of distribution, and Breusch-Pagan 
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heteroscedasticity analyses were conducted on each model to investigate whether the 
variance (actual versus predicted) in the residuals were dependent on the value of the 
dependent variable (duration of PTA).  
Diagnostic and agreement statistics were then conducted to compare the 
respective sensitivity and specificity of S100B and GCS in identifying future “Very 
Severe” PTA (as classified by the WPTA), and Receiver Operating Characteristics 
were conducted to determine the area under the curve (AUC) for each independent 
variable as an indicator of “Very Severe” PTA. 
 
6.2.5 Statistical Software and Manipulations 
6.2.5.1 Correlations and Multiple Linear Regressions  
Correlation and regression analyses were conducted utilising SPSS
®
 Version 
21 (IBM Corp., 2012). Further, this software was used to generate predicted values 
and residuals for each regression equation. Descriptive analyses were conducted to 
derive the skewness and kurtosis of the residuals for each equation in order to 
facilitate Jarque-Bera tests for normality. 
 
6.2.5.2 Tests for Normality 
Jarque-Bera tests for normality were computed by authoring formulas in 
Excel
 
2010 (Microsoft, 2010) for each equation. χ2 analyses were then conducted on 
the resulting Jarque-Bera values. The algorithm used for deriving Jarque-Bera values 
is depicted below in Equation 6.1, whereby n is the number of observations and S 
and K are the skewness and kurtosis of the residuals for the given equation. 
 
JB = n x (S
2
/6 + K
2
/24)       (Eq. 6.1) 
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6.2.5.3 Regression Equation Outliers 
For each regression equation, outliers were removed by satisfying two criteria 
for case removal. First, as per Tabachnick and Fidell (2013), any cases that had a 
standardised residual value of more than 3.3 or less than -3.3 were identified as an 
outlier. Secondly, as per Field (2013), leverage values were calculated to determine 
the influence of each case’s outcome on the model, and cases were identified as 
outliers if the leverage value was greater than 3(k+1)/n whereby k is the number of 
predictors and n is the number of observations. Only cases that were identified as 
outliers by both methodologies were excluded from analysis. 
 
6.2.5.4 Heteroscedasticity 
Breusch-Pagan tests for heteroscedasticity were conducted using SPSS
®
 
Version 21 to calculate the squared residuals, and then to compute a variable equal to 
the squared residual divided by the sum of the squared residuals, divided by the 
number of observations. Regression analyses were then conducted using the 
computed variable against the predicted values. The sum of squares resulting from 
these regression equations were then entered into Excel 2010 formulas to derive 
Breusch-Pagan values, and to conduct post-hoc χ2 analyses of the Breusch-Pagan 
value to determine statistical significance.  
  
6.2.5.5 Robust Regression Analyses 
For any equations that tested as significant for heteroscedasticity, post hoc 
robust regression analyses (using a macro authored by Hayes & Cai, 2007) were 
conducted in SPSS
®
 Version 21 to determine the significance of the coefficients to 
the adjusted standard errors. 
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6.2.5.6 Receiver Operating Characteristics and Diagnostic and Agreement Statistics 
SPSS
®
 Version 21 was used to conduct Receiver Operating Characteristics in 
order to determine the area under the curve (AUC) for each independent variable as 
an indicator (or criterion) for any classification. Cut-off points were determined for 
each independent variable to facilitate respective Diagnostic and Agreement 
statistical analyses. Diagnostic and Agreement statistics reported in this study were 
conducted using DAG_Stat (Mackinnon, 2000), which is a freely available Excel 
worksheet used to determine statistical sensitivity and specificity. Positive- and 
Negative-Predictive Values were not calculated, as empirically-derived base-rates for 
each classification (or condition) could not be determined. 
 
6.3 Results 
6.3.1 Classifications and Diagnostic Correlations 
The participants classified as having “Moderate” and “Severe” GCS scores 
had significantly higher S100B levels than those classified as “Mild,” t(24.501) = 
2.739, p <  .01, and the participants classified as having “Severe” GCS scores had 
significantly higher S100B levels than those classified as “Mild” and “Moderate” 
t(17.612) = 2.679, p < .05. Two-tailed Pearson’s correlations were conducted 
between serum S100B levels, depth of coma (GCS), and duration of post-traumatic 
amnesia (WPTA). As displayed in Table 6.5, serum S100B levels were significantly 
correlated with depth of coma (GCS) and duration of post-traumatic amnesia 
(WPTA).  
Table 6.5 
Correlations between Serum S100B, Glasgow Coma Scale, and Westmead Post-Traumatic Amnesia 
  S100B   GCS   WPTA 
S100B  -   -.419**   .415** 
GCS  -   -   -.550** 
WPTA  -    -   - 
Note. ** p < .01, two-tailed; N = 79. 
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6.3.2 Predicting Duration of Post-Traumatic Amnesia 
Following removal of three outlier cases, serum S100B levels significantly 
predicted duration of post-traumatic amnesia as measured by the WPTA, R
2
 = .361, 
F(1, 75) = 41.845, p < .001. The Jarque-Bera test for normality of the first model 
was not significant χ2(2, N=76) = 5.150, p=.076, and the algorithm for this model is 
presented in Equation 6.2. 
  
 WPTA = (S100B x 1.627) + 8.363      (Eq. 6.2) 
 
Depth of coma as measured by the Glasgow Coma Scale was added to this 
equation as an additional independent variable. Depth of coma significantly added to 
the variance accounted for by Equation 6.2, R
2
 = .474, ΔR2 = .113 F(2, 75) = 32.955, 
p < .001. The Jarque-Bera test for normality of the second model was significant 
χ2(2, N=76) = 10.447, p < .001, and the algorithm for this model is presented in 
Equation 6.3. 
  
WPTA = (S100B x 1.188) + (GCS x -1.302) + 25.420    (Eq. 6.3) 
 
6.3.3 Heteroscedasticity of T0 Regression Models 
Breusch-Pagan heteroscedasticity analyses were conducted on the two 
models to investigate whether the variance (actual versus predicted) in the residuals 
of each model were dependent on the value of the dependent variable (duration of 
PTA).  
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A Breusch-Pagan test conducted on Equation 6.2 (S100B predicting WPTA) 
was significant, χ2(1, N=76) = 21.211, p < .001. Robust regression analysis, 
however, revealed that S100B remained a significant predictor of WPTA, despite 
heteroscedasticity of the model (β=1.623, p < .05). A post-hoc bivariate Pearson’s 
correlation revealed a significant moderate correlation between duration of PTA and 
magnitude of error in the residuals (.542, p < .001).  
The Breusch-Pagan test conducted on the Equation 6.3 (S100B and GCS 
predicting WPTA) was significant, χ2(1, N=76) = 33.055, p < 0.001. However, a 
significant moderate correlation still remained between duration of PTA and the 
magnitude of error in the residuals (.479, p < .001). Figures 6.1 and 6.2 display the 
residual error across duration of PTA for each equation. 
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Figure 6.1 The residual error for Equation 6.2 across duration of post-traumatic amnesia 
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Figure 6.2. The residual error for Equation 6.3 across duration of post-traumatic amnesia. 
 
 
By restricting the range of duration of post-traumatic amnesia estimations to 
≤ 30 days, there was no significant correlation between duration of PTA and 
magnitude of error in the residuals for either Equation 6.2 (.012, p=.921), or 
Equation 6.3 (.169, p=.169). Figures 6.3 and 6.4 display the residual error across the 
first 30 days of PTA for each equation. 
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Figure 6.3. The residual error for Equation 6.2 across 30 days of post-traumatic amnesia. 
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Figure 6.4. The residual error for Equation 6.3 across 30 days of post-traumatic amnesia. 
 
 
6.3.4 Sensitivity and Specificity of Predicting “Very Severe” Post-Traumatic 
Amnesia 
40 of the 79 T0 participants were classified in the “Very Severe” range of 
post-traumatic amnesia as measured by the WPTA (≥ 8 days). Receiver operating 
characteristics conducted on S100B and “Very Severe” PTA indicated an AUC of 
.772. The S100B cut off point with the highest statistical efficiency (also known as 
“correct classification rate”) for identifying “Very Severe” post-traumatic amnesia 
was 0.97μg/L. Cohen’s Kappa analysis of this cut off point indicated moderate 
agreement for classification, κ = .493, p < .001. The participants classified as 
exhibiting “Very Severe” PTA had significantly higher S100B levels, t(48.330) = -
2.914, p < .01. 
Receiver operating characteristics conducted on GCS and “Very Severe” 
PTA indicated an AUC of .804. The GCS cut off point with the highest statistical 
efficiency for identifying “Very Severe” post-traumatic amnesia was 12 (this is also 
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the empirical/clinical cut off for “Moderate” TBI). Cohen’s Kappa analysis of this 
cut off point also indicated moderate agreement for classification, κ = .471, p < .001. 
The participants classified as exhibiting “Very Severe” PTA had significantly lower 
GCS scores, t(40.003) = -4.637, p < .01. 
The Receiver Operator Characteristics for S100B (AUC = .772) and GCS 
(AUC = .804) in identifying “Very Severe” range post-traumatic amnesia are 
depicted below in Figure 6.5 
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Figure 6.5 Receiver Operating Characteristics of S100B and GCS with “Very Severe” post-traumatic 
amnesia. 
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The diagnostic and agreement statistics for S100B using 0.97μg/L and GCS 
using 12 as respective cut-offs for identifying “Very Severe” range post-traumatic 
amnesia are displayed below in Table 6.6.  
 
 
Table 6.6 
Diagnostic and Agreement Statistics for Identifying “Very Severe” PTA 
    S100B    GCS 
Sensitivity   .775 (.615 – .892)  .525 (.361 – .685) 
Specificity   .718 (.551 – .850)  .949 (.827 – .994) 
Efficiency   .747 (.636 – .838)  .734 (.623 – .827) 
False Positive Rate  .282 (.150 – .449)  .051 (.006 – .173) 
False Negative Rate  .225 (.108 – .385)  .475 (.315 – .639) 
Misclassification Rate  .253 (.162 – .344)  .266 (.173 – .501) 
Note. 95% confidence intervals are displayed in parentheses. S100B cut off ≥ 0.97μg/L; GCS cut off ≤ 
12. 
 
 
 
Figures 6.6 through 6.9 on the following pages illustrate the respective 
sensitivity and specificity of S100B and GCS in identifying “Very Severe” post-
traumatic amnesia (WPTA ≥ 8 days). The respective cut-offs for each independent 
variable (established above) are depicted in each plot. 
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Figures 6.6 and 6.7 below plot the sensitivity and specificity of S100B in 
identifying “Very Severe” post-traumatic amnesia (WPTA ≥ 8 days), the cut off level 
with the highest efficiency (.97μg/L) is depicted in the plot. 
 
.97μg/L
0
0.1
0.2
0.3
0.4
0.5
0.6
0.7
0.8
0.9
1
0 1 2 3 4 5 6 7 8 9 10
 
 
Figure 6.6. The sensitivity of serum S100B levels in identifying “Very Severe” post-traumatic amnesia  
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Figure 6.7. The specificity of serum S100B levels in identifying “Very Severe” post-traumatic amnesia  
 
S100B Level (μg/L) 
S100B Level (μg/L) 
Sp
e
ci
fi
ci
ty
 
Se
n
si
ti
vi
ty
 
67 
 
Figures 6.8 and 6.9 below plot the sensitivity and specificity of depth of coma 
in identifying “Very Severe” post-traumatic amnesia, the cut off level with the 
highest efficiency (12) is depicted in the plot. 
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Figure 6.8. The sensitivity of GCS scores in identifying “Very Severe” post-traumatic amnesia (≥ 8 
Days). 
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Figure 6.9. The specificity of GCS scores in identifying “Very Severe” post-traumatic amnesia (≥ 8 
Days). 
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6.4 Discussion 
This study investigated the utility of serum S100B with reference to the 
diagnosis and management of TBI immediately following injury. More specifically, 
the present study elucidated the diagnostic, categorical, and operational utility of a 
single collection of serum S100B by identifying statistical relationships between 
serum levels of S100B and the current acute measures for classifying TBI severity – 
namely the Glasgow Coma Scale (GCS), and the Westmead Post-Traumatic Amnesia 
Scale (WPTA). 
The associated literature, discussed in the preceding literature review, 
indicates that the presence of S100B can be used  to discriminate TBI from non-TBI 
patients (Bohmer et al., 2011; Matek et al., 2012), and also to discriminate the 
severity of injury within TBI populations (Naeimi et al., 2006; Savola et al., 2004). 
Inherently, a statistical relationship could be hypothesised between level of serum 
S100B in the peripheral system immediately following injury, and the magnitude and 
severity of the injury itself. 
 
6.4.1 S100B and Depth of Coma 
In alignment with the aforementioned assumption, this study hypothesised a 
significant inverse correlation between serum S100B levels and GCS scores. Put 
simply, it was hypothesised that the higher the level of S100B, the deeper the coma 
following injury. This hypothesis was supported by the data, in that a significant 
negative correlation was found between serum S100B levels and GCS scores (r = -
.419). This finding is comparable to those of Herrmann et al. (2001), Watt et al. 
(2006), and Korfias et al. (2007), who found significant inverse relationships 
between S100B and GCS of r = -.570, -.470 and r = -.331 respectively. 
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 In addition to the inverse correlation found between serum S100B levels and 
GCS scores, this study also illustrated that S100B was able to categorically 
discriminate between mild, moderate, and severe depths of coma as measured by the 
GCS.  This finding extends the preliminary results reported by Naeimi et al. (2006) 
who found that S100B was able to discriminate between severe head injuries and 
mild and moderate injuries combined. However, this significant categorical result 
contrasts with the investigation conducted by Beers et al. (2007). In their study of 15 
paediatric patients, the researchers reported that S100B did not differ significantly 
across GCS categories. It should be noted that the present research utilised a 
significantly larger participant population, and the nature of the participant pool’s 
injuries was markedly more severe. The discrepancies between the findings of the 
current study and Beers et al.’s is likely to be attributable to these two constituents of 
methodological design. 
 
6.4.2 S100B and Post-Traumatic Amnesia 
As per the assumed relationship between level of S100B and the severity of 
injury, this study hypothesised a significant correlation between serum S100B levels 
and WPTA scores. Put simply, it was hypothesised that the higher the level of 
S100B, the longer the patient would remain in post-traumatic amnesia following 
their injury. This hypothesis was supported by the data, in that a significant 
correlation was found between serum S100B levels and WPTA scores (r = .415). 
This finding is comparable to that of Watt et al. (2006) who found a significant 
relationship between initial levels of S100B and WPTA of r = -.590. To date, Watt et 
al.’s study is the only published research to investigate the relationship between 
S100B and any quantifiable duration of post-traumatic amnesia.  
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It was further hypothesised in current study that WPTA scores could be 
algorithmically predicted by serum levels of S100B. It is argued that this final 
hypothesis held the strongest pertinence towards clinical utility and translational 
modelling. Being that duration of post-traumatic amnesia is the best indicator of the 
extent of cognitive and functional deficits that follow TBI (Khan et al., 2003), the 
ability to predict the days or weeks of post-traumatic amnesia that a patient is likely 
to endure, within hours of their injury, is of clear utility to the treating physicians and 
to the carers and family of the patient. S100B meets these criteria, with the addition 
of being unaffected by blood alcohol – unfortunately, depth of coma and duration of 
loss of consciousness cannot claim this desirable attribute.  
 In the present study, serum S100B levels were shown to be able to predict 
duration of post-traumatic amnesia as measured by the WPTA. Although S100B in 
isolation was only capable of accounting for 36.1% of the variance in WPTA 
outcome, including the patient’s GCS score (also attainable immediately following 
injury) to the algorithm resulted in a significant increase of variance accounted for. 
The results showed that any prognoses for post-traumatic amnesia beyond 30 days 
held unacceptable clinical confidence intervals, indicating the longer the prognosed 
post-traumatic amnesia, the larger the margin for error. However, by restricting the 
estimated range to less than 30 days, no correlation remained between the duration of 
post-traumatic amnesia and magnitude of error in the residuals. It could be 
reasonably argued that the unacceptable statistical error post 30 days is clinically 
irrelevant, and that the prediction of which patients will recover within the first few 
days and which will not is of the most pertinence to the medical management of TBI 
patients. 
  
71 
 
6.4.3 Conclusions 
The above findings contribute to the empirical research concerned with 
validation of S100B in the medical management of TBI. Further, these results extend 
the associated literature by investigating biomarker utility with a clinical variable that 
is currently used in the treatment and management of TBI – namely the WPTA. 
From a translational perspective within the context of the acute setting, it can be 
argued that for a biomarker to be clinically validated, it must be shown to have utility 
beyond mortality. For the treating clinicians, it is the medical management of the 
survivors of TBI which is of most relevance. 
Inarguably, the most pertinent finding from the current study was that S100B 
was able to statistically classify which patients would endure “Very Severe” post-
traumatic amnesia (greater than one week following injury) as measured by the 
WPTA. The results clearly demonstrated that, by using a cut-off of 0.97μg/L, S100B 
was able to identify those that endured “Very Severe” post-traumatic amnesia with 
comparable efficacy to that of the GCS (AUC = .772 and .804 respectively). Added 
to this, results indicated that the sensitivity and specificity of S100B identifying 
“Very Severe” post-traumatic amnesia (.775 and .718), was arguably better balanced 
than that of GCS (.525 and .949). In any case, the clinical and prognostic utility in 
combining serum S100B levels and GCS scores in acute TBI management is clearly 
evident. Clinicians making an unfavourable post-traumatic amnesia prognosis for 
patients with a serum S100B level greater than 0.97μg/L and a GCS score lower than 
13 can do so with confidence informed by concise convergent validation. 
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Chapter 7 
Study Two: Serum S100B and Cognitive Impairment (T60) 
7.1 Aims and Hypotheses 
The focus of Study Two: T60 was on predicting the cognitive impairment 
experienced by TBI patients 60 days following injury, based on information 
available at their acute presentation. Within this prognostic design, Study Two: T60 
aimed to quantify the accuracy that S100B holds in predicting the magnitude of 
ipsative impairment experienced by TBI patients, across a variety of gold-standard 
measures of cognitive ability. Operationally, ipsative impairment was defined in this 
study as being the magnitude of discrepancy between an individual’s cognitive 
performance and the quantified estimation of their premorbid ability. This model is 
markedly different to normative impairment whereby impairment is defined as 
discrepancy from a population norm. 
As discussed in the preceding literature review, higher levels of S100B have 
been shown to be associated with normative deficits in cognitive functioning within 
two weeks of emerging from post-traumatic amnesia (Watt et al., 2006), and at three 
and six months following injury (Ingebrigsten et al., 1999; Hermann et al., 2001). 
However these results have been contested by the results of other studies (Waterloo 
et al., 1997; De Boussard et al., 2005). Based on the associate literature, the 
hypotheses for Study Two: T60 were: 
H1: S100B levels would be significantly positively correlated with magnitude of 
ipsative impairment on measures of cognitive ability 
H2: As per H1, the relationship between S100B and cognitive ability would be 
such that ipsative impairment can be algorithmically predicted by S100B. 
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H3: The accuracy of such algorithms could be improved by incorporating GCS 
and WPTA scores in order to control for the unique variance accounted for by 
these measures. 
 
7.2 Method 
7.2.1 Participants 
In this study, participants who had a blood sample taken immediately 
following their injury, received a GCS score on admission, and completed the 
cognitive assessment battery 60 days post injury were included in analysis at the T60 
time point. The investigator conducting the cognitive assessment was blinded to the 
results of S100B analyses, and also to the patients’ GCS and WPTA scores. 
From the initial participant pool of 127 TBI patients, 53 participants met the 
inclusion criteria for the T60 time point. However, three of the participants were 
suspected of not giving genuine effort during testing (by testing positive on the Dot 
Counting Test, described in the Materials section), and as such, were removed from 
any further analyses. 38 of the 50 T60 participants received WPTA testing during 
their admission. Table 7.1 displays the TBI severity categorisation frequencies on the 
GCS and WPTA for the T60 participants.  
 
Table 7.1 
Severity Categorisation Frequencies for Glasgow Coma Scale and Westmead Post-Traumatic Amnesia 
Scale 
Glasgow Coma Scale n = 50   Definition  Frequency 
Mild      GCS = 13<15  39 (78.00%) 
Moderate     GCS = 9<12  3 (6.00%) 
Severe      GCS = 3<8  8 (16.00%) 
Westmead Post-Traumatic Amnesia Scale n = 38 Definition  Frequency 
Severe      WPTA = 1 to 7 days 15 (39.47%) 
Very Severe     WPTA = 8 days +  23 (60.53%) 
Note. N = 50. 
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7.2.2 Materials 
7.2.2.1 Test of Premorbid Functioning (TOPF) 
 The TOPF (Pearson, 2009) is a cognitive test that is used to make predictions 
of a patient’s premorbid intellectual functioning. The TOPF is a recent revision of 
the Wechsler Test of Adult Reading (WTAR; Holdnack, 2001) – however the name 
was changed to reduce confusion surrounding the use of “reading” and “test” in the 
name of the product. 
The task requires the reading of written words that are comprised of atypical 
grapheme-to-phoneme translations (e.g., “subtle”), as this task has been proven to be 
less susceptible to the effects of brain injury. The irregular pronunciation minimises 
the assessment of the examinee’s current abilities to apply standard pronunciation 
rules and maximizes the assessment of their previous learning of the word. 
During testing, the examinee is provided with the Test of Premorbid 
Functioning Word Card (Appendix D) and instructed to read each word aloud. The 
examiner marks the examinee’s responses as correct or incorrect, and the test is 
discontinued following five incorrect responses. The examinees raw score is then 
recorded as the total number of correct responses. 
The TOPF allows for “complex” and “simple” predictions of premorbid 
functioning. In the “complex” method, the examinee’s raw score is incorporated into 
a regression equation that is mediated by their geographical location, years of 
education, and highest level of employment. In the “simple” method, the examinee’s 
raw score alone is converted to an age-adjusted Standard Score. The present study 
utilised the “simple” method, as to date, the mediators of the “complex” method have 
not been validated with an Australian demographic sample. 
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The TOPF standard score has a mean of 100 and a standard deviation of 15, 
and this standard score is the examinee’s predicted premorbid full scale IQ (FSIQ).  
 
7.2.2.2 The Dot Counting Test (DCT) 
 The DCT (Boone, Lu, & Herzberg, 2002) is a widely utilised test used to 
confirm genuine task-taking effort during cognitive evaluations, rather than 
suppressed effort or “malingering.” This test was incorporated in the current study to 
identify any participants suspected of suppressing effort during evaluation – and to 
remove their data from statistical analyses. 
The DCT task simply requires the examinee to correctly count the amount of 
dots presented on a page, over a series of pages with varying (i.e., non-hierarchical) 
difficulty. Once the examinee has completed the series of pages, an “e-score” is 
determined based on the examinee’s completion time, errors made, and deviations 
from hierarchical performance. This study adopted the e-score cut-off for TBI 
populations, which has been validated by the authors as holding 81.6% sensitivity 
and 90.0% specificity for identifying “suspect effort.” 
 
7.2.2.3 Wechsler Adult Intelligence Scale – 4th Ed. Digit Span Subtest (WAIS-IV 
Digit Span) 
 The WAIS-IV (Wechsler, 2008) Digit Span subtest is the most recent 
revision of the long used digit span task. Historically, the digit span task has involved 
the examinee repeating verbally presented number strings in increasing length (Digit 
Span Forwards), and likewise, recalling verbally presented number strings in reverse 
order to their presentation (Digit Span Backwards).  
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Unlike previous incarnations, however, the WAIS-IV Digit Span has 
incorporated a third presentation – namely, Digit Span Sequencing. In Digit Span 
Sequencing, examinees are required to recall the presented numbers in ascending 
order (from smallest to largest). This third presentation of the task has been 
suggested to increase the role of mental manipulation and places greater demand on 
working memory relative to the other two tasks of WAIS-IV Digit Span (Drozdick, 
Wahlstrom, Zhu, & Weiss, 2012).  
 
7.2.2.4 Wechsler Adult Intelligence Scale – 4th Ed. Figure Weights Subtest (WAIS-IV 
Figure Weights) 
 The WAIS-IV Figure Weights Subtest is a recent addition to the WAIS-IV 
battery, and holds the strongest standalone psychometric properties as a measure of 
fluid intelligence (often referred to as Gf) in the WAIS-IV (Lichtenberger & 
Kaufman, 2013), and places a high demand on quantitative reasoning. As such, 
McCrea and Robinson (2011) recently reviewed the subtest as being a “significant 
and unique innovation with few if any parallels in the prior psychometric literature.” 
 In the task, the examinee views scales with missing weights and selects a 
response from five presented options that is best suited to keep the scales balanced. 
The subtest is similar to previously developed “balance beam” tasks where the 
examinee would be required to integrate weight data with proportional distance from 
the fulcrum. WAIS-IV Figure Weights, however, only uses different colours and 
shapes as weights without the necessity of incorporating proportional distance from 
the fulcrum. 
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7.2.2.5 Wechsler Adult Intelligence Scale – 4th Ed. Cancellation Subtest (WAIS-IV 
Cancellation) 
The WAIS-IV Cancellation subtest is a task that requires the examinee to 
scan a structured arrangement of coloured shapes and mark the targets and avoid the 
distracters whereby the distractors are paralleled with the targets by either shape or 
colour. As such, the examinee is required to discriminate and identify the targets 
(e.g., red squares and yellow triangles) from descriptively similar distracters (e.g., 
yellow squares and red triangles).  
WAIS-IV Cancellation is a recent addition to the WAIS-IV battery, and 
supplemental to the WAIS-IV Processing Speed Index. Although the subtest is 
primarily considered to be a measure of processing speed and visuomotor ability, it 
has also been shown to be a measure of visual selective attention and dual-tasking/ 
inhibition (McCrea & Robinson, 2011). In each of the three WAIS-IV subtests in this 
study (Digit Span, Figure Weights, and Cancellation), the examinee’s raw score is 
converted to an age-adjusted scaled score, with a mean of 10 and a standard 
deviation of 3. 
 
7.2.2.6 Delis-Kaplan Executive Function Scale Verbal Fluency Test Condition 1: 
Letter Fluency (D-KEFS VFT: 1) 
The D-KEFS (Delis, Kaplan, & Kramer, 2001). VFT: 1 subtest is a task that 
requires the examinee to simply list as many words as they can within 60 seconds 
that begin with a given letter, excluding proper nouns, numbers, and the same word 
with a different suffix. This process is repeated across three trials and the examinee’s 
raw score (total words across all trials) is converted to an age-adjusted scaled score, 
with a mean of 10 and a standard deviation of 3. 
78 
 
Verbal fluency is a longstanding paradigm in neuropsychological assessment, 
and found to be highly sensitive to the cognitive deficits following TBI. The letter (or 
phonemic) fluency subtest has been shown to measure auditory attention, lexical 
retrieval, processing speed, and the more global cognitive domain of executive 
functioning. 
 
7.2.2.7 Delis-Kaplan Executive Function Scale Trail Making Test Condition 4: 
Number-Letter Switching (D-KEFS TMT: 4) 
 The D-KEFS TMT: 4 subtest is a recent rendition of the classic trail making 
test that has been in the public domain and use since the mid-1940s whereby the 
examinee is required to draw lines connecting randomly arranged numbers and 
letters, switching back and forth between numbers and letters in ascending order (i.e., 
1, A, 2, B, 3, C etc.). However, the D-KEFS TMT: 4 revision of the classic test 
addresses the longstanding shortcoming in which there was a lack of sensitivity to 
mild executive deficits in individuals with high premorbid intellectual abilities by 
increasing the stimulus size (to A3, portrait orientation) and clustering “capture 
stimuli” (e.g., 8 close to 9, L close to M) in order to make the subtest more subtle to 
impairments in set-shifting.  
Beyond being a test of visual scanning and motor speed, the D-KEFS TMT: 4 
subtest measures executive functioning domains of cognitive flexibility, dual tasking, 
sequencing, and divided attention. In each of the D-KEFS subtests in this study 
(VFT: 1, and TMT: 4), the examinee’s raw score is converted to an age-adjusted 
scaled score, with a mean of 10 and a standard deviation of 3. 
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7.2.2.8 BIRT Memory and Information Processing Battery Processing Speed Task 
(BMIPB Speed of Information Processing). 
 The BMIPB (Coughlan, Oddy, & Crawford, 2007) Speed of Information 
Processing subtest requires the examinee to visually scan strings of five double-digit 
numbers, and mark the second highest number in each string. The sum of targets that 
the examinee successfully completes in four minutes is recorded as their Total Score. 
The examinee then completes a simple motor speed task, with no additional 
cognitive demands to provide a Motor Speed Score.  
To control for any motor deficits that may contribute to impaired processing 
speed, the Total score and the Motor Speed score are then cross-referenced to create 
an Adjusted Score. The examinee’s Total Score, Motor Speed Score, and Adjusted 
Score are then converted to age-adjusted scaled scores, with means of 10 and 
standard deviations of 3. 
 
7.2.2.9 T0 Materials used in Study Two: T60 
In addition to the cognitive measures outlined above, Study Two: T60 also 
incorporated serum S100 calcium binding protein B (S100B), the Glasgow Coma 
Scale (GCS), and the Westmead Post-Traumatic Amnesia Scale (WPTA). Detailed 
descriptions of these materials can be located in the Materials section for Study One: 
T0. 
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7.2.3 Procedure 
Participants were contacted by telephone and invited to participate in a 
cognitive evaluation (see Materials section) 60 days following their injury. 
Evaluations were conducted in an examination room and lasted approximately 40 
minutes. 
 
7.2.4 Design and Analyses for Study Two: T60  
In study two, patients’ S100B values, GCS scores, and WPTA scores 
constituted the independent variables, and the magnitude of ipsative impairment on 
each cognitive subtest at 60 days post injury constituted the dependent variables.  
For this study, ipsative impairment was defined and quantified as being the 
discrepancy between the participants’ performance on the given cognitive subtest 
(Scaled Score; M = 10, SD = 3) and their expected performance given their TOPF 
performance (Standard Score; M = 100, SD = 15). The curve of standardised 
distribution with Standard Scores and Scaled Scores is displayed in Figure 7.1.  
 
 
 
Figure 7.1. The standard distribution curve with standard scores and scaled scores 
 
 
81 
 
To facilitate the discrepancy analyses described above, conversions were 
made to cognitive subtest Scaled Scores to transform them to the Standard Score 
rubric. The algorithm used to convert Scaled Scores to the Standard Score rubric is 
depicted below in Equation 7.1. 
 
Standard Score = (Scaled Score – 10) x 5 + 100    (Eq. 7.1) 
 
Two-tailed bivariate correlations with Pearson coefficients were conducted to 
explore statistical relationships between S100B and the existing diagnostic variables 
(GCS and WPTA), with impairment on each of the cognitive subtests. The ability for 
S100B to predict impairment was examined using robust linear regression, and 
subsequent regressions investigated whether the proportion of variance accounted for 
could be improved by including GCS scores and WPTA in each prognostic model. 
 
7.2.5 Statistical Software and Manipulations 
As per Study One, correlations, robust regression analyses, and receiver 
operating characteristics were conducted using SPSS
®
 Version 21 (IBM Corp., 
2012). Jarque-Bera tests for normality, Breusch-Pagan tests for heteroscedasticity, 
and Diagnostic and Agreement statistics were computed using Excel 2010 
(Microsoft, 2010). Further information for these analyses can be found in the 
Materials section for Study One. 
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7.3 Results 
7.3.1 Ipsative Deficit Descriptives  
The mean level of premorbid functioning in the participant pool, as assessed 
by the TOPF was 94.12 (SD=13.35). Ipsative deficit for each subtest was determined 
by subtracting participants’ actual standard score performance from their expected 
premorbid performance as assessed by the TOPF. Table 7.2 displays the participants’ 
mean magnitude of ipsative deficit (in standard score points) for each of the 
cognitive subtests. 
 
 
Table 7.2 
Level of Ipsative Deficit on each of the Cognitive Subtests 
Subtest     M  SD  
D-KEFS Verbal Fluency   5.27  15.10 
D-KEFS Trail Making   5.02  14.73 
BMIPB Speed of Info Processing (Adjusted) 2.40  16.87 
- Total Score    2.92  16.49 
- Motor Speed   9.27  17.72 
WAIS-IV Cancellation   1.71  14.06 
WAIS-IV Digit Span (Total)   1.38  14.22 
- Forwards    1.08  15.27 
- Backwards    0.38  14.51 
- Sequencing    4.48  16.91 
WAIS-IV Figure Weights   3.30  19.21 
Note. N = 50. 
 
7.3.2 Correlations with Cognitive Impairment 
Two-tailed Pearson’s correlations were conducted between serum S100B 
levels, depth of coma (GCS), duration of post-traumatic amnesia (WPTA), and level 
of impairment on each of the cognitive subtests. 
As displayed in Table 7.3, S100B was not significantly correlated with any 
cognitive subtest deficit; GCS was significantly correlated with the motor speed 
component of the BMIPB Speed of Information Processing subtest; and WPTA was 
significantly moderately correlated with the WAIS-IV Cancellation subtest. 
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Table 7.3 
Correlations between S100B, GCS, and WPTA with Ipsative Deficit on each of the Cognitive Subtests 
Subtest     S100B (n=50) GCS (n=50) WPTA (n=38) 
D-KEFS Verbal Fluency   .066  .142  -.049 
D-KEFS Trail Making   .008  .205  -205 
BMIPB Speed of Info Processing (Adjusted) .196  -.034  -.246 
- Total Score    .216  -.078  -.218 
- Motor Speed   .173  -.371*  -.107 
WAIS-IV Cancellation   .081  .053  -.391* 
WAIS-IV Digit Span   .004  .130  -.074 
- Forwards    .091  .116  -.091 
- Backwards    .009  .015  -.001 
- Sequencing    .005  .166  -.146 
WAIS-IV Figure Weights   .234  -.217  -.042 
Note. *p < .05 
 
 
7.3.3 Predicting Cognitive Impairment 
Robust regression analyses were conducted for S100B, GCS, and WPTA 
predicting impairment for each of the cognitive subtests. Table 7.4 below displays 
the R
2
 values for each analysis, and the beta coefficient for each predictor.  As 
displayed in Table 7.4, cognitive impairment could only be significantly predicted 
for three subtests, namely: BMIPB Speed of Information Processing (Adjusted 
Score); BMIPB Speed of Information Processing Total Score; and, WAIS-IV Figure 
Weights. With reference to beta weight coefficients, the only significant 
contributions made by independent variables to models were WPTA to WAIS-IV 
Cancellation, and GCS to WAIS-IV Figure Weights. Serum S100B made no 
significant contributions to any cognitive impairment models. 
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Table 7.4 
Regression Analyses for predicting Ipsative Deficit on each of the Cognitive Subtests 
      β Coefficient   
Subtest    R
2
 S100B GCS WPTA Constant p 
D-KEFS Verbal Fluency Test: 1 .007 .273 .150 -.051 -5.515  .949 
D-KEFS Trail Making Test: 4 .043 .086 .092 -.283 -1.753  .596 
BMIPB Speed of Info Processing .110 .724 -.560 -.554 11.557  .026* 
- Total Score   .105 .781 -.596 -.511 10.823  .015* 
- Motor Speed  .151 .439 -.514 -1.789 19.209  .097 
WAIS-IV Cancellation  .200 .237 -.818 -.700* 15.990  .090 
WAIS-IV Digit Span  .009 .049 .304 -.061 -.838  .926 
- Forwards   .029 .644 .665 -.065 -7.765  .734 
- Backwards   .004 -.091 -.330 -.091 5.397  .976 
- Sequencing   .032 -.107 .486 -.157 3.612  .621 
WAIS-IV Figure Weights  .121 .619 -1.670* -.362 22.747*  .002* 
Note. N = 38; p < .05 
 
 
7.3.4 Sensitivity and Specificity of Predicting “Diffuse Cognitive Impairment” 
Of the 50 T60 participants who sustained a TBI, 8 participants were classified 
as exhibiting “Diffuse Cognitive Impairment,” operationally defined as 
demonstrating impairment greater than one standard deviation (15 standard score 
points) from premorbid functioning, in at least six assessed cognitive subtests. 
Receiver operating characteristics conducted on S100B and “Diffuse 
Cognitive Impairment” indicated an AUC of .585. As per Study One, the S100B cut 
off point was set at 0.97μg/L for these analyses. Cohen’s Kappa analysis of this cut 
off point was non-significant, and indicated only a slight agreement for classification, 
κ = .095, p = .370. The participants classified as exhibiting “Diffuse Cognitive 
Impairment” did not have significantly higher S100B levels, t(40.003) = .840, p = 
.261 
Receiver operating characteristics conducted on GCS and “Diffuse Cognitive 
Impairment” indicated an AUC of .579. Consistent with Study One, a GCS score of 
12 (“Moderate” severity) was used as the cut off point for these analyses. Cohen’s 
Kappa analysis of this cut off point was also non-significant, and indicated only a 
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below chance agreement for classification, κ = -.114, p = .406. The participants 
classified as exhibiting “Diffuse Cognitive Impairment” did not have significantly 
lower GCS scores, t(14.110) = -1.107, p = .144 
Receiver operating characteristics conducted on WPTA and “Diffuse 
Cognitive Impairment" indicated an AUC of .721. As per Study One, the WPTA 
“Very Severe” classification (≥8 days) was used as the cut off point for these 
analyses. Cohen’s Kappa analysis of this cut off point was also non-significant, and 
indicated only a slight agreement for classification, κ = .050, p = .635. The 
participants classified as exhibiting “Diffuse Cognitive Impairment” did not have 
significantly higher WPTA scores, t(6.374) = 1.676, p = .503. 
The Receiver Operator Characteristics for S100B (AUC = .585), GCS (AUC 
= .579) and WPTA (AUC = .721) in identifying “Diffuse Cognitive Impairment” are 
depicted below in Figure 7.2.  
 
0
0.1
0.2
0.3
0.4
0.5
0.6
0.7
0.8
0.9
1
0 0.1 0.2 0.3 0.4 0.5 0.6 0.7 0.8 0.9 1
S100B
GCS
WPTA
 
 
Figure 7.2. Receiver Operating Characteristics of S100B, GCS and WPTA with “Diffuse Cognitive 
Impairment.” 
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The diagnostic and agreement statistics for S100B using 0.97μg/L; GCS 
using ≥12; and, WPTA using ≥ 8 days as respective cut offs for identifying “Diffuse 
Cognitive Impairment” are displayed below in Table 7.5.  
 
 
Table 7.5 
Diagnostic and Agreement Statistics for identifying “Diffuse Cognitive Impairment” using S100B, GCS, 
and WPTA 
   S100B   GCS   WPTA 
Sensitivity  .625 (.245 – .915) .125 (.003 – .527) .667 (.223 – .957) 
Specificity  .548 (.387 – .702) .738 (.580 – .861) .438 (.264 – .623) 
Efficiency  .560 (.413 – .700) .640 (.492 – .771) .474 (.310 – .642) 
False Positive Rate .452 (.298 – .613) .262 (.139 – .420) .563 (.377 – .736) 
False Negative Rate .375 (.085 – .755) .875 (.473 – .997) .333 (.043 – .777) 
Misclassification Rate .440 (.300 – .345) .360 (.229 – .458) .526 (.358 – .403) 
Note. 95% confidence intervals are displayed in parentheses. S100B cut off ≥ 97μg/L, n = 50; GCS cut 
off ≤ 12, n = 50; WPTA cut off ≥ 8 days, n = 38. 
 
 
Figures 7.3 through 7.8 on the following pages illustrate the respective 
sensitivity and specificity of S100B, GCS and WPTA in identifying “Diffuse 
Cognitive Impairment” (ipsatively impaired on ≥ 6 subtests). The respective cut-offs 
for each independent variable (established above) are depicted in each plot. 
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Figures 7.3 and 7.4 below plot the sensitivity and specificity of S100B in 
identifying “Diffuse Cognitive Impairment,” the cut off level of .97μg/L is depicted 
in the plot. 
 
.97μg/L
0
0.1
0.2
0.3
0.4
0.5
0.6
0.7
0.8
0.9
1
0 1 2 3 4 5 6 7 8 9 10
 
 
Figure 7.3. The sensitivity of serum S100B levels in identifying “Diffuse Cognitive Impairment.” 
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Figure 7.4. The specificity of serum S100B levels in identifying “Diffuse Cognitive Impairment.” 
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Figures 7.5 and 7.6 below plot the sensitivity and specificity of depth of coma 
(as measured by the GCS) in identifying “Diffuse Cognitive Impairment,” the GCS 
cut off score of 12 is depicted in the plot. 
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Figure 7.5. The sensitivity of GCS scores in identifying “Diffuse Cognitive Impairment.” 
 
 
GCS = 12
0.0
0.1
0.2
0.3
0.4
0.5
0.6
0.7
0.8
0.9
1.0
3 4 5 6 7 8 9 10 11 12 13 14 15
 
 
Figure 7.6. The specificity of GCS scores in identifying “Diffuse Cognitive Impairment.” 
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Figures 7.7 and 7.8 below plot the sensitivity and specificity of duration of 
post-traumatic amnesia (as measured by the WPTA) in identifying “Diffuse 
Cognitive Impairment,” the WPTA cut off level of ≥8 days is depicted in the plot. 
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Figure 7.7. The sensitivity of WPTA Scores in identifying “Diffuse Cognitive Impairment.” 
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Figure 7.8. The specificity of WPTA scores in identifying “Diffuse Cognitive Impairment.” 
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7.4 Discussion 
As an ideal, a proteomic biomarker of TBI outcome should indicate damage 
to neurological networks and also to specific brain cells that are known to support 
cognitive functioning. As such, it would be beneficial for the prognostication of 
cognitive impairment following TBI to explore the mechanisms that underlie 
changes in proposed biomarkers of TBI (Papa et al., 2013). In alignment with the  
phases of biomarker development modelled by Pepe et al. (2013), the present study 
investigated the prognostic utility of serum S100B with reference to cognitive 
impairment experienced by TBI patients 60 days post injury. More specifically, the 
present study quantified the accuracy that S100B holds in predicting the magnitude 
of ipsative impairment experienced by TBI patients, across a variety of standardised 
measures of cognitive ability. This study utilised an ipsative impairment model, 
rather than a normative deficit model, in order to investigate discrepancies between 
participants’ cognitive performances and quantifiable estimations of their premorbid 
abilities. 
The associated research, discussed in the preceding literature review, 
indicates that disrupted S100B levels are associated with altered learning and 
memory in rodent models of injury (Mello e Souza et al., 2000; Winocur et al., 
2001). Further, within human models of injury, higher levels of S100B have been 
shown to be associated with normative deficits in cognitive functioning within two 
weeks of emerging from post-traumatic amnesia (Watt et al., 2006), and at three and 
six months following injury (Ingebrigsten et al., 1999; Hermann et al., 2001). As 
such, a meta-analysis conducted by Sun and Feng (2013) concluded that a substantial 
body of evidence now exists to suggest that a relationship exists between post-
traumatic biomarker dysfunction and cognitive impairment. 
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In alignment with the aforementioned relationship, this study hypothesised 
that serum S100B levels would be significantly correlated with the magnitude of 
ipsative impairment on each of the measures of cognitive ability. It was further 
hypothesised that ipsative impairment in each domain could be algorithmically 
predicted by serum concentrations of S100B. Contrary to these hypotheses, however, 
S100B was not significantly correlated with ipsative impairment on any of the 
cognitive subtests utilised in this study. Further, regression analyses for cognitive 
impairment illustrated that S100B made no significant contributions to any 
prognostic models. Despite the absence of clinical significance, all correlations 
between serum concentrations of S100B and ipsative cognitive impairment were 
found to be in the hypothesised direction. This direction-consistent result was also 
found for duration of post-traumatic amnesia, but not found for depth of coma. 
 
7.4.1 Comparisons to the Empirical Literature 
The current findings are in contrast to some of the results contained in the 
pioneering study conducted by Waterloo et al. (1997). The researchers compared 
cognitive abilities, one year post injury, between seven participants with mild TBI 
and seven age- and sex-matched controls without detectable levels of S100B. 
Elevated levels of S100B were found to be correlated with cognitive impairment on 
measures of complex reaction time which demanded an increased amount of 
attention and information processing. No significant relationships were found, 
however, between concentrations of S100B and measures of immediate memory, 
delayed memory, dual-tasking, or perseveration/inhibition. Of note, the published 
data suggests that the researchers used the raw scores of subtests as the dependent 
variables in their experimental design rather than scaled scores for normative 
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comparison. Further, Waterloo et al.’s findings are limited to mild TBIs, and the 
sample size of seven limits the strength of the conclusions and implications that are 
able to be drawn from the study for cognitive outcomes following TBI.  
The present study’s findings also conflict with those of Ingebrigsten et al. 
(1999)’s study of 50 mild TBI patients’ cognitive outcomes three months post injury. 
The researchers reported trends towards significance for higher serum S100B levels 
being associated with impaired attention, memory, and speed of information 
processing. Given the absence of statistical significance and reliance on trends to 
declare implications, it could be argued that these conclusions are somewhat bold. 
Further, it should be noted that, methodologically, Ingebrigsten et al. recruited only 
patients with mild injuries, and stratified their participants by the presence or absence 
of S100B. 
Similar to Waterloo et al. (1997) and Ingebrigsten et al. (1999), Herrmann et 
al. (2001) found that patients with higher serum concentrations of S100B exhibited 
more pronounced cognitive impairment at six months post injury. In their study of 29 
mild TBI patients, the researchers reported correlations between S100B levels and 
poorer performance on measures of attention, perceptual reasoning, and verbal 
fluency. It is important to note, however, that the persistence of cognitive 
dysfunction in 69% of their participant sample is remarkably atypical with mild TBI 
populations. Further, the participants’ premorbid intellectual functioning was not 
incorporated into the experimental design – consequently, it is possible that the 
participants’ poor performances may have reflected lower premorbid levels of 
cognitive functioning and other nonorganic factors that influence injury. The present 
study made attempts to control for these factors by assessing premorbid functioning, 
age-referencing performances, and screening for less than genuine effort. 
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Perhaps the study of most direct comparison to the present study is that of 
Watt et al. (2006). Using a matched-control longitudinal design, the researchers 
investigated the neuropsychological performance of 23 severe TBI patients within 
two weeks of emerging from post-traumatic amnesia, as assessed by the WPTA. 
Results indicated that acute S100B samples were correlated with performance on 
tasks involving visual memory, verbal memory and list learning, auditory working 
memory, speed of information processing, verbal fluency, and reaction time. 
However, no significant correlations were found between S100B concentrations and 
Full Scale IQ, Verbal IQ, Performance IQ, attention/concentration, or delayed recall. 
Despite similar experimental designs, it should be noted that the current study 
did not incorporate any measures of immediate or delayed memory or reaction time. 
Further, participants in Watt et al’s study underwent neuropsychological assessment 
in the sub-acute setting (less than one month post injury) where deficits are most 
pronounced, whereas the present study conducted assessments in the post-
acute/recovery stage (greater than two months post injury) where individual deficits 
are most variable. 
 
7.4.2 Conclusions 
While results indicated that S100B concentrations were not associated with 
the magnitude of any ipsative cognitive impairment, it should be acknowledged that 
GCS and WPTA scores could not prognosticate impairment either. None of the 
independent variables held significant cut-offs for correctly classifying “diffuse 
cognitive impairment” as operationalised in this design. While the WPTA held a fair 
area under the curve for classification, the participants classified as exhibiting 
“diffuse cognitive impairment” did not experience significantly longer periods in 
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post-traumatic amnesia. In summary, the results from this study illustrate that 
although post-traumatic amnesia is known to be the best indicator of functional 
deficits that follow TBI (Khan et al., 2003), enduring future cognitive impairment is 
remarkably difficult to predict from information available in the acute setting.   
 More broadly, this study extends the associated biomarker literature by 
incorporating an ipsative impairment model of post injury cognitive functioning as a 
dependent variable. Beyond S100B specifically, there is potential for biomarkers 
being used as a screening tool for injury at a cellular level – and in doing so, 
clinicians may be able to intervene pharmacologically in efforts to interrupt the 
development of secondary pathologies known to affect cognitive functioning (Sun & 
Feng, 2013). As such, any proposed biomarker undergoing clinical validation for 
TBI management would not only benefit from incorporating functional longitudinal 
design, but also from developing the understanding of the structural and cellular 
mechanisms that underlie changes in the biomarker itself. 
 From a translational perspective, this study illustrates that any accurate 
prognoses relating to cognitive impairment following TBI require acute 
neuropsychological assessment and consultation, and that prognoses based on 
biological factors alone while in an acute setting remains elusive, if not illusive. For 
the patient who has suffered a TBI, clinical examination of indices of brain injury 
severity, medical imaging, comprehensive history taking and neuropsychological 
assessment remains the best practice for attaining an accurate prognosis. That being 
said, as new biomarkers emerge, the onus is on the medical and neuropsychological 
literature to incorporate these biomarkers into experimental design – and potentially, 
into clinical practice.  
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Chapter 8 
Study Three: Serum S100B and Post-Concussion Syndrome  
and Quality of Life (T180) 
8.1 Aims and Hypotheses 
The focus of Study Three: T180 was on predicting the severity of symptoms of 
post-concussion syndrome and quality of life experienced by TBI patients 180 days 
following injury, based on information available at their acute presentation. As such, 
Study Three: T180 aimed to quantify the accuracy that S100B holds in predicting the 
presence and severity of PCS symptoms and quality of life, and whether the accuracy 
of such predictions can be improved by incorporating GCS and WPTA scores. In 
short, the aim was to quantify whether the symptoms that TBI patients experience six 
months post injury can be predicted from their acute presentation. 
As discussed in the preceding literature review, S100B has been shown to be 
associated with symptoms of PCS at two weeks post-injury (Savola & Hillborn, 
2003), and three months post-injury (Bazarian et al., 2006). Further, S100B has been 
shown to be associated with poorer quality of life (Woertgen et al., 2002), prolonged 
time to return to work (Stranjalis et al., 2004; Metting et al., 2012), poorer somatic 
health (Stålnacke et al., 2013), and symptoms related to stress disorders (Sojka et al., 
2006). Based on the literature, the hypotheses for Study Three: T180 were: 
H1: S100B levels would be significantly positively correlated with severity of 
symptoms of post-concussion syndrome. 
H2: S100B levels would be significantly negatively correlated with domains 
associated with quality of life.  
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H3: The sensitivity and specificity of S100B in identifying post-concussion 
syndrome severity and poor quality of life would be superior to that of GCS 
and WPTA. 
 
8.2 Method 
8.2.1 Participants 
Participants who had blood taken immediately following their injury, 
received a GCS score on admission, and completed the British Columbia Post-
Concussion Symptom Inventory and The Quality of Live Inventory (both inventories 
discussed below in Materials) 180 days post injury were included in analysis at the 
T180 time point.  
From the initial participant pool of 127 TBI patients, 52 participants met the 
inclusion criteria for the T180 time point. One of the participants’ blood samples 
encountered an error during analysis, and therefore was not included in statistical 
analyses incorporating S100B. 36 of the 52 T180 participants received WPTA testing 
during their admission. Table 8.1 displays the TBI severity categorisation 
frequencies on the GCS and WPTA for the T180 participants.  
 
Table 8.1 
TBI Severity Categorisation Frequencies for Glasgow Coma Scale and Westmead Post-Traumatic 
Amnesia Scale 
Glasgow Coma Scale n = 52   Definition  Frequency 
Mild      GCS = 13<15  44 (84.62%) 
Moderate     GCS = 9<12  3 (5.77%) 
Severe      GCS = 3<8  5 (9.62%) 
Westmead Post-Traumatic Amnesia Scale n = 36 Definition  Frequency 
Severe      WPTA = 1 to 7 days 18 (50%) 
Very Severe     WPTA = 8 days +  18 (50%) 
Note. N = 52. 
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8.2.2 Materials 
8.2.2.1 British Columbia Post-Concussion Symptom Inventory (BC-PSI) 
The BC-PSI (Iverson, 2006) is a 16 item self-report measure used to assess 
the presence and severity of post-concussion symptoms across the last two weeks. 
The examinee simply rates the frequency and intensity of thirteen items, and then 
rates the effect of three life problems on daily living. The thirteen symptoms  
measured by the BC-PSI are: headaches; dizziness/light-headed; nausea/feeling sick; 
fatigue; extra sensitive to noises; irritable; feeling sad; nervous or tense; temper 
problems; poor concentration; memory problems; difficulty reading; and poor sleep. 
The frequency of each symptom is rated on a six-point Likert scale: 0 = not at all; 2 = 
1-2 time; 2 = several times; 3 = often; 4 = very often; and, 5 = constantly. Similarly, 
the severity of each symptom is also rated on a six point Likert scale: 0 = not at all; 1 
= very mild problem; 2 = mild problem; 3 = moderate problem; 4 = severe problem; 
and, 5 = very severe problem.  
 Following the thirteen symptom items, the three life problems of daily living 
measured by the BC-PSI are: does alcohol affect you more than in the past?; do you 
find yourself worrying and dwelling on the symptoms above?; and, do you believe 
you have damage to your brain? The magnitude of each life problem of daily living 
is rated on a five point Likert scale: 1 = not at all; 3 = somewhat; 5 = very much. 
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For each of the thirteen BC-PSI symptoms, the frequency and the severity are 
multiplied to create Product Scores (min. = 0, max. =25). For clinical interpretation, 
Product Scores are then converted to Item Scores (0-1 = 0; 2-3 = 1; 4-6 = 2; 8-12 = 3; 
and, 15+ = 4) and classified on the following reference ranges: 0 = “none;” 1-2 = 
“mild;” 3 = “moderate;” and, 4 = “severe.” Item Scores are totalled for a BC-PSI 
Total Score to reflect global post-concussion symptom severity. For clinical 
interpretation, BC-PSI Total scores are classified based on the following reference 
ranges: 0 = “low;” 1-9 = “normal;” 10-14 = “unusually high;” and, 15+ = “extremely 
high.” Product Scores, BC-PSI Total Scores, and clinical classifications are used for 
this study’s analyses. 
 
8.2.2.2 The Quality of Live Inventory (QOLI) 
The QOLI (Frisch, 1994) is a sixteen item self-report questionnaire that is 
used to measure a patients overall life satisfaction. The questionnaire requires the 
examinee to rate their current level of importance and satisfaction across 16 domains 
of quality of life. The domains measured by the QOLI are: Health; Self Esteem; 
Goals and Values; Money; Work; Play; Learning; Creativity; Helping; Love; 
Friends; Children; Relatives; Home; Neighbourhood; Community 
The importance of each domain is rated on a three-point unipolar Likert scale, 
namely 0 = not important; 1 = important; and, 2 = extremely important. Unlike the 
importance scale, the satisfaction of each domain is rated on a six point bipolar 
Likert scale, namely -3 = very dissatisfied; -2 = somewhat dissatisfied; -1 = a little 
dissatisfied; 1= a little satisfied; 2 = somewhat satisfied; and 3 = very satisfied.  
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For each of the sixteen QOLI domains, the importance and satisfaction scores 
are multiplied to create Weighted Scores (min. -6, max. 6). Total Scores are then 
calculated by dividing the sum of Weighted Scores by the number of domains that 
the examinee identified as being either “important” or “extremely important” (i.e., 
“not important”). Total Scores are then converted to T-Scores, with a mean of 50 and 
a standard deviation of 10. For clinical interpretation, overall quality of life is 
classified based on the following T-Score reference ranges: 0-36 = “Very Low;” 37-
42 = “Low;” 43-57 = “Average;” and, 58-77 = “High.”  
Confirmatory factor analyses conducted by Thomas, McGrath and Skilbeck 
(2012), using a non-clinical Australian sample, found a three-factor structure to the 
QOLI. The authors classified the three factors as: “Self-Functioning & Activity” 
(Health, Self-Esteem, Work, and Goals and Values); “Self-Actualisation” (Play, 
Learning, Creativity, and Helping); and, “Family and Environment” (Money, Love, 
Relatives, Home, Neighbourhood, and Community).  
Weighted Scores for each domain, Thomas et. al (2012) factor scores, QOLI 
Total Scores, T-Scores, and clinical classifications (based on T-Scores) are used for 
this study’s analyses. 
 
8.2.2.3 T0 Materials used in Study Three: T180 
In addition to the post-concussion syndrome and quality of life measures 
outlined above, Study Three also incorporated serum S100 calcium binding protein B 
(S100B), the Glasgow Coma Scale (GCS), and the Westmead Post-Traumatic 
Amnesia Scale (WPTA). These materials are outlined in the Materials section for 
Study One: T0. 
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8.2.3 Procedure 
Participants were sent a mail-out pack, 180 days following their injury. Mail-
out packs consisted of a covering letter, a brief questionnaire, a QOLI form and a 
BC-PSI form (all contained in Appendix E), and a stamped addressed return 
envelope. Participants had the option to not put their name on any of the T180 
materials as each form had been pre-named with their de-identified study code. 
 
8.2.4 Design and Analyses 
In study three, patients’ S100B values, GCS scores, and WPTA scores 
constituted the independent variables, and the severity of post-concussion symptoms 
(as measured by the BC-PSI) and their satisfaction with domains of quality of life (as 
measured by the QOLI) 180 days post-injury constituted the dependent variables.  
Relationships between the independent and dependent variables were 
explored by conducting two-tailed bivariate correlations with Pearson coefficients. 
For all significant correlations between S100B and BC-PSI symptoms and QOLI 
domains, linear regressions were conducted, and subsequent regressions investigated 
whether the proportion of variance accounted for could be improved by including 
GCS scores and WPTA in each prognostic model. Jarque-Bera tests were conducted 
on the skewness and kurtosis of each model to test for normality of distribution, and 
Breusch-Pagan heteroscedasticity analyses were conducted on each model to 
investigate whether the variance (actual versus predicted) in the residuals were 
dependent on the value of the dependent variable (severity of the BC-PSI symptom; 
“Weighted Satisfaction” of the QOLI domain).  
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Diagnostic and agreement statistics and receiver operating characteristics 
were then conducted to compare the respective sensitivity, specificity, and area under 
the curve (AUC) of S100B, GCS, and WPTA in independently identifying future 
“Unusually High” and “Extremely High” post-concussion syndrome (as measured by 
the BC-PSI), and “Low” and “Very Low” quality of life (as measured by the QOLI). 
 
8.2.5 Statistical Software and Manipulations 
As per Study One, correlations, robust regression analyses, and receiver 
operating characteristics were conducted using SPSS
®
 Version 21 (IBM Corp., 
2012). Jarque-Bera tests for normality, Breusch-Pagan tests for heteroscedasticity, 
and Diagnostic and Agreement statistics were computed using Excel 2010 
(Microsoft, 2010). Further information for these analyses can be found in the Method 
section for Study One. 
 
8.3 Post-Concussion Syndrome Results 
As per the BC-PSI protocol (Iverson, 2006), the frequency (how often) and 
intensity (how bad) of each BC-PSI item were multiplied to produce product scores. 
Product scores are used to make symptom classification as “none,” “mild,” or 
“moderate-severe.” Product scores were added together to create total scores. Total 
scores are used to make total classification as “low,” “normal,” “unusually high,” and 
“extremely high.” Table 8.2 displays frequencies for each BC-PSI symptom and 
Total BC-PSI score at each classification level. 
 
102 
 
Table 8.2 
Classification Frequencies for BC-PSI Symptom Product Scores and Total Score 
Symptom  None  Mild  Moderate-Severe   
Headaches  36 (69.23%) 12 (23.08%) 4 (7.69%) 
Dizziness/light-headed 34 (65.38%) 13 (25.00%) 5 (9.62%) 
Nausea/feeling sick 45 (86.54%) 5 (9.62%) 2 (3.85%) 
Fatigue   25 (48.08%) 14 (26.92%) 13 (25.00%) 
Extra sensitive to noises 30 (57.69%) 13 (25.00%) 9 (17.31%) 
Irritable   34 (65.38%) 14 (26.92%) 4 (7.69%) 
Feeling Sad  27 (51.92%) 17 (32.69%) 8 (15.38%) 
Nervous or tense  33 (63.46%) 11 (21.15% 8 (15.38%) 
Temper problems 37 (71.15%) 10 (19.23%) 5 (9.62%) 
Poor concentration 32 (61.54%) 11 (21.15%) 9 (17.31%) 
Memory problems 28 (53.85%) 10 (19.23%) 14 (26.92%) 
Difficulty reading  36 (69.23%) 9 (17.31%) 7 (13.46%) 
Poor sleep  26 (50.00%) 11 (21.15%) 15 (28.85%) 
   Low  Normal  Unusually High Extremely High 
Total BC-PSI Score 7 (13.46%) 19 (36.54%) 10 (19.23%) 16 (30.77%) 
Note. N = 52. 
 
 
 
8.3.1 Correlations with Symptoms of Post-Concussion Syndrome 
Two-tailed Pearson’s correlations were conducted between serum S100B 
levels, depth of coma (GCS), duration of post-traumatic amnesia (WPTA), and 
symptoms of post-concussion syndrome as assessed by the BC-PSI. 
As displayed in Table 8.3, S100B was significantly moderately correlated 
with nausea/feeling sick, feeling sad, poor concentration, and worrying and dwelling 
on symptoms; GCS was significantly moderately correlated with memory problems; 
and WPTA was significantly moderately correlated with poor concentration, memory 
problems, and the extent to which participants believed they have damage to their 
brain. 
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Table 8.3 
Correlations between S100B, GCS, and WPTA with the Symptoms, Total, and Classification of the BC-
PSI 
Symptom    S100B (n=51) GCS (n=52) WPTA (n=36) 
Headaches    -.027  -.117  .072 
Dizziness/light-headed   .196  -.054  .229 
Nausea/feeling sick   .310*  -.045  .273 
Fatigue     .105  -.121  .182 
Extra sensitive to noises   -.123  -.005  .080 
Irritable     .119  -.112  .003 
Feeling Sad    .337*  -.144  .253 
Nervous or tense    .230  -.075  .209 
Temper problems   .168  -.237  .321 
Poor concentration   .342*  -.059  .337* 
Memory problems   .227  -.311*  .418* 
Difficulty reading    .006  .092  .128 
Poor sleep    .153  .122  .067 
Alcohol affecting more   .101  -.023  -.072 
Worrying and dwelling on symptoms .319*  .041  .250 
Believed damage to your brain  .215  -.273  .493** 
Total Score    .218  -.138  .264 
Classification    .233  -.215  .298 
Note. *p < .05 ** p < .01, two-tailed; N = 52. 
 
 
 
8.3.2 Predicting Severity of Post-Concussion Syndrome Symptoms 
Robust linear regression analyses were conducted for S100B predicting each 
of the significantly correlated symptoms of post concussion syndrome, and Jarque-
Bera tests for normality were conducted for each regression model. Depth of coma 
and duration of post-traumatic amnesia were added to each model to investigate any 
significant contributions to variance accounted for by each model. 
Breusch-Pagan heteroscedasticity analyses were then conducted for each 
model to investigate whether the variance (actual versus predicted) in the residuals of 
each model are dependent on the value of the dependent variable (severity of the 
symptom). 
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8.3.3 BC-PSI Total Score 
After removal of one outlier case, serum S100B levels significantly predicted 
the severity of the BC-PSI Total Score (sum of the product scores for each BC-PSI 
symptom), R
2
 = .089, F(1, 49) = 4.707, p < .05. The Jarque-Bera test for normality of 
this model was significant χ2(2, N=50) = 14.138, p < .001, and the algorithm for this 
model is presented in Equation 8.1. Depth of coma did not significantly add to the 
variance accounted for by Equation 8.1 R
2
 = .094, ΔR2 = .005 F(2, 49) = 2.434, p = 
.099, nor did duration of post-traumatic amnesia R
2
 = .169, ΔR2 = .051 F(2, 33) = 
3.157, p = .056.  
 
BC-PSI Total Score = (S100B x 2.881) + 27.986    (Eq. 8.1) 
 
A Breusch-Pagan test for heteroscedasticity conducted on Equation 8.1 
(S100B predicting BC-PSI Total Score) was significant, χ2(1, N=50) = 8.170, p < 
.001., and robust regression analysis revealed that S100B was no longer a significant 
predictor of BC-PSI Total Scores after accounting for heteroscedasticity of the model 
(β=1.623, p < .05). A post-hoc bivariate Pearson’s correlation revealed a significant 
moderate correlation between BC-PSI Total Score, and magnitude of error in the 
residuals (.782, p < .001). The residual error across BC-PSI Total Scores for 
Equation 8.1 can be found in Appendix F. 
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8.3.4 Sensitivity and Specificity of Predicting “Unusually High” Post-Concussion 
 Syndrome 
Of the 52 T180 participants who sustained a TBI, 26 participants were 
classified in the “Unusually High” (n = 10) or “Extremely High” (n = 16) range of 
post-concussion syndrome severity as measured by the BC-PSI Total Score. The 
following diagnostic and agreement statistics are for identifying the participants who 
experienced at least “Unusually High” post-concussion syndrome severity (n = 26). 
Receiver operating characteristics conducted on S100B and “Unusually 
High” BC-PSI Total Scores indicated an AUC of .552. As per Study One and Study 
Two, the S100B cut off point for identifying “Unusually High” BC-PSI Total Scores 
was set at 0.97μg/L for these analyses. Cohen’s Kappa analysis of this cut off point 
was non-significant, and indicated only a slight agreement for classification, κ = 
.176, p = .210. The participants classified as exhibiting “Unusually High” BC-PSI 
Total Scores did not have significantly higher S100B levels, t(42.040) = -.920, p = 
.174. 
Receiver operating characteristics conducted on GCS and “Unusually High” 
BC-PSI Total Scores indicated an AUC of .408. Consistent with Study One and 
Study Two, a GCS score of 12 (“Moderate” severity) was used as the cut off point 
for identifying “Unusually High” BC-PSI Total Scores. Cohen’s Kappa analysis of 
this cut off point was also non-significant, and indicated only a slight agreement for 
classification, κ = .154, p = .124. The participants classified as exhibiting “Unusually 
High” BC-PSI Total Scores had significantly lower GCS scores, t(35.934) = 1.671, p 
< .01. 
106 
 
Receiver operating characteristics conducted on WPTA and “Unusually 
High” BC-PSI Total Scores indicated an AUC of .557. The WPTA “Very Severe” 
classification (≥8 days) was used as the cut off point for identifying “Unusually 
High” BC-PSI Total Scores. Cohen’s Kappa analysis of this cut off point was also 
non-significant, and indicated a fair agreement for classification, κ = .111, p = .505. 
The participants classified as exhibiting “Unusually High” BC-PSI Total Scores had 
significantly higher WPTA scores, t(30.086) = -1.029, p < .05. 
The Receiver Operator Characteristics for S100B (AUC = .585), GCS (AUC 
= .579) and WPTA (AUC = .721) in identifying “Unusually High” BC-PSI scores 
are depicted below in Figure 8.01.  
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Figure 8.01. Receiver Operating Characteristics of S100B, GCS and WPTA with “Unusually High” BC-
PSI Total Scores. 
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The diagnostic and agreement statistics for S100B using 0.97μg/L; GCS 
using ≥ 12; and, WPTA using ≥ 8 days as respective cut offs for identifying 
“Unusually High” BC-PSI Total Scores are displayed below in Table 8.4.  
 
 
Table 8.4 
Diagnostic and Agreement Statistics for identifying “Unusually High” BC-PSI Scores using S100B, GCS, 
and WPTA 
   S100B   GCS   WPTA 
Sensitivity  .615 (.406 – .798) .231 (.090 – .436) .556 (.308 – .785) 
Specificity  .560 (.349 – .756) .923 (.749 – .991) .556 (.308 – .785) 
Efficiency  .588 (.442 – .724) .577 (.432 – .713) .556 (.308 – .785) 
False Positive Rate .440 (.244 – .651) .077 (.009 – .251) .444 (.215 – .692) 
False Negative Rate .385 (.202 – .594) .769 (.564 – .910) .444 (.215 – .692) 
Misclassification Rate .412 (.276 – .548) .423 (.287 – .689) .444 (.279 – .619) 
Note. 95% confidence intervals are displayed in parentheses. S100B cut off ≥ 97μg/L, n = 51; GCS cut 
off ≤ 12, n = 52; WPTA cut off ≥ 8 days, n = 36. 
 
 
 
Figures 8.02 through 8.07 on the following pages illustrate the respective 
sensitivity and specificity of S100B, GCS and WPTA in identifying “Unusually 
High” post-concussion syndrome severity (BC-PSI Total Score ≥ 10). The respective 
cut-offs for each independent variable (established above) are depicted in each plot. 
108 
 
Figures 8.02 and 8.03 below plot the sensitivity and specificity of S100B in 
identifying “Unusually High” post-concussion syndrome severity (BC-PSI Total 
Score), the cut off level of .97μg/L is depicted in the plot. 
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Figure 8.02. The sensitivity of serum S100B levels in identifying “Unusually High” post-concussion 
syndrome severity. 
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Figure 8.03. The specificity of serum S100B levels in identifying “Unusually High” post-concussion 
syndrome severity. 
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Figures 8.04 and 8.05 below plot the sensitivity and specificity of depth of 
coma (as measured by the GCS) in identifying “Unusually High” post-concussion 
syndrome severity (BC-PSI Total Score), the GCS cut off score of 12 is depicted in 
the plot. 
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Figure 8.04. The sensitivity of GCS scores in identifying “Unusually High” post-concussion syndrome 
severity. 
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Figure 8.05. The specificity of GCS scores in identifying “Unusually High” post-concussion syndrome 
severity. 
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Figures 8.06 and 8.07 below plot the sensitivity and specificity of duration of 
post-traumatic amnesia (as measured by the WPTA) in identifying “Unusually High” 
post-concussion syndrome severity (BC-PSI Total Score), the WPTA cut off level of 
≥ 8 days is depicted in the plot. 
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Figure 8.06. The sensitivity of WPTA scores in identifying “Unusually High” post-concussion 
syndrome severity. 
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Figure 8.07. The specificity of WPTA scores in identifying “Unusually High” post-concussion 
syndrome severity. 
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8.3.5 Sensitivity and Specificity of Predicting “Extremely High” Post-Concussion  
 Syndrome 
Of the 52 T180 participants who sustained a TBI, 16 participants were 
classified in the “Extremely High” range of post-concussion syndrome severity as 
measured by the BC-PSI Total Score. The following diagnostic and agreement 
statistics are for identifying the participants who experienced “Extremely High” post-
concussion syndrome severity. 
Cohen’s Kappa analysis of using a S100B cut off point of  ≥ .97μg/L for 
identifying “Extremely High” BC-PSI Total Scores was significant, and indicated a 
fair agreement for classification, κ = .271, p < .05, and receiver operating 
characteristics indicated an AUC of .659. The participants classified as exhibiting 
“Extremely High” BC-PSI Total Scores had significantly higher S100B levels, 
t(17.939) = -1.796, p < .01. 
Cohen’s Kappa analysis of using a GCS cut off point of ≤ 12 (“Moderate” 
depth of coma) for identifying “Extremely High” BC-PSI Total Scores was non-
significant, and indicated only a slight agreement for classification, κ = .161, p = 
.200, and receiver operating characteristics indicated an AUC of .529. The 
participants classified as exhibiting “Extremely High” BC-PSI Total Scores 
demonstrated a trend towards lower GCS scores, t(19.843) = .841, p = .059. 
Cohen’s Kappa analysis of using a WPTA cut off point of ≥ 8 days (“Very 
Severe” post-traumatic amnesia) for identifying “Extremely High” BC-PSI Total 
Scores was significant, and indicated a fair agreement for classification, κ = .348, p < 
.05, and receiver operating characteristics indicated an AUC of .668. The participants 
classified as exhibiting “Extremely High” BC-PSI Total Scores did not have 
significantly higher WPTA scores, t(17.471) = 1.713, p = .165. 
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The Receiver Operator Characteristics for S100B (AUC = .585), GCS (AUC 
= .579) and WPTA (AUC = .721) in identifying “Extremely High” BC-PSI Total 
Scores are depicted below in Figure 8.08.  
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Figure 8.08. Receiver Operating Characteristics of S100B, GCS and WPTA with “Extremely High” BC-
PSI Total Scores. 
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The diagnostic and agreement statistics for S100B using ≥ 0.97μg/L; GCS 
using ≤ 12; and, WPTA using ≥ 8 days as respective cut offs for identifying  
“Extremely High” BC-PSI Total Scores are displayed below in Table 8.5. 
 
 
 
Table 8.5 
Diagnostic and Agreement Statistics for identifying “Extremely High” BC-PSI Scores using S100B, GCS, 
and WPTA 
   S100B   GCS   WPTA 
Sensitivity  .750 (.476 – .927) .250 (.073 – .524) .750 (.428 – .945) 
Specificity  .571 (.394 – .737) .889 (.739 – .969) .625 (.406 – .812) 
Efficiency  .627 (.481 – .759) .692 (.549 – .813) .667 (.490 – .814) 
False Positive Rate .429 (.263 – .606) .111 (.031 – .261) .375 (.188 – .594) 
False Negative Rate .250 (.073 – .524) .750 (.476 – .927) .250 (.055 – .572) 
Misclassification Rate .373 (.241 – .356) .308 (.187 – .535) .333 (.186 – .386) 
Note. 95% confidence intervals are displayed in parentheses. S100B cut off ≥ .97μg/L, n = 51; GCS cut 
off ≤ 12, n = 52; WPTA cut off ≥ 8 days, n = 36. 
 
 
Figures 8.09 through 8.14 on the following pages illustrate the respective 
sensitivity and specificity of S100B, GCS and WPTA in identifying “Extremely 
High” post-concussion syndrome severity (BC-PSI Total Score ≥ 15). The respective 
cut-offs for each independent variable (established above) are depicted in each plot. 
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Figures 8.09 and 8.10 below plot the sensitivity and specificity of S100B in 
identifying “Extremely High” post-concussion syndrome severity (BC-PSI Total 
Score), the cut off level of .97μg/L is depicted in the plot. 
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Figure 8.09 The sensitivity of serum S100B levels in identifying “Extremely High” post-concussion 
syndrome severity. 
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Figure 8.10. The specificity of serum S100B levels in identifying “Extremely High” post-concussion 
syndrome severity. 
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Figures 8.11 and 8.12 below plot the sensitivity and specificity of depth of 
coma (as measured by the GCS) in identifying “Extremely High” post-concussion 
syndrome severity (BC-PSI Total Score), the GCS cut off score of 12 is depicted in 
the plot. 
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Figure 8.11. The sensitivity of GCS scores in identifying “Extremely High” post-concussion syndrome 
severity. 
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Figure 8.12. The specificity of GCS scores in identifying “Extremely High” post-concussion syndrome 
severity. 
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Figures 8.13 and 8.14 below plot the sensitivity and specificity of duration of 
post-traumatic amnesia (as measured by the WPTA) in identifying “Extremely High” 
post-concussion syndrome severity (BC-PSI Total Score), the WPTA cut off level of 
≥8 days is depicted in the plot. 
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Figure 8.13. The sensitivity of WPTA scores in identifying “Extremely High” post-concussion 
syndrome severity. 
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Figure 8.14. The specificity of WPTA scores in identifying “Extremely High” post-concussion 
syndrome severity. 
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8.3.6 Nausea/Feeling Sick 
Serum S100B levels significantly predicted the severity of the 
“nausea/feeling sick” BC-PSI item, R2 = .096, F(1, 50) = 5.201, p < .05. The Jarque-
Bera test for normality of this model was significant, χ2(2, N=50) = 344.080, p < 
.001, and the algorithm for this model is presented in Equation 8.2. Depth of coma 
did not significantly add to the variance accounted for by Equation 8.2, R
2
 = .111, 
ΔR2 = .015 F(2, 50) = 2.995, p = .373, nor did duration of post-traumatic amnesia, R2 
= .161, ΔR2 = .013 F(2, 34) = 3.059, p = .488.  
 
Nausea/Feeling Sick = (S100B x .193) + .320     (Eq. 8.2) 
 
A Breusch-Pagan test for heteroscedasticity conducted on Equation 8.2 
(S100B predicting severity of “Nausea/Feeling Sick”) was significant, χ2(1, N=51) = 
144.080, p < .001. Robust regression analysis, however, revealed that S100B 
remained a significant predictor of WTPA, despite heteroscedasticity of the model 
(β=.193, p < .05). A post-hoc bivariate Pearson’s correlation revealed a significant 
strong correlation between severity of nausea, and magnitude of error in the residuals 
(.921, p < .001). The residual error across severity of nausea/feeling sick for 
Equation 8.2 can be found in Appendix F. 
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8.3.7 Feeling Sad 
Serum S100B levels significantly predicted the severity of the “feeling sad” 
BC-PSI item, R
2
 = .113, F(1, 50) = 6.271, p < .05. The Jarque-Bera test for normality 
of this model was significant, χ2(2, N=51) = 83.073, p < .001, and the algorithm for 
this model is presented in Equation 8.3. Depth of coma did not significantly add to 
the variance accounted for by Equation 8.3, R
2
 = .118, ΔR2 = .004 F(2, 50) = 3.208, p 
= .625, nor did duration of post-traumatic amnesia, R
2
 = .140, ΔR2 = .011 F(2, 34) = 
2.608, p = .533.  
 
Feeling Sad = (S100B x .390) + 2.077     (Eq. 8.3) 
 
A Breusch-Pagan test for heteroscedasticity conducted on Equation 8.3 
(S100B predicting severity of “Feeling Sad”) was not significant, χ2(1, N=51) = 
0.033, p = .856. A post-hoc bivariate Pearson’s correlation revealed a significant 
moderate correlation between severity of feeling sad, and magnitude of error in the 
residuals (.718, p < .001). The residual error across severity of feeling sad for 
Equation 8.3 can be found depicted in Appendix F. 
  
119 
 
8.3.8 Poor Concentration 
Serum S100B levels significantly predicted the severity of the “poor 
concentration” BC-PSI item, R2 = .117, F(1, 50) = 6.503, p < .05. The Jarque-Bera 
test for normality of this model was significant, χ2(2, N=51) = 47.126, p < .001, and 
the algorithm for this model is presented in Equation 8.4. Depth of coma did not 
significantly add to the variance accounted for by Equation 8.4, R
2
 = .118, ΔR2 = 
.001 F(2, 50) = 3.202, p = .862, nor did duration of post-traumatic amnesia, R
2
 = 
.143, ΔR2 = .048 F(2, 34) = 2.669, p = .189.  
 
Poor Concentration = (S100B x .427) + 2.035    (Eq. 8.4) 
 
A Breusch-Pagan test for heteroscedasticity conducted on Equation 8.4 
(S100B predicting severity of “Poor Concentration”) was not significant, χ2(1, N=51) 
= 1.385, p = .239. A post-hoc bivariate Pearson’s correlation revealed a significant 
moderate correlation between severity of poor concentration, and magnitude of error 
in the residuals (.782, p < .001). The residual error across severity of poor 
concentration for Equation 8.4 can be found depicted in Appendix F. 
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8.3.9 Worrying and Dwelling 
Serum S100B levels significantly predicted the severity of the “worrying and 
dwelling” BC-PSI item, R2 = .102, F(1, 50) = 5.569, p < .05. The Jarque-Bera test 
for normality of this model was not significant, χ2(2, N=51) = 4.621, p=.099, and the 
algorithm for this model is presented in Equation 8.5. Depth of coma did not 
significantly add to the variance accounted for by Equation 8.5, R
2
 = .118, ΔR2 = 
.001 F(2, 50) = 3.202, p = .862, nor did duration of post-traumatic amnesia, R
2
 = 
.146, ΔR2 = .007 F(2, 34) = 2.741, p = .600.  
 
Worrying and Dwelling = (S100B x .089) + 1.758    (Eq. 8.5) 
 
A Breusch-Pagan test for heteroscedasticity conducted on Equation 8.5 
(S100B predicting severity of “Worrying and Dwelling”) was not significant, χ2(1, 
50) = 1.145, p = .285. A post-hoc bivariate Pearson’s correlation revealed a 
significant moderate correlation between severity of worrying and dwelling, and 
magnitude of error in the residuals (.477, p < .001). The residual error across severity 
of poor concentration for Equation 8.5 can be found depicted in Appendix F. 
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8.4 Quality of Life Results 
As per the QOLI protocol (Frisch, 1994), the importance and satisfaction of 
each QOLI domain were multiplied to produce Weighted Satisfaction Scores for 
each domain. Table 8.6 displays the participant means and standard deviations for 
importance, satisfaction, and weighted satisfaction for each of the QOLI domains. 
 
Table 8.6 
Participant Means and Standard Deviations for the Domains of the QOLI 
Domain    Importance Satisfaction Weighted Satisfaction 
Health    1.65 (0.52) 0.65 (2.03) 1.12 (3.65) 
Self-Esteem   1.44 (0.64) 1.06 (1.80) 1.62 (3.16) 
Goals and Values   1.48 (0.58) 1.00 (1.90) 1.62 (3.21) 
Money    1.08 (0.62) 0.75 (1.87) 0.58 (2.52) 
Work    1.12 (0.51) 0.60 (1.98) 0.46 (2.62) 
Play    1.46 (0.58) 1.21 (1.64) 1.87 (2.77) 
Learning    1.12 (0.65) 1.29 (1.60) 1.54 (2.30) 
Creativity   1.08 (0.71) 1.02 (1.59) 1.25 (2.21) 
Helping    1.29 (0.64) 1.10 (1.62) 1.69 (2.45) 
Love    1.50 (0.67) 1.04 (1.96) 1.83 (3.48) 
Friends    1.50 (0.67) 2.04 (1.43) 3.48 (2.58) 
Children    1.25 (0.79) 2.00 (1.40) 2.81 (2.85) 
Relatives   1.25 (0.65) 1.88 (1.38) 2.87 (2.35) 
Home     1.60 (0.50)  2.02 (1.38) 3.27 (2.50) 
Neighbourhood   1.13 (0.56) 1.81 (1.46) 2.37 (2.21) 
Community   1.15 (0.64) 1.38 (1.39) 1.88 (2.13) 
Note. N = 52. 
 
 
QOLI Total Scores are calculated by dividing the total sum of Weighted 
Satisfaction Score by the number of domains that the respondent cited as being either 
“important” or “extremely important” (i.e., not “not important”). Table 8.7 displays 
frequencies for Total QOLI scores at each classification level.  
 
Table 8.7 
Classification Frequencies for QOLI Total Scores 
    Very Low Low  Average  High 
Total Score   14 (26.92%) 5 (9.62%) 20 (38.46%) 13 (25.00%) 
Note. N = 52. 
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8.4.1 Correlations with Domains of Quality of Life 
Two-tailed Pearson’s correlations were conducted between serum S100B 
levels, depth of coma (GCS), duration of post-traumatic amnesia (WPTA), and 
domains of quality of life as assessed by the QOLI. Correlation analyses were also 
conducted for S100B, GCS, and WPTA with QOLI Total Scores, and Thomas et. al’s 
(2012) QOLI Factor Scores (Factor 1: Self-Functioning & Activity; Factor 2: Self-
Actualisation; and, Factor 3: Family & Environment) 
As displayed in Table 8.8, S100B was significantly moderately correlated 
with QOLI Total Score, Thomas et al.’s Factor 2 (Self-Actualisation), goals and 
values, learning, creativity, helping, and love; GCS was significantly moderately 
correlated with helping, and friends; and WPTA was significantly moderately 
correlated with QOLI Total Score, Thomas et. al’s Factor 3 (Family & Environment), 
love, friends, and home. 
 
 
Table 8.8 
Correlations between S100B, GCS, and WPTA with the Total Score, Thomas et al. Factors, and 
Domains of the QOLI 
Factor/Domain    S100B (n=51) GCS (n=52) WPTA (n=36) 
QOLI Total Score    -.282*  -.150  -.344 
Thomas et al. Factor 1   -209  .067  -.242 
Thomas et al. Factor 2   -.303*  .198  -.256 
Thomas et al. Factor 3   -.253  .150  -.363* 
Health     -.125  -.062  -.102 
Self-Esteem    -.241  .077  -.290 
Goals and Values    -.287*  .008  -.263 
Money     -.158  .163  -.226 
Work     -.038  .257  -.190 
Play     -.088  .075  -.116 
Learning     -.303*  .102  -.191 
Creativity    -.301*  .164  -.315 
Helping     -.321*  .308*  -.237 
Love     -.323*  .255  -.474** 
Friends     -.013  .274*  -.346* 
Children     -.196  -.130  -.052 
Relatives    -.078  -.140  -.014 
Home      -.143  .109  -.398* 
Neighbourhood    -.213  .019  -.011 
Community    -.016  .110  -.034 
Note. *p < .05 ** p < .01, two-tailed; N = 52. 
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8.4.2 QOLI Total Score 
Serum S100B levels significantly predicted participants’ QOLI Total Score, 
R
2
 = .079, F(1, 50) = 4.220, p < .05. The Jarque-Bera test for normality of this model 
was not significant, χ2(2, N=51) = 1.822, p = .402, and the algorithm for this model is 
presented in Equation 8.6. Depth of coma did not significantly add to the variance 
accounted for by Equation 8.6, R
2
 = .086, ΔR2 = .006 F(2, 50) = 2.251, p = .116 , nor 
did duration of post-traumatic amnesia, R
2
 = .127, ΔR2 = .065 F(2, 34) = 2.326, p = 
.114. 
  
QOLI Total Score = (S100B x -1.914) + 35.005    (Eq. 8.6) 
 
A Breusch-Pagan test for heteroscedasticity conducted on Equation 8.6 was 
not significant, χ2(1, N=51) = .040, p = .842. A post-hoc bivariate Pearson’s 
correlation revealed there was no significant correlation between QOLI Total Scores 
and magnitude of error in the residuals (-.250, p=.077). The residual error across 
QOLI Total Scores (expressed as T-Scores for clinical interpretation) for Equation 
8.6 can be found depicted in Appendix F. 
 
8.4.3 Sensitivity and Specificity of Predicting “Low” Quality of Life 
Of the 52 T180 participants who sustained a TBI, 19 participants were 
classified in the “Low” (T-Score = 37-42; n = 5) or “Very Low” (T-Score = 0-36; n = 
14) range of quality of life as measured by the QOLI Total Score. The following 
diagnostic and agreement statistics are for identifying the participants who 
experienced at least “Low” (T-Score ≤ 42; n = 19) overall quality of life. 
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Using ≥ .97μg/L as a S100B cut-off point for identifying “Low” QOLI Total 
scores, Cohen’s Kappa analysis of this cut off point was non-significant and 
indicated a fair agreement, κ = .259, p = .055, and receiver operating characteristics 
indicated an AUC of .633. The participants classified as exhibiting “Low” QOLI 
Total Scores had significantly higher S100B levels, t(24.041) = -1.501, p < .05. 
Cohen’s Kappa analysis using ≤ 12 as a GCS cut-off point for identifying 
“Low” QOLI Total scores was non-significant, and indicated only a slight agreement 
for classification, κ = .102, p = .390, and receiver operating characteristics indicated 
an AUC of .524. The participants classified as exhibiting “Low” QOLI Total Scores 
had significantly lower GCS scores, t(23.947) = -1.036, p < .05. 
Cohen’s Kappa analysis using a WPTA cut off point of ≥ 8 days (“Very 
Severe” post-traumatic amnesia) for identifying “Low” QOLI Total Scores was non-
significant, and indicated only a slight agreement for classification, κ = .167, p = 
.298, and receiver operating characteristics indicated an AUC of .640. The 
participants classified as exhibiting “Low” QOLI Total Scores did not have 
significantly higher WPTA scores, t(19.691) = -1.390, p = .147. 
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The Receiver Operator Characteristics for S100B (AUC = .633), GCS (AUC 
= .524) and WPTA (AUC = .640) in identifying “Low” QOLI Total Scores are 
depicted below in Figure 8.15.  
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Figure 8.15. Receiver Operating Characteristics of S100B, GCS and WPTA with “Low” QOLI Total 
Scores. 
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The diagnostic and agreement statistics for S100B using ≥ .97μg/L; GCS 
using ≤ 12; and, WPTA using ≥ 8 days as respective cut offs for identifying “Low” 
QOLI Total Scores are displayed below in Table 8.9 
 
 
Table 8.9 
Diagnostic and Agreement Statistics for identifying “Low” QOLI Scores using S100B, GCS, and WPTA 
   S100B   GCS   WPTA 
Sensitivity  .684 (.434 – .874) .211 (.061 – .456) .615 (.316 – .861) 
Specificity  .594 (.406 – .763) .879 (.718 – .966) .565 (.345 – .768) 
Efficiency  .627 (.481 – .759) .635 (.490 – .764) .583 (.408 – .745) 
False Positive Rate .406 (.237 – .594) .121 (.034 – .282) .435 (.232 – .655) 
False Negative Rate .316 (.126 – .566) .789 (.544 – .939) .385 (.139 – .684) 
Misclassification Rate .373 (.241 – .428) .365 (.236 – .606) .417 (.255 – .514) 
Note. 95% confidence intervals are displayed in parentheses. S100B cut off ≥ .97μg/L, n = 51; GCS cut 
off ≤ 12, n = 52; WPTA cut off ≥ 8 days, n = 36. 
 
 
 
Figures 8.16 through 8.21 on the following pages illustrate the respective 
sensitivity and specificity of S100B, GCS and WPTA in identifying “Low” quality of 
life (QOLI Total T-Score ≤ 42). The respective cut-offs for each independent 
variable (established above) are depicted in each plot. 
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Figures 8.16 and 8.17 below plot the sensitivity and specificity of S100B in 
identifying “Low” quality of life (QOLI Total Score), the cut off level of .97μg/L is 
depicted in the plot. 
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Figure 8.16. The sensitivity of serum S100B levels in identifying “Low” quality of life. 
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Figure 8.17. The specificity of serum S100B levels in identifying “Low” quality of life. 
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Figures 8.18 and 8.19 below plot the sensitivity and specificity of depth of 
coma (as measured by the GCS) in identifying “Low” quality of life (QOLI Total 
Score), the cut off level of 12 is depicted in the plot. 
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Figure 8.18. The sensitivity of GCS scores in identifying “Low” quality of life. 
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Figure 8.19. The specificity of GCS scores in identifying “Low” quality of life. 
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Figures 8.20 and 8.21 below plot the sensitivity and specificity of duration of 
post-traumatic amnesia (as measured by the WPTA) in identifying “Low” quality of 
life (QOLI Total Score), the cut off level of ≥ 8 days is depicted in the plot. 
 
≥ 8 Days
0.0
0.1
0.2
0.3
0.4
0.5
0.6
0.7
0.8
0.9
1.0
0 7 14 21 28 35
 
 
Figure 8.20. The sensitivity of WPTA scores in identifying “Low” quality of life. 
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Figure 8.21. The specificity of WPTA scores in identifying “Low” quality of life. 
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8.4.4 Sensitivity and Specificity of Predicting “Very Low” Quality of Life 
Of the 52 T180 participants who sustained a TBI, 14 participants were 
classified in the “Very Low” range of quality of life as measured by the QOLI (T-
Score ≤ 36). The following diagnostic and agreement statistics are for identifying the 
participants who experienced “Very Low” quality of life. 
Using .97μg/L as a S100B cut off point for identifying “Very Low” QOLI 
Total scores, Cohen’s Kappa analysis of this cut off point was non-significant and 
indicated only a slight agreement for classification, κ = .145, p = .242. Receiver 
operating characteristics indicated an AUC of .583. The participants classified as 
exhibiting “Very Low” QOLI Total Scores had significantly higher S100B levels, 
t(14.947) = -1.375, p < .01. 
Cohen’s Kappa analysis using ≤ 12 as a GCS cut-off point for identifying 
“Very Low” QOLI Total scores was non-significant, and indicated only a slight 
agreement for classification, κ = .102, p = .390. Receiver operating characteristics 
indicated an AUC of .477. The participants classified as exhibiting “Very Low” 
QOLI Total Scores had significantly lower GCS scores, t(14.853) = 1.302, p < .001. 
Cohen’s Kappa analysis using a WPTA cut off point of ≥ 8 days (“Very 
Severe” post-traumatic amnesia) for identifying “Very Low” QOLI Total Scores was 
non-significant, and indicated only a slight agreement for classification, κ = .222, p = 
.109. Receiver operating characteristics indicated an AUC of .723. The participants 
classified as exhibiting “Very Low” QOLI Total Scores had significantly higher 
WPTA scores, t(8.647) = -1.798, p < .05. 
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The Receiver Operator Characteristics for S100B (AUC = .633), GCS (AUC 
= .524) and WPTA (AUC = .640) in identifying “Very Low” QOLI Total Scores are 
depicted below in Figure 8.22.  
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Figure 8.22. Receiver Operating Characteristics of S100B, GCS and WPTA with “Very Low” QOLI Total 
Scores. 
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The diagnostic and agreement statistics for S100B using ≥ .97μg/L; GCS 
using ≤ 12; and, WPTA using ≥ 8 days as respective cut offs for identifying “Very 
Low” QOLI Total Scores are displayed below in Table 8.10. 
 
 
Table 8.10 
Diagnostic and Agreement Statistics for identifying “Very Low” QOLI Scores using S100B, GCS, and 
WPTA 
   S100B   GCS   WPTA 
Sensitivity  .643 (.351 – .872) .286 (.084 – .581) .750 (.349 – .968) 
Specificity  .541 (.369 – .705) .895 (.752 – .971) .571 (.372 – .755) 
Efficiency  .569 (.422 – .707) .731 (.590 – .844) .611 (.435 – .769) 
False Positive Rate .459 (.295 – .631) .105 (.029 – .248) .429 (.245 – .628) 
False Negative Rate .357 (.128 – .649) .714 (.419 – .916) .250 (.032 – .651) 
Misclassification Rate .431 (.293 – .421) .269 (.156 – .481) .389 (.231 – .349) 
Note. 95% confidence intervals are displayed in parentheses. S100B cut off ≥ .97μg/L, n = 51; GCS cut 
off ≤ 12, n = 52; WPTA cut off ≥ 8 days, n = 36. 
 
 
 
Figures 8.23 through 8.28 on the following pages illustrate the respective 
sensitivity and specificity of S100B, GCS and WPTA in identifying “Very Low” 
quality of life (QOLI Total T-Score ≤ 36). The respective cut-offs for each 
independent variable (established above) are depicted in each plot. 
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Figures 8.23 and 8.24 below plot the sensitivity and specificity of S100B in 
identifying “Very Low” quality of life (QOLI Total Score), the cut off level of 
.97μg/L is depicted in the plot. 
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Figure 8.23. The sensitivity of serum S100B levels in identifying “Very Low” quality of life. 
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Figure 8.24. The specificity of serum S100B levels in identifying “Very Low” quality of life. 
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Figures 8.25 and 8.26 below plot the sensitivity and specificity of depth of 
coma (as measured by the GCS) in identifying “Very Low” quality of life (QOLI 
Total Score), the cut off level of GCS = 12 is depicted in the plot. 
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Figure 8.25. The sensitivity of GCS scores in identifying “Very Low” quality of life. 
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Figure 8.26. The specificity of GCS scores in identifying “Very Low” quality of life. 
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Figures 8.27 and 8.28 below plot the sensitivity and specificity of duration of 
post-traumatic amnesia (as measured by the WPTA) in identifying “Very Low” 
quality of life (QOLI Total Score), the cut off level of ≥ 8 days is depicted in the 
plot. 
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Figure 8.27. The sensitivity of WPTA scores in identifying “Very Low” quality of life. 
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Figure 8.28. The specificity of WPTA scores in identifying “Very Low” quality of life. 
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8.4.5 Thomas et. al.’s Factor 2: Self-Actualisation 
Serum S100B levels significantly predicted scores on the Thomas et. al’s 
(2012)  “Self-Actualisation” QOLI Factor, R2 = .092, F(1, 50) = 4.965, p < .05. The 
Jarque-Bera test for normality of this model was not significant, χ2(2, N=51) =.917, 
p=.632, and the algorithm for this model is presented in Equation 8.7. Depth of coma 
did not significantly add to the variance accounted for by Equation 8.7, R
2
 = .107, 
ΔR2 = .015 F(2, 50) = 2.885, p = .066, nor did duration of post-traumatic amnesia, R2 
= .111, ΔR2 = .015 F(2, 34) = 1.992, p = .153.  
 
Self-Actualisation = (S100B x -.147) + 1.948     (Eq. 8.7) 
 
A Breusch-Pagan test for heteroscedasticity conducted on Equation 8.7 was 
not significant, χ2(1, N=51) = .031, p = .861. A post-hoc bivariate Pearson’s 
correlation revealed there was no significant correlation between Self-Actualisation 
scores and magnitude of error in the residuals (.159, p=.264). The residual error 
across Self-Actualisation for Equation 8.7 can be found depicted in Appendix F. 
 
8.4.6 Goals and Values 
Serum S100B levels significantly predicted the weighted satisfaction of the 
“Goals and Values” QOLI domain, R2 = .082, F(1, 50) = 4.403, p < .05. The Jarque-
Bera test for normality of this model was not significant, χ2(2, N=51) = 2.640, 
p=.276, and the algorithm for this model is presented in Equation 8.8. Depth of coma 
did not significantly add to the variance accounted for by Equation 8.8, R
2
 = .087, 
ΔR2 = .005 F(2, 50) = 2.287, p = .113, nor did duration of post-traumatic amnesia, R2 
= .119, ΔR2 = .016 F(2, 34) = 2.164, p = .131.  
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Goals and Values = (S100B x -.228) + 2.187     (Eq. 8.8) 
 
A Breusch-Pagan test for heteroscedasticity conducted on Equation 8.8 was 
not significant, χ2(1, N=51) = 1.239, p = .266. A post-hoc bivariate Pearson’s 
correlation revealed a significant weak correlation between weighted satisfaction of 
goals and values, and magnitude of error in the residuals (.335, p < .05). The residual 
error across weighted satisfaction of goals and values for Equation 8.8 can be found 
depicted in Appendix F. 
 
8.4.7 Learning 
Serum S100B levels significantly predicted the weighted satisfaction of the 
“Learning” QOLI domain, R2 = .092, F(1, 50) = 4.969, p < .05. The Jarque-Bera test 
for normality of this model was significant, χ2(2, N=51) = 19.615, p < .001, and the 
algorithm for this model is presented in Equation 8.9. Depth of coma did not 
significantly add to the variance accounted for by Equation 8.9, R
2
 = .092, ΔR2 = 
.000 F(2, 50) = 2.439, p = .098, nor did duration of post-traumatic amnesia, R
2
 = 
.106, ΔR2 = .001 F(2, 34) = 1.905, p = .165.  
 
Learning = (S100B x -.167) + 1.904      (Eq. 8.9) 
 
A Breusch-Pagan test for heteroscedasticity conducted on Equation 8.9 was 
not significant, χ2(1, N=51) = .005, p = .947. A post-hoc bivariate Pearson’s 
correlation revealed there was no significant correlation between weighted 
satisfaction of “Learning”, and magnitude of error in the residuals (.164, p=.250). 
The residual error across weighted satisfaction of learning for Equation 8.9 can be 
found depicted in Appendix F. 
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8.4.8 Creativity 
Serum S100B levels significantly predicted the weighted satisfaction of the 
“Creativity” QOLI domain, R2 = .091, F(1, 50) = 4.890, p < .05. The Jarque-Bera 
test for normality of this model was significant, χ2(2, N=51) = 61.200, p < .001, and 
the algorithm for this model is presented in Equation 8.10. Depth of coma did not 
significantly add to the variance accounted for by Equation 8.10, R
2
 = .100, ΔR2 = 
.009 F(2, 50) = 2.659, p = .080, nor did duration of post-traumatic amnesia, R
2
 = 
.106, ΔR2 = .030 F(2, 34) = 3.016, p = .063.  
 
Creativity = (S100B x -.166) + 1.685      (Eq. 8.10) 
 
A Breusch-Pagan test for heteroscedasticity conducted on Equation 8.10 was 
not significant, χ2(1, N=51) = .001, p = .982. A post-hoc bivariate Pearson’s 
correlation revealed there was no significant correlation between weighted 
satisfaction of “Creativity,” and magnitude of error in the residuals (.043, p=.764). 
The residual error across weighted satisfaction of creativity for Equation 8.10 can be 
found depicted in Appendix F. 
 
8.4.9 Helping 
Serum S100B levels significantly predicted the weighted satisfaction of the 
“Helping” QOLI domain, R2 = .103, F(1, 50) = 5.614, p < .05. The Jarque-Bera test 
for normality of this model was not significant χ2(2, N=51) =.519, p=.771, and the 
algorithm for this model is presented in Equation 8.11. Depth of coma did not 
significantly add to the variance accounted for by Equation 8.11 R
2
 = .162, ΔR2 = 
.058 F(2, 50) = 4.606, p = .074, nor did duration of post-traumatic amnesia R
2
 = .109, 
ΔR2 = .013 F(2, 34) = 1.960, p = .502.  
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Helping = (S100B x -.196) + 2.218      (Eq. 8.11) 
 
A Breusch-Pagan test for heteroscedasticity conducted on Equation 8.11 was 
not significant, χ2(1, N=51) = .080, p = .777. A post-hoc bivariate Pearson’s 
correlation revealed there was no significant correlation between weighted 
satisfaction of “Helping,” and magnitude of error in the residuals (.042, p=.772). The 
residual error across weighted satisfaction of helping for Equation 8.11 can be found 
depicted in Appendix F. 
 
8.4.10 Love 
Serum S100B levels significantly predicted the weighted satisfaction of the 
“Love” QOLI domain, R2 = .103, F(1, 50) = 5.690, p < .05. The Jarque-Bera test for 
normality of this model was significant χ2(2, N=51) = 21.964, p < .001, and the 
algorithm for this model is presented in Equation 8.12. Depth of coma did not 
significantly add to the variance accounted for by Equation 8.12 R
2
 = .146, ΔR2 = 
.042 F(2, 50) = 4.106, p = .131 – however, duration of post-traumatic amnesia 
significantly added to the variance accounted for by this equation R
2
 = .273, ΔR2 = 
.144 F(2, 34) = 6.007, p < .05. The Jarque-Bera test for normality of this improved 
model was not significant χ2(2, N=35) =.098, p=.952, and the algorithm for this 
model is presented in Equation 8.13. 
  
Love = (S100B x -.276) + 2.651      (Eq. 8.12) 
 
Love = (S100B x -.134) x (WPTA x 155) + 4.071    (Eq. 8.13) 
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A Breusch-Pagan test for heteroscedasticity conducted on Equation 8.12 was 
not significant, χ2(1, N=51) = 1.355, p = .244. A post-hoc bivariate Pearson’s 
correlation revealed there was no significant correlation between weighted 
satisfaction of “Love,” and magnitude of error in the residuals (-.200, p=.160). 
A Breusch-Pagan test for heteroscedasticity conducted on Equation 8.13 was 
not significant, χ2(1, N=35) =.124, p = .725. A post-hoc bivariate Pearson’s 
correlation revealed there was no significant correlation between weighted 
satisfaction of “Love,” and magnitude of error in the residuals (-.066, p=.706). The 
residual error across weighted satisfaction of love for Equation 8.12 and Equation 
8.13 can be found depicted in Appendix F. 
 
8.5 Discussion 
 This study investigated the prognostic utility of serum S100B concentrations 
with reference to the severity of symptoms of post-concussion syndrome (PCS) and 
quality of life experienced by TBI patients 180 days following injury. More 
specifically, the present study quantified the accuracy that S100B holds in predicting 
the presence and severity of PCS symptoms and factors relating to quality of life that 
can be chronic and enduring for patients that have suffered a TBI. 
  
8.5.1 S100B and Post-Concussion Syndrome 
 S100B has been shown to be associated with symptoms of PCS at two weeks 
to eight months post-injury (Savola & Hillborn, 2003), and three months post-injury 
(Ingebrigsten et al., 2000). However, no such significant associations were found in 
the studies of Bazarian et al. (2006), and Stålnacke et al. (2005). In alignment with 
the proposed relationship, however, the current study hypothesised that serum 
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concentrations of S100B would be significantly correlated with the presence and 
severity of PCS symptoms, and as a result, the clinical classification of PCS could be 
predicted by patients’ S100B values.  
These hypotheses were supported by the data in that S100B was significantly 
moderately correlated with PCS symptoms of feeling sad, nausea and feeling sick, 
poor concentration, and worrying and dwelling on symptoms. Further, regression 
analyses illustrated that neither GCS nor WPTA accounted for any significant 
additional variance in the outcome of these symptoms. This result supports the 
results of Ingebrigsten et al. (2000) who reported that mild TBI patients who tested 
positive for S100B, exhibited increased frequencies of somatic and cognitive 
symptoms three months post injury, rather than symptoms of psychological origin. 
Although the primary complaints identified in the present study were poor sleep, 
memory problems, and fatigue, with over 25% of the participants rating these 
symptoms as “Moderate-Severe,” it can be argued that S100B’s ability to account for 
variance in the less endorsed symptoms gives it clinical utility towards the more 
variable nuances of post TBI sequelae. 
Further to the above, the results of the present study illustrated that S100B 
was able to categorically discriminate between those that reported “Extremely High” 
range post-concussion symptomatology, as assessed by the BC-PCSI, and those that 
did not. This result extends the implications drawn by Savola and Hillbom’s (2003) 
study of 172 mild TBI patients. The researchers interviewed patients using a 
modified Rivermead Post-Concussion Symptoms Questionnaire (RPQ; King et al., 
1995), and a follow-up interview at eight months to ensure chronicity of the endorsed 
symptoms. Savola and Hillbom concluded that S100B can be used as a specific 
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predictor of PCS, and that their results indicate an organic aetiology for the PCS 
symptoms that are associated with elevated serum concentrations of S100B. 
 While the area under the curve for S100B correctly classifying “Extremely 
High” PCS symptomatology was only poor to fair, and comparable to that of the 
WPTA, it should be noted that those patients had significantly higher serum S100B 
levels, but not significantly longer durations of post-traumatic amnesia. Further, 
S100B and WPTA held identically moderate properties of sensitivity indicating 
equivalent clinical risk of false-positive classification, whereas WPTA held stronger 
specificity indicating less risk of false-negative classification. As such, clinicians 
considering both serum S100B levels and WPTA scores in a combined prognostic 
rubric would benefit from increased accuracy in identifying those patients at risk of 
enduring chronic severe PCS symptomatology. 
 
8.5.2 S100B and Quality of Life 
As discussed in the preceding literature review, S100B has been shown to be 
associated with poorer quality of life (Woertgen et al., 2002), prolonged return to 
work (Stranjalis et al., 2004; Metting et al., 2012), poorer somatic health (Stålnacke 
et al., 2013), and symptoms related to stress disorders (Sojka et al., 2006). Consistent 
with the associated literature, this study hypothesised that serum concentrations of 
S100B would be significantly inversely correlated with domains of quality of life 
following TBI, and further, that the clinical classification of poorer quality of life 
could be predicted by patients’ serum concentrations of S100B. 
 These hypotheses were somewhat supported by the data of the present study, 
in that overall quality of life, as assessed by the QOLI Total Score, could be 
predicted by serum S100B levels, and neither GCS scores nor WPTA duration 
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significantly accounted for any additional variance. While there was no statistical 
issue with residual error across the continuum of quality of life, it should be noted 
that S100B only accounted for eight percent of the variance in this measure. Further, 
despite significantly higher S100B levels being found for the patients who 
experienced “Low” and “Very Low” quality of life, S100B was inefficient in 
correctly classifying these patients. Similar results were found for GCS and WPTA 
indicating that no acute independent variable was statistically efficient in identifying 
those that experienced poorer overall quality of life, and those that did not. 
 In light of the above, S100B concentrations were shown to be significantly 
correlated with various domains of quality of life – namely: self-actualisation; goals 
and values; learning; creativity; helping; and love. Neither GCS nor WPTA 
significantly accounted for any additional variance in these domains except for 
WPTA to the domain of love. Interestingly, the domains of quality of life that S100B 
was correlated with were also the domains that the participants rated as being least 
satisfied with.  
These domain specific findings are consistent with the longitudinal research 
by Oddy, Coughlan, and Tyerman (1985) who observed that most TBI patients 
experienced pronounced difficulty in successfully establishing romantic relationships 
after their injury. Further, Stålnacke et al.’s (2005) study of S100B and life 
satisfaction one year post TBI found that patients with higher levels of S100B had 
poorer life satisfaction, largely attributable to higher levels of disability. The 
researchers added that the domains where TBI patients were “very dissatisfied” were 
those of finances, leisure, sex life, and relationships. The present study extends this 
area of the literature by evidencing a potential biological constituent and predictor of 
such outcomes. Further, this study is the first to have utilised the QOLI, a well 
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established measure with validation within TBI populations, as a dependent variable 
in the examination of the prognostic utility of serum S100B. 
 
8.5.3 Conclusions 
 Following the acute treatment of management of TBI, the longer term 
chonicity of post-concussion symptoms and their effect on daily life and functioning 
is difficult to predict. For most patients, these symptoms typically abate across the 
first six months following their injury – however, for some patients, these impacts 
are enduring. Findings of the present study indicated that serum concentrations of 
S100B are significantly correlated with various symptoms of PCS and domains of 
quality of life following TBI.  Although S100B in isolation offers insufficient 
prognostic accuracy for these clinical outcomes, the results of the present study hold 
implications for future research into biomarkers for TBI. The study contributes to the 
associated literature by incorporating extensively validated measures of outcome. 
Future research into S100B, or any other potential biomarker for TBI, would benefit 
from the translational implications of using such measures. 
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Chapter 9 
General Discussion 
9.1 Discussion of Findings 
The aim of the present thesis was to investigate the prognostic utility for 
serum S100B following TBI, with specific emphasis on neuropsychological 
functioning as the definable outcomes. As such, this thesis aimed to elucidate the 
ability for S100B to make prognoses for duration of post-traumatic amnesia, severity 
of cognitive impairment, presence of symptoms of post-concussion syndrome, and 
deficits in domains that are associated with quality of life. 
Study One: T0 investigated the utility of serum S100B with reference to the 
diagnosis and management of TBI immediately following injury. More specifically, 
the first study elucidated the diagnostic, categorical, and operational utility of a 
single collection of serum S100B by identifying statistical relationships between 
serum levels of S100B and the current acute measures for classifying TBI. Consistent 
with hypotheses, serum S100B concentrations were found to be significantly 
correlated with GCS and WPTA scores. In short, the higher the level of S100B, the 
deeper the coma following injury and the longer the post-traumatic amnesia 
experienced by the patient. Categorically, S100B was able to discriminate between 
mild, moderate, and severe depths of coma as measured by the GCS, and also, which 
patients would endure “Very Severe” post-traumatic amnesia (greater than one week 
following injury) as measured by the WPTA. The results of the first study contribute 
to the empirical research concerned with validation of S100B in the medical 
management of TBI, and extend the associated literature by investigating the 
biomarker’s utility with a clinical variable that is currently used in the treatment and 
management of TBI – namely the WPTA. 
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Study Two: T60 investigated the prognostic utility of serum S100B with 
reference to cognitive impairment experienced by TBI patients 60 days post injury. 
More specifically, the second study aimed to quantify the accuracy that S100B holds 
in predicting the magnitude of ipsative impairment experienced by TBI patients, 
across a variety of standardised measures of cognitive ability. It was hypothesised 
that serum S100B levels would be significantly correlated with the magnitude of 
ipsative impairment on each of the measures of cognitive ability. Contrary to 
hypotheses, however, S100B was not significantly correlated with ipsative 
impairment on any of the cognitive subtests utilised in this study. Further, regression 
analyses for cognitive impairment illustrated that S100B made no significant 
contributions to any prognostic models. Despite the absence of clinical significance, 
all correlations between serum concentrations of S100B and ipsative cognitive 
impairment were found to be in the hypothesised direction.  
Although results of the second study indicated that S100B concentrations 
were not significantly correlated with the magnitude of any ipsative cognitive 
impairment, it should be acknowledged that GCS and WPTA scores could not 
prognosticate impairment either. The results illustrate that cognitive impairment is 
remarkably difficult to predict from information available in the acute setting. 
Further, from a translational perspective, the second study illustrates that any 
accurate prognoses relating to cognitive impairment following TBI require acute 
neuropsychological assessment and consultation, and that prognoses based on 
biological factors alone while in an acute setting remains elusive, if not illusive. By 
incorporating an ipsative impairment model of post injury cognitive functioning as a 
dependent variable, the second study extends the associated TBI biomarker literature. 
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Study Three: T180 investigated the prognostic utility of serum S100B 
concentrations with reference to the severity of symptoms of post-concussion 
syndrome (PCS) and quality of life experienced by TBI patients 180 days following 
injury. More specifically, the third study aimed to quantify the accuracy that S100B 
holds in predicting the presence and severity of PCS symptoms and factors relating 
to quality of life that can be chronic and enduring for patients that have suffered a 
TBI. As hypothesised, S100B was significantly moderately correlated with PCS 
symptoms of feeling sad, nausea and feeling sick, poor concentration, and worrying 
and dwelling on symptoms. Further, S100B levels were able to categorically 
discriminate between those that reported “Extremely High” range post-concussion 
symptomatology, as assessed by the BC-PCSI, and those that did not – however, the 
area under the curve for correctly classifying “Extremely High” PCS 
symptomatology was only poor to fair.  
With reference to quality of life, S100B concentrations were shown to be 
significantly correlated with various domains of quality of life as measured by the 
QOLI – namely: self-actualisation; goals and values; learning; creativity; helping; 
and love. Neither GCS nor WPTA significantly accounted for any additional 
variance in these domains except for WPTA to the domain of love. Results of the 
third study also showed that overall quality of life, as assessed by the QOLI Total 
Score, could be predicted by serum S100B levels, and neither GCS scores nor WPTA 
duration significantly accounted for any additional variance. It should be noted that 
S100B only accounted for eight percent of the variance in this measure, and despite 
significantly higher S100B levels being found for the patients who experienced 
“Low” and “Very Low” quality of life, S100B was inefficient in correctly classifying 
these patients. Similar results were found for GCS and WPTA indicating that no 
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acute independent variable was statistically efficient in identifying those that 
experienced poorer overall quality of life and those that did not. Overall, results of 
the third study indicated that serum concentrations of S100B are significantly 
correlated with various symptoms of PCS and domains of quality of life following 
TBI. Although S100B in isolation offers insufficient prognostic accuracy for these 
clinical outcomes, the results of the present study hold directions for future research 
into S100B and other biomarkers for TBI, and translational implications for “bench 
top to bedside” experimental methodology. 
Taken together, results of the present thesis possess some clinical 
implications for the use of serum S100B following TBI. First, by ascertaining a 
patient’s S100B level and depth of coma on arrival at hospital, clinicians making an 
unfavourable post-traumatic amnesia prognosis can do so with confidence informed 
by concise convergent validation. Unfortunately, however, S100B cannot be used to 
prognose cognitive impairment. Clinical examination of indices of brain injury 
severity, medical imaging, comprehensive history taking, and neuropsychological 
assessment remain the best practice for attaining an accurate prognosis for cognitive 
functioning following TBI. Further, despite correlations suggesting a relationship 
between S100B levels and the longer term chonicity of post-concussion symptoms 
and their effect on daily life and functioning, S100B in isolation offers insufficient 
prognostic accuracy for these clinical outcomes. This thesis contributes to the 
associated literature by incorporating extensively validated measures of functional 
outcome that are of direct relevance to the survivors of TBI. Future research into 
S100B, or any other potential biomarker for TBI, would benefit from the 
translational implications of using such measures and methodologies. 
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9.2 Limitations and Considerations 
Despite the growth in S100B research, most studies are difficult to compare 
because the methodology and statistical reporting between studies is often not 
uniform (Papa et al., 2013). Timing of blood collection is perhaps the least 
uniformed constituent in the experimental designs of the associated literature, and 
Ohrt-Nissen et al. (2011) suggest that blood samples should be collected at a 
consistent and specific time point after the injury. S100B levels used in this thesis 
were ascertained by analysing an aliquot of serum from each patient’s earliest 
collected sample. Although the mean collection time in this study is comparable to 
most studies, the methodology used in this thesis meant that post-injury collection 
times were not standardised. No corrective manipulations were made to serum 
S100B levels used in this study. 
 Beyond standardising a consistent post-injury collection time, the optimal 
time for sampling S100B in serum has been widely discussed in the associated 
literature. Typically, serum S100B levels are at their maximum shortly after injury 
before progressively dropping in concentration across the next one to two days 
(Egea-Guerrero et al., 2013). The present study utilised patients’ first available blood 
collection, and in Thelin et al.’s (2013) metaanalysis, the authors consider initial 
samples to be the most important in predicting outcome. However, other studies have 
markedly different methodologies. For example, some studies have collected serum 
across several time-points and used the mean of these collections as the independent 
variable (Ucar et al., 2004; Pelinka et al., 2004; Naemi et al., 2006), whereas others 
have used the peak level obtained across the collections (Raabe et al., 1999; 
Woertgen et al., 1999; Townend et al., 2002).  
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Being that this study was granted ethical approval on the basis that no 
additional procedures would be necessary for the patient, and that analyses would be 
performed on aliquots from routinely collected samples, standardised sampling and 
serial sampling was not possible. Consistent with the assertions of Papa et al. (2013), 
future studies of biomarkers will require more rigorous and uniform research 
methodology. As such, efforts should be made in future research towards identifying 
the optimal sampling time for determining prognoses. 
 A further limitation of this study is that no controls were made for potential 
extracranial sources of S100B, and therefore, some participants’ serum 
concentrations may have been elevated attributable to sources beyond the nature of 
their TBI pathology. S100B’s expression in adipocytes, chondrocytes, and 
melanocytes are argued to conflict and confuse the data in TBI studies (Walder et al., 
2013; Yokobori et al., 2013), and impact on its prognostic utility as a biomarker for 
TBI (Ohrt-Nissen et al., 2011). Given the aetiologies of injury in the present thesis, it 
can be assumed that many of the participants would have suffered extracerebral 
injuries, comorbid to their TBI. These comorbid traumas, particularly to regions of 
the body with higher adiposity, have been shown to result in significantly higher 
S100B levels than head injuries in isolation (Ohrt-Nissen et al., 2011). However, this 
result was not evident in the research conducted by Pham et al. (2010), and it is 
further argued that any elevations in S100B concentrations from extracranial sources 
are clinically inconsequential to a confirmed TBI, as their contribution to levels are 
significantly lower than the contribution made by TBI (Lange et al., 2010). 
Nevertheless, the present thesis did not collect data pertaining to extracranial trauma, 
nor investigate the significance of participants’ comorbid injuries to their serum 
S100B concentrations. Future research may need to consider these investigations. 
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Lastly, although the initial participant sample of 127 is one of the largest in 
S100B/TBI research – regrettably, the number of participants meeting criteria at each 
of the three time points (T0 N = 79; T60 N = 50; T180 N = 52) impacts the power of the 
analyses and the conclusions that can be drawn from the findings. This research is 
currently being continued by another team of researchers, and it is anticipated that 
the increased participant pool from their studies will strengthen the findings of the 
current thesis. 
 
9.3 Future Directions for TBI Biomarkers 
 Beyond S100B, other serum proteins are emerging in the associated literature 
as potential biomarkers for TBI. One such protein is glial fibrillary acidic protein 
(GFAP). GFAP is expressed in the central nervous system, and its breakdown 
products (GFAP-BDP) are released following parenchymal brain injury. Recent 
exploratory studies have shown GFAP and GFAP-BDP to reliably distinguish the 
presence and severity of CT imaging results (Okonkwo et al., 2013), and to 
discriminate between TBI patients and healthy controls (Diaz-Arrastia et al., 2013). 
Other proteomic biomarker candidates that have emerged in the recent TBI literature 
include ubiquitin c-terminal hydrolase (UCHL1; Berger et al., 2012), alpha-II 
spectrin breakdown products (αII-SBDP; Weiss et al., 2009), heart fatty acid binding 
protein (Walder et al., 2013), interleukin 8 (IL-8; Stein et al., 2012), and interleukin 
10 (IL-10; Soares et al., 2012). Given the methodology of the present thesis, it is 
possible to analyse the stored serum samples for concentrations of any of the above 
proteins in order to directly compare and contrast their diagnostic and prognostic 
utility for neuropsychological outcomes. 
152 
 
Jeter et al. (2013) argue that, based on the biomarkers tested to date, it is 
unlikely that a single biomarker will have sufficiently robust utility to serve as a 
standalone diagnostic test for TBI, or to predict which patients are most likely to 
experience unfavourable outcomes. Sharma and Laskowitz (2012) add that the 
direction of future research may be to enhance sensitivity and specificity by 
combining a panel of biomarkers, similar to troponin and creatine kinase isoenzymes 
M and B for diagnosis in myocardial infarction (Guzy, 1977). Papa et al (2013) add 
that, due to the heterogeneity of TBI pathologies, devising a panel of biomarkers may 
prove to be useful in distinguishing the various pathoanotomic processes that occur 
during injury. Devising such a panel is the intended direction for future research to 
come from the present thesis. 
Further to the specific biomarker being studied, the statistical modelling 
techniques for future prognostic research deserve methodological consideration. One 
such emerging technique is group-based trajectory modelling (GBTM; Niyonkuru et 
al., 2013). In the GBTM approach, clusters of individuals following similar 
biomarker trajectories over time are identified and stratified. The methodology 
assumes that the clinical population is composed of distinct groups, defined by their 
biomarker trajectories, and these groups are therefore likely to have heterogeneous 
outcomes. Further, the prognostic utility of S100B has been shown to be enhanced by 
the algorithmic inclusion of clinical variables, such as the GCS (Lo et al., 2010; Wolf 
et al., 2013). Future research may benefit from investigating the inclusion of other 
clinical variables such as imaging classification (Marhall et al., 1992) or acute 
neuropsychological examination results in order to investigate any mediation effects 
on the accuracy of functional prognoses. 
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9.4 Summary 
This thesis aimed to quantify the prognostic utility of S100B for 
neuropsychological outcomes including duration of post-traumatic amnesia, severity 
of cognitive impairment, presence of symptoms of post-concussion syndrome, and 
deficits in domains that are associated with quality of life. The clinical implications 
from this research indicate that serum S100B can be used by clinicians to make 
prognoses for a patient’s post-traumatic amnesia, however it cannot be used to 
prognose cognitive impairment. Further, despite correlations suggesting a 
relationship between S100B levels and the longer term chonicity of post-concussion 
symptoms and their effect on daily life and functioning, S100B in isolation offers 
insufficient prognostic accuracy for these clinical outcomes. 
This thesis possesses several limitations. Firstly, although the mean collection 
time in this study is comparable to most studies, the methodology used in this thesis 
meant that post-injury collection times were not standardised and serial sampling was 
not possible. Further, no controls were made for potential extracranial sources of 
S100B – however, the impact of the contribution made by these sources is equivocal 
in the associated literature. Lastly, the number of participants meeting criteria at each 
of the three time points impacts the power of the analyses and the conclusions that 
can be drawn from the findings. 
Future TBI prognostic research would benefit from investigating proteomic 
candidates as they emerge, and considering a biomarker panel in order to distinguish 
various pathoanotomic processes that occur during injury. Further, from a 
translational perspective, future TBI biomarker research would benefit from utilising 
neuropsychological outcomes in their experimental design in order to make direct 
implications to the unique symptoms that are experienced by survivors of TBI. 
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